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Cell wall biosynthesis is a crucial process for bacterial growth and a well-validated 
source of targets for existing antimicrobials. Among such targets are the penicillin-
binding proteins (PBPs), which act within multiprotein complexes to assemble 
peptidoglycan from Lipid II, catalysing both glycosyltransferase (GT) and 
transpeptidase (TP) activities. This work focussed on the PBPs of Streptococcus 
pneumoniae, a key pathogen in terms of its healthcare burden and the prevalence of 
pneumococcal resistance to b-lactams.  
 
The requirement for both PBP modification and branched muropeptides in the 
pneumococcal b-lactam resistance mechanism has been well documented. Progress 
in demonstrating the mechanistic link between these two factors has historically been 
limited by availability of the native substrates. We aimed to address the hypothesis 
that branching of precursors is beneficial for competition of PG substrates against b-
lactams, and also to explore the impact of lipid environment on PBP1a activity, based 
upon previous observations with the MurM protein that generates branched Lipid II 
precursors. 
We used chemoenzymatic methods to demonstrate the first synthesis of potential 
donor- and acceptor-only amidated substrates, in addition to branched precursors, for 
pneumococcal PBPs. These substrates will provide valuable tools for study of 
pneumococcal PBP function with natural substrates, which is key for addressing 
pneumococcal b-lactam resistance.  
A novel spectrophotometric assay for transpeptidation was used to attempt 
observation of in vitro transpeptidase activity by PBP1a. Mass spectrometry revealed 
that D,D-carboxypeptidase activity alone occurred under the current reaction 
conditions. We discuss possible further work to establish in vitro transpeptidase 
activity. 
Established assays for GT activity were used to identified a novel link between 
pneumococcal membrane phospholipids and the activity of PBP1a. This is the first 
observation of the impact of cardiolipin on the activity of a PBP, and corresponds with 
growing evidence in support of a role for cardiolipin in regulation of cell division 
proteins. 
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Chapter 1: Introduction 
1.1 Antibiotic resistance 
 
1.1.1 The history and current use of antibiotics 
Antibiotics are the drugs used to kill or arrest the growth of bacteria. Antibiotics 
have been unknowingly used by humans for thousands of years prior to the 
development of industrial chemical processes for their manufacture, such as 
by the use of extracts from moulds in ancient civilisations (Mohr, 2016). 
 
Whilst the early 1900s yielded several treatments for infection including 
salvarsan and neosalvarsan, the application of these was limited by their 
severe side effects and narrow spectrum of activity (Kardos & Demain, 2011). 
Multiple reports emerged in the 19th Century of antibiotic effects by moulds, 
including that of Ernest Duchesne, who described the treatment of Escherichia 
coli and Salmonella typhi infection of guinea pigs by use of a mould 
suspension (Duchesne, 1897; as reviewed by Mohr (2016)). Penicillin, one 
compound responsible for such observations, was famously discovered in 
1928 by Alexander Fleming (Fleming, 1929; Chain et al., 1940), and 
subsequent work by Chain, Florey and others resulted in the development of 
methods for the mass production of penicillin. Penicillin thus was a key 
contributor to the treatment of infections during and after World War II, made 
possible by the cheap cost, safety and wide spectrum of the drug (Kardos & 
Demain, 2011).  
 
In addition to infectious disease management, antibiotics are crucial in the 
management of a number of other conditions, to prevent and treat 
complications caused by infections. These include cancer, surgical 
interventions including joint replacement and organ transplants, and 





1.1.2 The threat of antibiotic resistance 
1.1.2.1 Definition of resistance, statistics on worldwide burdens 
The essentiality of antibiotics to modern healthcare highlights the severity of 
the threat posed by antibiotic resistance. Antibiotic resistance refers to the 
development of tolerance in bacteria to antibiotic drugs. Whilst some bacteria 
exhibit primary (or ‘natural’) resistance to particular antibiotics, the 
development of secondary (or ‘acquired’) resistance has frequently been 
observed for many clinically important pathogens.  
Antimicrobial susceptibility is assessed by interpretation of minimal inhibitory 
concentration (MIC) according to breakpoint values. Breakpoints are devised 
from data including the distribution of susceptibilities, the pharmacological 
properties of the drug, and clinical outcomes (MacGowan & Wise, 2001; 
Turnidge & Paterson, 2007). Treatment failure under standard dosage would 
be expected for an isolate designated as ‘resistant’ to an antibiotic by 
evaluation of breakpoints (Turnidge & Paterson, 2007). 
 
Antibiotic resistance, whilst a natural phenomenon, has developed at an 
accelerated rate, due in part to the misuse of antibiotics. Such misuse includes 
inappropriate and empirical prescribing, and poor regulation of access to 
antibiotics (Aminov, 2010). Antibiotic resistance limits the available treatment 
options, and resistant infections are associated with higher healthcare costs 
and higher mortality (World Health Organisation, 2018). It is currently 
estimated that without significant prevention efforts, deaths resulting from 
antibiotic resistant infections could reach 10 million a year worldwide by 2050 
(O’Neill, 2014). This figure was drawn from commissioned reports modelling 
the rise in morbidity and mortality due to resistant infections by a subset of 
medically important pathogens, using different projected resistance rates 
(Taylor et al., 2014; KPMG, 2014). The accuracy of these projections was 
limited by the available data on current incidences of infection and resistance 




1.1.2.2 Key pathogens in antibiotic resistance: WHO priority pathogens and 
ESKAPES 
Among the various bacteria which have been observed to be decreasing in 
susceptibility to key antibiotics, the World Health Organisation (WHO) have 
designated a subset of priority pathogens for research and development of 
new antimicrobials (Tacconelli et al., 2018). Among the criteria for inclusion 
were their treatability, the prevalence of resistance, and the current pipeline 
for new agents. The chosen priority pathogens were itemised (with the 
exception of Mycobacterium tuberculosis, as this was an existing global health 
priority) into categories of critical, high and medium priority for research and 
development of new antibiotics (Figure 1.1).  
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In addition, the ESKAPE pathogens panel notes the most common pathogens 
associated with nosocomial infections, which show worldwide prevalence of 
antibiotic resistance. The panel includes Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, 
Pseudomonas aeruginosa, and Enterobacter species (Boucher et al., 2009). 
 
Figure 1.1 Organisms included in the WHO priority pathogens and 
ESKAPE panel. The WHO priority pathogens (listed with the most significant 
resistance phenotypes) were chosen based on criteria of treatability, pipeline for new 
antimicrobials, and the prevalence of resistance (Tacconelli et al., 2018). The ESKAPE 
panel includes those pathogens most commonly associated with nosocomial 
infections and which show notable worldwide prevalence of antibiotic resistance 
(Boucher et al., 2009). 
ESKAPE panel of nosocomial pathogens 
      WHO priority pathogens for R&D of new antibiotics 
MDR/XDR Mycobacterium tuberculosis 
 
CRITICAL 
Acinetobacter baumanii (carbapenem) 
Pseudomonas aeruginosa (carbapenem) 
Enterobacteriaceae (carbapenem, 3
rd
 gen. cephalosporin) 
 
HIGH 
Enterococcus faecium (vancomycin) 
Staphylococcus aureus (methicillin, vancomycin) 
Helicobacter pylori (clarithromycin) 
Campylobacter spp. (fluoroquinolone) 
Salmonella spp. (fluoroquinolone) 
Neisseria gonorrhoeae (3
rd
 gen. cephalosporin, fluoroquinolone) 
 
MEDIUM 
Streptococcus pneumoniae (penicillin) 
Haemophilus influenzae (ampicillin) 
Shigella spp. (fluoroquinolone) 




1.1.2 Streptococcus pneumoniae as a key pathogen for new 
antimicrobial research and development 
Penicillin non-susceptible S. pneumoniae is one important target for research 
and development of new antibiotics (World Health Organization, 2017). S. 
pneumoniae is a Gram-positive opportunistic pathogen. Pneumococci 
asymptomatically colonise the nasopharynx, with carriage rates in young 
children reported between 30 and 70 % (Regev-Yochay et al., 2004). Such 
asymptomatic carriage is the precursor to development of invasive 
pneumococcal disease, and has enabled rapid dispersal of resistant strains.  
Invasive pneumococcal disease is a major cause of mortality in the very young 
and elderly population. Invasive pneumococcal disease includes conditions 
such as pneumonia, meningitis and sepsis (Cartwright, 2002). S. pneumoniae 
is the second most common cause of meningitis after meningococci, and is 
the most common cause of bacterial pneumonia in children aged under two 
(Randle et al., 2011). An estimated 294 000 deaths due to pneumococcal 
infection were reported in 2015, with an additional 8.9 million cases of 
pneumococcal pneumonia (Wahl et al., 2018).  
The greatest disease burden is observed in India, Nigeria, the Democratic 
Republic of Congo and Pakistan, with half of the reported deaths from these 
countries (Figure 1.2). 
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Penicillin non-susceptible pneumococcal isolates have been detected across 
the globe (Figure 1.3). The current European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) clinical breakpoint is 0.06 µg.mL-1 for 
penicillin-susceptible pneumococci (EUCAST, 2018). In isolates from 
meningitis cases, MICs > 0.06 µg.mL-1 are designated resistant, whereas in 
non-meningitis cases, MICs in the range of 0.06 – 2 µg.mL-1 are taken as 
intermediate susceptibility, with resistance if MIC > 2 µg.mL-1; this difference 
in breakpoint according to clinical context is necessitated by the limited 
penetration of the blood-brain barrier by penicillin (Weinstein et al., 2009). 
 
Penicillin non-susceptible pneumococcal isolates were first detected in 1967, 
and subsequently emerged throughout Europe, Africa, Asia and North and 
South America by the late 1990s (Linares et al., 2010). Analysis of 
pneumococcal isolates from respiratory tract infections in the course of the 
PROTEKT study revealed rates of penicillin non-susceptibility (with 
intermediate and resistant isolates respectively) at 42 % and 15.9 % in Greece; 
40.4% and 15.9 % in France; and 29.4 % and 13.1 % in Spain (Felmingham 
et al., 2007). 
Figure 1.2 Mortality rates and deaths due to pneumococcal infection in 
2015. Mortality and death rates in HIV-negative children aged 1-59 months are 
displayed per country, per 100 000 children in the age bracket. The greatest 
proportion of deaths were observed in India, Pakistan, Nigeria and the Democratic 
Republic of Congo. 





1.1.2.1 Vaccination against S. pneumoniae 
More than 90 pneumococcal serotypes have been identified, based on the 
variation in capsular polysaccharides (Henrichsen, 1995). Prior to 2000, the 
pneumococcal serotypes associated with the greatest disease burden were 4, 
6B, 9V, 14, 18C, 19F, and 23F, whilst those that demonstrated the highest 
rate of resistance to penicillin and erythromycin were 6B, 6A, 9V, 14, 15A, 19F, 
19A and 23F (Linares et al., 2010). The seven-valent pneumococcal conjugate 
vaccine against serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F (PCV7) was 
introduced into the UK routine childhood immunisation programme in 2006 
(Randle et al., 2011). Whilst introduction of PCV7 was associated with a 
decline in pneumococcal penicillin resistance rates, serotype replacement has 
resulted in increasing burden of invasive pneumococcal disease (IPD) 
associated with non-vaccine serotypes, including multiresistant serotype 19A 
(Linares et al., 2010). Subsequent PCVs have been marketed with coverage 
of 10 (PCV10: PCV7 plus serotypes 1, 5 and 7F) and 13 (PCV13: PCV10 plus 
serotypes 3, 6A and 19A) pneumococcal serotypes respectively, in order to 
Figure 1.3 Percentage of invasive isolates of S. pneumoniae resistant 
to penicillin by country. Reported percentages refer to resistance in isolates 
from blood and cerebrospinal fluid from patients of all ages. Figure source: The 
Center for Disease Dynamics Economics & Policy. ResistanceMap: Antibiotic 
Resistance. 2018. https://resistancemap.cddep.org/AntibioticResistance.php. Date 
accessed: 28th April 2019.  
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address those serotypes identified in strain replacement (Lee et al., 2014). In 
addition, a 23-valent pneumococcal polysaccharide vaccine (PPSV23, 
covering serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) is available as a follow-up to 
PCV13 for particularly high-risk cases (American Academy of Pediatrics 
Committee on Infectious Diseases, 2010; Nuorti & Whitney, 2010). 
 
1.1.2.2 Pneumococcal ecology 
Pneumococci are aerotolerant anaerobes, although they lack the expected 
mechanisms for detoxifying reactive oxygen species (Pesakhov et al., 2007). 
Pneumococci produce hydrogen peroxide as a by-product of aerobic 
metabolism of pyruvate (Bättig & Mühlemann, 2008). Release of hydrogen 
peroxide by pneumococci has been suggested to play a role in virulence, 
contributing to the toxicity of pneumolysin (Hirst et al., 2000) and inducing DNA 
double-strand breaks (resulting in apoptosis) in lung cells in the context of 
pneumococcal pneumonia (Rai et al., 2015). There has also been discussion 
of a role for hydrogen peroxide production by S. pneumoniae and viridans 
streptococci in inter-species competition for colonisation of the upper 
respiratory tract, based on inhibition of growth of S. aureus by pneumococcal 
culture supernatant (McLeod & Gordon, 1922; Regev-Yochay et al., 2006). 
Whilst negative correlation has been reported between the upper airway 
colonisation rates of S. pneumoniae and S. aureus (Bogaert et al., 2004; 
Regev-Yochay et al., 2004), some studies have supported the role of 
hydrogen peroxide in inter-bacterial competition in vivo (Park et al., 2008), 
whilst others have disputed this interaction (Margolis, 2009). 
 
Competence-driven genetic transformation is a key component of the ecology 
of S. pneumoniae. Competence has been proposed to compensate for the 
lack of the ordinary SOS stress response (as seen in other bacteria), with 
competence stimulating peptide (CSP) mediating a stress signal to 
pneumococcal communities (Prudhomme et al., 2006). Competence has been 
found to be induced by the stress of treatment of pneumococci by 
fluoroquinolones and mitomycin C (Prudhomme et al., 2006). Horizontal gene 
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transfer is a key component of the pneumococcal b-lactam resistance 
mechanism, as further discussed in Section 1.6.3. 
 
Pneumococcal virulence factors include the capsule, which inhibits 
interactions with complement and neutrophils (Hyams et al., 2010); the 
pneumococcal exoglycosidases (such as neuraminidase and b-galactosidase) 
which expose host receptors and provide a carbon source; and the pore-
forming toxin, pneumolysin, which has been suggested to be a key contributor 
to the pathology of pneumococcal pneumonia (Weiser, 2010). 
1.2 Cell wall architecture and peptidoglycan 
One of the major targets of antibiotics is peptidoglycan biosynthesis. This 
cross-linked polymer is found in bacterial cell walls and confers strength 
against the internal turgor of bacterial cells (Vollmer and Bertsche, 2008), in 
addition to providing a support for attachment of surface proteins. 
 
1.2.1 Gram positive and Gram negative cell wall architecture  
Bacteria are broadly classified according to the structure of the cell wall, with 
a few exceptions such as the Mycobacteria. Various important distinctions 
between the cell wall of Gram positive and Gram negative bacteria (as defined 
based on the Gram staining reaction (Gram, 1884)) affect the interaction of 
these bacteria with host cells and their environment, and the ease with which 
various antibiotics can gain access to the periplasm. Schematic structures of 






Figure 1.4 Schematic representation of the Gram positive and Gram negative cell walls. Gram positive cell walls have a thick 
layer of peptidoglycan that incorporates teichoic and lipoteichoic acids. Gram negative cell walls have a comparatively thinner layer of 
peptidoglycan, in addition to an outer membrane from which the lipopolysaccharide layer extends. Porin proteins mediate access of small 
molecules to the periplasm. 
After Cabeen & Jacobs-Wagner (2005), and Madigan et al. (2010).  
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1.2.1.1 The Gram positive cell wall 
The majority of the Gram positive cell wall consists of a thick layer of 
peptidoglycan (Shockman & Barren, 1983). Further molecules including 
teichoic acids are embedded in the peptidoglycan layer. Teichoic acids 
comprise polymers of glycerol phosphate or ribitol phosphate, and are 
distinguished based on their mode of attachment to the cell wall. Lipoteichoic 
acids are covalently linked to membrane phospholipids, whereas wall teichoic 
acids are linked to the MurNAc sugars of peptidoglycan (Weidenmaier & 
Peschel, 2008). Proposed functions of the teichoic acids include cation 
homeostasis, control of membrane permeability, and acting as a scaffold for 
cell wall enzymes such as hydrolases (Swoboda et al., 2010). In place of the 
outer membrane observed in Gram negative bacterial cell walls, Gram positive 
bacteria may encompass a protective structure such as a capsule 
(Weidenmaier & Peschel, 2008). As previously described (Section 1.1.2.1), 
variation in the saccharide composition of the capsule defines the serotypes 
of pneumococci (Henrichsen, 1995).  
 
1.2.1.2 The Gram negative cell wall 
The Gram negative cell wall includes a thinner layer of peptidoglycan, in 
comparison to the Gram positive cell wall. In addition, the peptidoglycan layer 
is surrounded by an outer membrane, from which the lipopolysaccharide layer 
extends (Osborn, 1969). The outer membrane is anchored to the 
peptidoglycan layer by lipoproteins (Cabeen & Jacobs-Wagner, 2005). The 
outer membrane acts as a further permeability barrier to the bacterial cell 






1.2.2 Peptidoglycan structure 
The mesh structure of the peptidoglycan polymer is created by glycan strands 
of alternating N-acetylmuramyl (MurNAc) and N-acetylglucosaminyl (GlcNAc) 
sugars linked by b-(1,4)-glycosidic bonds (Figure 1.5). These glycan strands 
are cross-linked via stem peptides extending from the lactyl moiety of the 
MurNAc sugars (Vollmer and Bertsche, 2008).  
In addition to the variation depicted at positions two and three of the peptide 
stem in Figure 1.5, variation in the peptidoglycan structure is found at the level 
of modifications to the sugars; to the residues of the peptide stem; and at the 
inclusion of direct and indirect cross links (Vollmer, Blanot, et al., 2008). These 
modifications have known functions including modulation of immune 
recognition of PG fragments, and conferral of resistance to enzymes such as 
lysozyme (Sobhanifar et al., 2013). Particular structural variations that are of 
interest to the pneumococcal b-lactam resistance mechanism will be 






Figure 1.5 General structure of peptidoglycan. A schematic of the mesh 
structure is presented, demonstrating the glycan strands of alternating sugars 
(coloured purple to indicate N-acetylglucosaminyl (GlcNAc) sugars, and green for 
N-acetylmuramyl (MurNAc) sugars) which are cross linked between strands via the 
peptide stems (shown in blue). The general chemical structure of the repeating unit 
in peptidoglycan is shown, with the pentapeptide stem appended to the lactyl 
moiety of the MurNAc sugar. Residue numbers are indicated in brackets.  
Made with reference to Madigan et al. (2010). 
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1.3 Biosynthesis pathway and cell division apparatus 
The biosynthesis of peptidoglycan is compartmentalised into cytoplasmic, 
membrane-linked and extracytoplasmic steps (Figure 1.6). In the cytoplasmic 
step, the Park nucleotide (UDP-MurNAc pentapeptide) is synthesised by 
MurA-MurF (Barreteau et al., 2008). Phospho-MurNAc pentapeptide is 
transferred from UDP-MurNAc pentapeptide to the lipid carrier undecaprenyl 
monophosphate, in a reaction catalysed by MraY to form Lipid I. The muramyl 
sugar ring of Lipid I is glucosaminylated by MurG to furnish Lipid II. It has been 
suggested that the enzymes that form the Lipid II biosynthetic pathway are 
assembled into multi-enzyme clusters, which would allow metabolic 
channelling, and also mask active sites from inhibitors (Laddomada et al., 
2016).  
 
The Lipid II peptidoglycan precursor is translocated across the plasma 
membrane by the activity of a flippase enzyme. Whilst differing experimental 
approaches lent support to FtsW (Mohammadi et al., 2011) and MurJ (Sham 
et al., 2014) as the candidate flippase, the current consensus supports the 
conclusion that MurJ coordinates the flippase activity. FtsW was subsequently 
found to exhibit glycosyltransferase activity (Taguchi et al., 2018; see Section 
1.4.1.3). 
On the extracellular face of the cell membrane, Lipid II is polymerised by 
glycosyltransferases (with release of undecaprenyl pyrophosphate as a by-
product), and the resulting polymers of GlcNAc-MurNAc pentapeptide are 
cross-linked by transpeptidation (Vollmer and Bertsche, 2008). The 
attachment of nascent peptidoglycan to the sacculus in E. coli is similarly 
mediated by transpeptidation (Born et al., 2006). Both glycosyltransferase 




Figure 1.6 Peptidoglycan biosynthesis pathway The UDP-MurNAc sugar is synthesised from UDP-GlcNAc by MurA and MurB. Amino acids 
are then sequentially added to UDP-MurNAc by the MurC-F, and this precursor is then linked to the lipid carrier undecaprenyl phosphate by MraY. MurG 
links the GlcNAc sugar residue to Lipid I to generated Lipid II, the peptidoglycan precursor. This precursor is flipped across the cytoplasmic membrane by 
MurJ, following which the glycosyltransferases (GTases) generate glycan strands by formation of glycosidic bonds between Lipid II units. Finally, cross link 
formation between glycan strands is catalysed by transpeptidases (TPases). The amino acid incorporated by MurE (L-X) is L-Lys is Gram positives, and 
meso-diaminopimelic acid (mDAP) in Gram negatives. Undecaprenyl pyrophosphate released as a by-product of glycosyltransfer is converted to 
undecaprenyl phosphate by an undecaprenyl phosphatase (UPPs - e.g. BacA), and flipped to the cytoplasmic face of the cytoplasmic membrane by an 
unidentified flippase. 
PEP, phosphoenolpyruvate; L-X, L-Lys or meso-diaminopimelic acid (mDAP); GTases, glycosyltransferases; TPases, transpeptidases. 
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catalysed by penicillin binding proteins (PBPs), in addition to other enzyme 
classes catalysing glycosyltransfer (1.4.1.4).  
The lipid carrier undecaprenyl phosphate is recycled. Undecaprenyl 
pyrophosphate is dephosphorylated to yield undecaprenyl phosphate. This 
activity can be catalysed by phosphatases including BacA, PgpB and YbjG 
(Hernández-Rocamora et al., 2018). Undecaprenyl phosphate is then flipped 
to the cytoplasmic face of the membrane by a yet unidentified flippase (Manat 
et al., 2014). 
1.4 Penicillin-binding proteins 
PBPs are classified according to function; Class A PBPs are bifunctional, i.e. 
with both N-terminal GT and C-terminal TP domains. Class B PBPs are 
monofunctional C-terminal transpeptidases with unknown N-terminal activity; 
and Class C PBPs are monofunctional carboxypeptidases (Sauvage et al., 
2008).  
High molecular mass (HMM) PBPs (Class A or B) have a cytoplasmic tail, 
transmembrane anchor, and two domains extending from the extracellular 
face of the cytoplasmic membrane, with the C-terminal TP domain linked to 
the N-terminal domain via a  -rich linker (Sauvage et al., 2008). Whilst the N-
terminal domain in Class A PBPs is the GT domain, in Class B PBPs the 
Figure 1.7 Domain structure of Class A, B and C penicillin binding 
proteins in S. pneumoniae. Schematic view of the domain structures of the 
Class A, B and C penicillin binding proteins of S. pneumoniae. The Class C domain 
structure can be considered to be conserved across a variety of species. 
TM, transmembrane domain; GT, glycosyltransferase domain, PB, penicillin 
binding domain; N. ter, N-terminal domain; P, PASTA domain; C. ter, C-terminal 
domain. 
Made with reference to Macheboeuf et al. (2006). 
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function of this domain is poorly characterised, although it has been suggested 
to participate in protein-protein interactions (Den Blaauwen et al., 2008). 
It has been suggested that PBPs may switch between active and inactive 
states (Macheboeuf et al., 2006). In the case of E. coli PBP1a and PBP1b, 
activator proteins that mediate these transitions have been identified, where 
PBP1a and PBP1b are activated by lipoproteins LpoA and LpoB respectively. 
These proteins are anchored in the outer membrane and stimulate activity of 
their respective targets, although the mechanism of this stimulation remains 
unknown (Typas et al., 2010). In addition, it has been suggested that a 
mechanism of coordination exists between the GT and TP activities in 
bifunctional PBPs. This is based on observations that no unattached 
oligomeric glycan chain intermediates are found in living cells (suggesting 
simultaneous polymerisation and attachment via transpeptidation of nascent 
glycan chains) (Goodell et al., 1983). Also, GT activity has been found to 
predicate TP activity in vitro (Egan et al., 2015, Bertsche et al., 2005). 
1.4.1 Glycosyltransferase activity 
The glycan backbone of peptidoglycan is generated by GT activity, which links 
Lipid II units via the sugar moieties. Synthesis of glycan polymers generally 
follows a processive mechanism (Yuan et al., 2007), though particular 
enzymes differ in their in vitro maximum glycan chain length (Wang et al., 
2008). Differences in the processivity of various glycosyltransferases have 
been demonstrated by SDS-PAGE analysis of glycan assembly, with longer 
glycan chains synthesised by E. coli PBP1b as compared to the shorter glycan 
chains synthesised by Thermotoga maritima PBP1a (Offant et al., 2010); and 
greater processivity of E. coli PBP1a than Aquifex aeolicus PBP1a, based on 
the comparative lack of shorter glycan polymers with the former enzyme 
(Barrett et al., 2007). 
Usage of monomeric and oligomeric substrates has been compared to 
analyse the processive activity of glycosyltransferases. Zhang et al. (2007) 
demonstrated that whilst both E. coli PBP1a and PBP1b were able to couple 
a chemo-enzymatically synthesised heptaprenyl Lipid IV to heptaprenyl Lipid 
II, PBP1a could also ligate Lipid IV units to each other. This data thus 
demonstrated potential for variation in substrate usage between 
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glycosyltransferases. Barrett et al. (2007) further demonstrated, using GT 
domain constructs of E. coli and Aquifex aeolicus PBP1a, that use of Lipid IV 
as a substrate was associated with a distributive mechanism (with frequent 
release of short glycan polymers) compared to the processive mechanism 
observed with Lipid II. Longer oligomers than Lipid IV were not used as 
substrates in self-coupling, but could be used as substrates in the presence of 
Lipid II. These data supported a processive mechanism of GT activity.  
 
A lag phase in in vitro GT activity was described by Schwartz et al. (2002), 
who ascribed the observation to initial slow coupling of Lipid monomers, 
followed by a processive extension phase. Chen et al. (2003) suggested that 
the lag was instead due to slow conformational change to the active state, as 
the lag could be shortened by preincubating in the appropriate detergent. 
 
1.4.1.1 Subdomains and key motifs of the glycosyltransferase domain 
The globular, all a-helical GT domain comprises two subdomains; a head 
subdomain; and the jaw subdomain. The groove between these subdomains 
contains the GT active site. The GT domain contains five conserved motifs, 
within which lie residues involved in binding of the Lipid II substrate, and 
catalysis (Figure 1.8a). Motif I contains the catalytic glutamate. Motif II creates 
the active site cleft, and contains residues that coordinate the pyrophosphate 
of the donor molecule. Motif III forms the active site pocket, containing donor 
site residues. Motif IV is purported to facilitate conformational changes to the 
jaw subdomain. Motif V contains an arginine residue that stabilises the active 
site glutamate. 
 
A crystal structure of the GT domain of A. aeolicus PBP1a (Yuan et al., 2007) 
revealed a hydrophobic patch adjacent to the membrane, past which the 
polyprenol chain of Lipid II was proposed to extend towards the membrane. 
Part of the active site cleft was found to be obscured by a flap created by the 




a) key motifs of the GT active site b) proposed mechanism of glycosyltransfer 
Figure 1.8 Glycosyltransferase activity: structure of the active site and mechanism. a) the key motifs of the glycosyltransferase 
active site, as seen in a crystal structure of S. aureus PBP2 in complex with moenomycin. Motif I contains the catalytic glutamate (E114PBP2, E100MGT; part 
of the acceptor site). Motif II creates the active site cleft, and contains residues that interact with the pyrophosphate of the donor molecule (K155PBP2, 
K140MGT). Motif III forms the active site pocket, containing donor site residues (E171PBP2, E156MGT). Motif IV is purported to facilitate conformational changes 
to the jaw subdomain. Motif V contains an arginine residue (R167PBP2, R241MGT) that stabilises the active site glutamate.  
b) The proposed mechanism of glycosyltransfer, as inferred from crystal structure of S. aureus MGT. Two Lipid II molecules first enter the active site (i), one 
at the donor (D) and one at the acceptor (A) site. The catalytic E100 residue deprotonates the 4-OH of the acceptor Lipid II molecule (ii), which then reacts 
to form a b-1,4 glycosidic bond with the donor molecule. Interactions with K140 and R148 facilitate the departure of undecaprenyl pyrophosphate (C55-PP) 
(iii). The Lipid IV product is shuttled to the donor site (iv), and another Lipid II molecule enters the acceptor site (v). A, glycosyl acceptor site; D, glycosyl 
donor site; C55-PP, undecaprenyl pyrophosphate. Figure combines images modified from (a) Lovering et al. (2008); and (b) Huang et al. (2012). 
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The authors proposed that the flap region prevented dissociation of the 
nascent glycan strand from the active site cleft, and the movement of the 
glycan strand would then position the newly added reducing end of the glycan 
chain into the active site to act as a donor for the next round of glycosyltransfer. 
 
The jaw subdomain was recently shown to bind a second molecule of 
moenomycin, in addition to that bound at the GT donor site, and with positive 
cooperativity between these two binding events (Punekar et al., 2018). Further 
structural analysis of the jaw subdomain by Punekar et al. (2018) suggested 
that the hydrophobic properties allowed positioning of the GT active site for 
optimal access to lipid substrate. 
 
1.4.1.2 Mechanism of glycosyltransfer 
Glycan chain synthesis extends from the reducing end of the polymer, with the 
4-OH of an incoming Lipid II acting as the acceptor for C1 of the donor polymer 
(Perlstein et al., 2007; Ward & Perkins, 1973; Weston et al., 1977). The 
mechanism of glycosyltransfer is illustrated in Figure 1.8b. The catalytic 
glutamate residue (motif I) deprotonates the 4-OH of the acceptor Lipid II, 
which can then react to form a b-1,4-glycosidic bond (Lovering et al., 2008). 
The release of undecaprenyl pyrophosphate from the donor is facilitated by 
interactions with a lysine (of motif II) and an arginine residue in the donor site. 
The polymeric product is shuttled to the donor site, and the catalytic cycle 
repeats with binding of a new acceptor Lipid II molecule.  
 
1.4.1.3 Non-PBP glycosyltransferases 
In addition to the GT activity of Class A PBPs, glycan polymer assembly by at 
least two further enzyme classes has been demonstrated. Monofunctional 
glycosyltransferase enzymes, which structurally resemble the GT domain of 
Class A PBPs, have been identified in bacteria including E. coli and S. aureus 
(Sauvage et al., 2008). In addition, activity of a monofunctional 
glycosyltransferase in pneumococcal membrane preparations has been 
identified (Park et al., 1985; Wang et al. 2001) demonstrated in vitro Lipid II 
polymerisation by MGT of S. aureus. 
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The identification of the shape, elongation, division and sporulation (SEDS) 
proteins constituted a major new discovery in cell wall biosynthesis. 
 
1.4.1.3.1 SEDS proteins 
The polymerisation of Lipid II had been thought to be wholly coordinated by 
PBPs. However, this was disputed by observations that bifunctional PBPs 
could be deleted in B. subtilis, with no resultant loss of viability or rod 
morphology (McPherson & Popham, 2003). The in vivo activity of the unknown 
GT was insensitive to moenomycin inhibition. The existence of an unidentified 
glycosyltransferase was similarly revealed in E. faecalis in the course of 
experiments designed to identify the glycosyltransferase partner of PBP5. 
Despite deletion of the three class A PBPs in E. faecalis, cells remained viable 
(Arbeloa et al., 2004). These observations were subsequently explained by 
the discovery of the GT activity of the SEDS proteins. 
 
The SEDS proteins are required for in vivo peptidoglycan synthesis 
(Henrichfreise et al., 2016), and were originally considered to function as Lipid 
II flippases (Mohammadi et al., 2011). The Rod complex of PG synthesis in 
Bacillus subtilis was shown to be active in mutants lacking the four Class A 
PBPs, and the SEDS protein RodA was identified as the unknown 
glycosyltransferase enzyme of the Rod complex (Meeske et al., 2016). RodA 
was further identified as the moenomycin-insensitive glycosyltransferase that 
conferred the intrinsic resistance of B. subtilis to moenomycin (Emami et al., 
2017). Glycosyltransferase activity by FtsW has also been demonstrated 





1.4.2 The penicillin-binding domain and transpeptidase activity 
The penicillin-binding domain comprises a five-stranded, antiparallel b-sheet 
surrounded by a-helices, with a1 and a11 on one side, opposite a8 on the 
other (Figure 1.9); this fold is broadly conserved among the Class A and B 
PBPs of a number of bacterial species (Macheboeuf et al., 2006).  
1.4.2.1 Mechanism 
Reactions catalysed by the penicillin binding domain include transpeptidation 
(TP) and D,D-carboxypeptidation (CP). TP and CP activities are catalysed by 
Class A and B PBPs, and proceed via a common mechanism (Sauvage et al., 
2008). The first step is the reversible formation of an Henri-Michaelis complex 
between the enzyme and the donor stem peptide; followed by nucleophilic 
attack at the carbonyl carbon of the N-terminal D-Ala of the D-Ala-D-Ala 
peptide by the active site serine side chain to form an acyl-enzyme 
intermediate, with release of D-Ala. Finally, deacylation releases the active 
site serine. The identity of the acceptor for deacylation forms the distinction 
between TP and CP activities. For transpeptidation, nucleophilic attack of the 
acyl-enzyme intermediate by the amine of an additional stem peptide acts as 
an acceptor, thus releasing the active site serine and forming a peptide bond 
(Terrak et al., 1999). By contrast, in CP activity the acceptor is water, and so 
the overall outcome of the reaction with the penicillin binding domain is 
hydrolytic removal of the terminal D-Ala to create a truncated stem peptide 
(Sauvage et al., 2008). Structural data on Class A PBPs has offered 
explanation for apparent transition between active and inactive states, alluded 
to by Macheboeuf et al. (2006). An apo crystal structure of S. pneumoniae 
PBP1b (Macheboeuf et al., 2005) revealed an apparent closed active site 
conformation. Comparison to the acyl-enzyme showed movement of the loop 
between b3 and b4. This movement resulted in blocking of the active site cleft 
by Asn656, with formation of a hydrogen bond with the Ala499 backbone. The 
catalytic serine was also in contact with b3 rather than the other catalytic 
residues of the penicillin binding domain. Acyl-enzyme structures obtained 
with nitrocefin and cefotaxime demonstrated a transition from the closed 
conformation, to an open conformation amenable to acylation by b-lactams. 
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Figure 1.9 Characteristic fold of the penicillin-binding domain. A crystal 
structure of S. pneumoniae PBP1a, with domain structure (a) and ribbon diagram 
(b) (with colouring to indicate domains as shown in (a)). The penicillin-binding 
domain is typified by a five-stranded antiparallel b-sheet, surrounded by two alpha 
helices opposite a third on the other side of the b-sheet.  
TM, transmembrane helix; GT, glycosyltransferase domain; TP, transpeptidase 
domain. 
Parts a) and b) reproduced from Figure 1, Contreras-Martel et al. (2006) © Journal 
of Molecular Biology. Part c) reproduced from Figure 2, Sauvage et al. (2008) © 


















1.4.2.2 Conserved residues of the transpeptidase active site 
There are 3 conserved motifs observed in the active site of D,D-
transpeptidases. These include the SXXK tetrad, encompassing the catalytic 
serine and a lysine residue that activates the serine; the SXN (or YSN in 
Streptomyces R61) motif; and the KTG(T/S) motif (Sauvage et al., 2008). The 
positioning of the transpeptidase donor stem peptide in the active site is such 
that the methyl group of the penultimate D-Ala is positioned in a hydrophobic 
pocket (Macheboeuf et al., 2006), and the carbonyl oxygen is positioned in the 
oxyanion hole. 
 
The conserved motifs of the transpeptidase active site participate in activation 
of nucleophiles for catalysis (Sauvage et al., 2008). Prior to acylation of the 
active site serine by the donor stem peptide, a proton is abstracted by the 
conserved Lysine residue of the SXXK motif. For deacylation, the Lysine 
residue of the third motif abstracts a proton from the acceptor, to confer upon 






Figure 1.10 Transpeptidase mechanism as represented in S. pneumoniae PBP1a. The PBP forms a Michaelis complex with a Lipid 
II substrate or its polymeric GT product. Attack by the active site serine on the carbonyl carbon of the subterminal D-alanine residue results in 
formation of an acyl enzyme intermediate, with associated release of the terminal D-Ala. In S. pneumoniae PBP1a, the active site serine is activated 
by deprotonation via the lysine residue of the SXXK motif (indicated in magenta). Deacylation occurs by nucleophilic attack of the acyl enzyme 
intermediate by an adjacent stem peptide, releasing the active site serine and forming a peptide bond between the two stem peptides. The identity 
of the acceptor (pink boxes) determines the outcome of deacylation. TP, transpeptidase; CP, D,D-carboxypeptidase; PG, peptidoglycan. 
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1.4.3 Lipoprotein activators of PBPs 
Lipoprotein activators have been identified for several Gram-negative, Class 
A PBPs. These activators were discovered on the basis of a transposon 
insertion screen exploiting the synthetic lethality of PBP1A and PBP1B in E. 
coli (Paradis-Bleau et al., 2010). LpoA and LpoB were found to be essential 
for the function of E. coli PBP1a and PBP1b respectively. The interaction of 
the cognate lipoprotein:PBP pairs was demonstrated to increase the rate of 
glycosyltransferase activity (Paradis-Bleau et al., 2010) and the extent of 
cross-linking (Typas et al., 2010) by each of the Class A PBPs. The synthetic 
lethal screen was subsequently used to identify LpoP, a lipoprotein activator 
of Pseudomonas aeruginosa PBP1b (Greene et al., 2018); and MacP, a 
phosphorylation-dependent protein activator of S. pneumoniae PBP2a 
(Fenton et al., 2018). 
 
1.5 Bacterial cell wall biosynthesis inhibitors  
The essentiality of cell wall biosynthesis makes it an attractive target for 
antibacterials. Inhibitors of enzymes throughout the three compartmentalised 
stages of peptidoglycan biosynthesis have been identified. These include 
binders of the PG precursor, such as the glycopeptides teicoplanin and 
vancomycin which bind the terminal D-Ala-D-Ala moiety of the stem peptide in 
Lipid II (Bugg et al., 2011); and substrate mimetics such as b-lactams and 
moenomycin, which inhibit transpeptidase and glycosyltransferase activities 
respectively (Schneider & Sahl, 2010). Bacitracin binds undecaprenyl 
pyrophosphate to prevent recycling of the lipid carrier (Winkelman & Gratton, 
1989). Agents targeting the cytoplasmic steps of PG biosynthesis include 
fosfomycin, which inhibits MurA (Kahan et al., 1974); and D-cycloserine, which 
inhibits both DdlB (Neuhaus & Lynch, 1964) and alanine racemase (Lambert 







Figure 1.11 Cell wall biosynthesis inhibitors. Cell wall active compounds include enzyme inhibitors, PG-cleaving enzymes and substrate 
binders. Inhibitors to all three stages (cytoplasmic, membrane-associated and lipid-linked) of peptidoglycan biosynthesis have been identified. 
PEP, phosphoenolpyruvate; L-X, L-Lys or meso-diaminopimelic acid (mDAP); GTases, glycosyltransferases; TPases, transpeptidases. 
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1.5.1 Mode of action of b-lactams 
β-lactam antibiotics inhibit peptidoglycan biosynthesis; the molecule acts as a 
structural mimetic of the terminal D-Ala-D-Ala moiety of the donor stem 
peptide in transpeptidation. The b-lactam acylates the active site serine of the 
transpeptidase, forming an acyl-enzyme intermediate. Although this 
intermediate can be hydrolysed to recover the enzyme, the rate of hydrolysis 
is vastly slower relative to the rate of cell division, as the bulky leaving group 
prevents access of water to the active site to release the b-lactam (Ghuysen, 
1991). The TP reaction is thus inhibited, weakening the structure of 
peptidoglycan due to the decreased extent of cross-linking, and culminating in 
cell lysis. 
Key benefits of b-lactams as antibiotics include their efficacy, specificity and 
the accessibility of the target (Wilke et al., 2005). However, the clinical use of 
this class of antibiotics is threatened by the development of resistance in a 
variety of important human pathogens. 
 
1.5.2 Resistance mechanisms to b-lactams 
Several key mechanisms of resistance to b-lactams are found among both 
Gram positive and Gram negative bacteria. As with other antibacterials, 
resistance mechanisms can be broadly categorised into drug modification, 
altered access to the target, and target modification. 
 
1.5.2.1 b-lactamases 
Evolutionarily linked to PBPs, the b-lactamases encompass 4 classes of 
enzymes which hydrolyse b-lactams (Poole, 2004). These can broadly be 
defined as serine b-lactamases and metallo-b-lactamases (MBLs) (which 
require divalent cations as cofactors) (Walsh et al., 2005). Predominantly 
Gram negative organisms express b-lactamases, and these enzymes can be 




Serine b-lactamase inhibitors have been used to restore the efficacy of b-
lactams through coadministration. For example, combination therapies such 
as co-amoxiclav, where the b-lactamase inhibitor clavulanic acid is 
coadministered with ampicillin, have restored clinical efficacy to the latter 
(Walsh et al., 2005). Development of MBL inhibitors offers additional 
challenges, such as the potential for cross-reactivity with mammalian 
enzymes, and the variation in active site structure between MBLs (Walsh et 
al., 2005). 
Deacylation of PBPs is 6 orders of magnitude slower than b-lactamases, and 
crucially, takes longer than the doubling time of the bacteria (Fisher et al., 
2005). In class A b-lactamases, Glu166 at the bottom of the active site cleft 
coordinates a water molecule, which may participate in a proton shuttle to 
deprotonate the catalytic serine; or may be activated to attack the acyl-enzyme 
to release bound b-lactam, thus accounting for the rapid deacylation step in 
such b-lactamases (Macheboeuf et al., 2006). 
 
1.5.2.2 Porins and efflux pumps 
Modulation of access to the periplasm is a key resistance mechanism in Gram-
negative bacteria in particular. Both plasmid and chromosomally encoded 
efflux mechanisms have been identified. Among the five classes of efflux 
pumps, examples of resistance-nodulation-division (RND) and ATP-binding 
cassette (ABC) transporters have been identified that mediate efflux of b-
lactam antibiotics (Poole, 2005). Clinical P. aeruginosa meropenem resistance 
has been linked to reduced expression of the outer membrane porin OprD, 
along with increased expression of the MexAB-OprM efflux pump (Köhler et 
al., 1999; Pai et al., 2001). 
 
1.5.2.3 Target modification 
In bacteria including S. pneumoniae (Dowson et al., 1989), S. aureus 
(Chambers, 1997) and Neisseria gonorrhoeae (Faruki & Sparling, 1986), 
resistance develops through modification of the PBPs such that affinity of the 
transpeptidase active site for b-lactams is decreased, whilst maintaining 
affinity for the natural substrate. In the case of pneumococci and N. 
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gonorrohoaea, this is a process of generation of mosaic PBP genes, through 
uptake and homologous recombination of exogenous DNA from oral 
streptococci (Dowson et al., 1993) and commensal Neisseria species (Bowler 
et al., 1992) respectively. The specific amino acid changes contributing to low 
affinity of streptococcal PBPs will be discussed in Chapter 4. 
 
Methicillin-resistant S. aureus (MRSA) strains acquire b-lactam resistance via 
intact acquisition of the mecA gene, encoding PBP2a. PBP2a has low b-
lactam affinity, and can therefore catalyse transpeptidation in the presence of 
inhibitor concentrations that would otherwise arrest growth. Lim and Strynadka 
(2002) concluded from structural data that decreased b-lactam susceptibility 
arose due to the reduced acylation rate of PBP2a, likely as a consequence of 
the aberrant positioning of the active-site serine (Ser403) for nucleophilic attack 
of the b-lactam. Significant conformational changes in the transition from 
Michaelis complex to acyl-enzyme were proposed to slow the acylation rate, 
whereas in comparison to the apo and acyl-enzyme structure for b-lactam 




Enterococci have been demonstrated to exhibit intrinsic low-susceptibility to 
penicillin. Enterococcus faecium expresses Ldtfm, an active site cysteine 
enzyme which catalyses L,D-transpeptidation (Mainardi et al., 2005) and 
confers high-level b-lactam resistance. The TP activity of Ldtfm was found to 
use a tetrapeptide donor stem (as generated by a D,D-carboxypeptidase), 
following which cross-linking was catalysed by this PBP between the a-
carbonyl of the Lysyl residue in the third position of the donor stem peptide 
(instead of the sub-terminal D-Ala), and the a-amino group of the D-
Asparaginyl moiety of the acceptor stem peptide (Mainardi et al., 2000). 
Crystallographic data revealed putative transpeptidase donor and acceptor 
binding sites comprising two paths accessing the buried pocket of the 
transpeptidase active site of Ldtfm (Biarrotte-Sorin et al., 2006). Due to the 
structural disparity between D,D-transpeptidases and L,D transpeptidases, b-
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lactams such as penicillins cannot inhibit the latter class of enzymes, although 
carbapenems are active against L,D transpeptidases (Ealand et al., 2018).  
1.6 Cell division in S. pneumoniae 
Peptidoglycan is built from Lipid II by several families of peptidoglycan 
synthases, which participate in multiprotein complexes. Site-specific insertion 
of new peptidoglycan is coordinated by proteins that recruit peptidoglycan 
synthases to defined locations around the cell envelope, thus effecting cell 
division and maintaining cell shape (Cabeen & Jacobs-Wagner, 2005). 
 
According to the two-site model of peptidoglycan biosynthesis in rod-shaped 
bacteria such as E. coli, synthesis of peptidoglycan was proposed to be 
coordinated by two separate machineries; the divisome, which creates the 
septum and divides the cell; and the elongasome, which lengthens the cell to 
maintain the rod shape of the sacculus (Lutkenhaus et al., 2012). FtsZ forms 
the Z ring, to which the proteins of the divisome localize (Adams & Errington, 
2009). The proteins of the divisome have been found to assemble at the 
septum in a defined order, with FtsZ leading, followed by FtsA, ZipA and ZapA 
to stabilise the Z ring; followed by further divisome proteins (Macheboeuf et 
al., 2006).  
 
Peptidoglycan hydrolase (autolysin) enzymes perform multiple functions 
including cleavage of existing peptidoglycan to enable insertion of new 
material; regulation of the thickness of the peptidoglycan layer; and effecting 
cell separation, by cleavage of glycoside and amide bonds (Vollmer, Joris, et 
al., 2008). In Gram negative organisms, soluble peptidoglycan fragments are 
recycled, whereas this phenomenon has not been observed (or occurs to a 
much lesser extent) in Gram positive bacteria (Park & Uehara, 2008). Insertion 
of newly synthesised peptidoglycan into the existing sacculus has been 
suggested to occur by the action of bifunctional synthases participating in 
enzyme complexes, with simultaneous polymerisation of glycans and 
attachment via transpeptidation (Typas et al., 2012). More recent models of 
peptidoglycan biosynthesis have proposed the leading action of hydrolases in 
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separating existing peptidoglycan for insertion of new material (H. Zhao et al., 
2017). 
 
1.6.1 Divisome organisation in S. pneumoniae 
Unlike the spatially separated divisome and elongasome complexes in rod-
shaped bacteria, the pneumococcal cell wall biosynthesis proteins have been 
observed to cluster around the division site (Pinho et al., 2013). It has been 
proposed that the elongasome in ovococci is responsible for synthesis of new 
peptidoglycan either side of the septum and between the equatorial rings. The 
cell is thus elongated and divided to create two daughter cells. Ovococci also 
differ from model rod-shaped bacteria in the division planes that are formed. 
In ovococci, two equatorial rings are first formed, and peripheral PG synthesis 
then lengthens the cell until these equatorial rings reach the distance for the 
midcell of the daughter cells to be formed. Septation then occurs to separate 
the daughter cells, culminating in cell division in parallel planes (Zapun et al., 
2008). 
 
S. pneumoniae has six PBPs; five HMM PBPs, of which three are bifunctional 
(PBP1a, PBP1b and PBP2a) and two monofunctional (PBP2b and PBP2x); 
and one low molecular mass (LMM) PBP (PBP3, a D,D-carboxypeptidase) 
(Sauvage et al., 2008). Among the bifunctional PBPs of S. pneumoniae, 
PBP1a and PBP2a form a synthetic lethal pairing (Hoskins et al., 1999; Paik 
et al., 1999). 
 
The role of pneumococcal Class A PBPs was recently called into question by 
the discovery of the SEDS proteins, and the findings of Straume et al. (2019). 
These authors found that the peptidoglycan hydrolase CbpD cleaved septal 
peptidoglycan synthesised by PBP2x, such that preferential inhibition of 
PBP2x using oxacillin was associated with a ‘resistant phase’ to CbpD culture 
lysis. The resistance to CbpD was reasoned to result from a Class A PBP-
catalysed remodelling of septal peptidoglycan, based upon the loss of 
resistance to CbpD when cultures were treated with moenomycin, which 
inhibits the glycosyltransferase activity of the Class A PBPs, but not of the 
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SEDS proteins. Though no structural modifications could be demonstrated to 
lead to the alteration in sensitivity as a consequence of Class A PBP activity, 
Straume et al. (2019) proposed that Class A PBPs were involved in creating a 
tightly interwoven mesh structure to create resistance to CbpD, building upon 
the PG structure generated by divisome synthases FtsW/PBP2x. 
 
1.6.2 Peptidoglycan structure in S. pneumoniae 
Species-specific modifications to the basic peptidoglycan structure are 
observed in pneumococci (Figure 1.12). As in several other species, the 
modifications found in pneumococcal peptidoglycan have important links to 
the b-lactam resistance mechanism. 
 
1.6.2.1 Amidation in Gram positives 
Amidation of the second position amino acid in the peptide stem (thus giving 
an isoglutamine at that position instead of glutamate) has been identified in 
the peptidoglycan of Gram positive organisms including S. pneumoniae, S. 
aureus and E. faecalis (Schleifer & Kandler, 1972). The introduction of this 
modification to the lipid substrate was demonstrated by Siewert and 




Figure 1.12 Additional stages in the peptidoglycan biosynthesis pathway of S. pneumoniae. Prior to the flipping of Lipid II the 
the extracytoplasmic face of the membrane by MurJ, two further modifications are made to Lipid II in pneumococci (yellow box). MurM and 
MurN catalyse addition of two further amino acids to the e-amino group of L-Lysine in the stem peptide, and the MurT/GatD complex catalyses 
amidation of the D-glutamate C1 carboxylate. The order of these additional steps is currently unconfirmed. Undecaprenyl phosphate recycling 




 enzyme preparations. The Lipid substrate was surmised to be the acceptor 
of ammonia, as amidated UDP-MurNAc pentapeptide was found to be a poor 
substrate for MraY (Siewert & Strominger, 1968). In addition, cell wall 
synthesis inhibitors including vancomycin, bacitracin and penicillin G did not 
impact the extent of formation of amidated muropeptides, suggesting overall 
that amidation occurred at the lipid-linked steps of peptidoglycan synthesis.  
 
The amidotransferase activity was identified by Munch et al. (2012) to be 
conferred in S. aureus by the enzyme complex MurT/GatD. The GatD 
amidotransferase uses L-glutamine as a nitrogen donor and transfers 
ammonia to the MurT active site, which catalyses the ATP-dependent 
amidation of the second position amino acid (Figure 1.13). The subsequently 
named murT/gatD locus was found to be a component of the b-lactam 
resistance mechanism on the basis of a phenotypic screen (Figueiredo et al., 
2012; Lee et al., 2011). Zapun et al. (2013) identified a comparable operon 
in S. pneumoniae strain R6, and demonstrated the essentiality of the 
encoded amidotransferase. The structure of the amidase complex in S. 
pneumoniae was published by Morlot et al. (2018). 
L-Glutamine is also used as a nitrogen donor by GlmS, which converts 
fructose-6-phosphate to glucosamine-6-phosphate in the reaction pathway 
that culminates in generation of UDP-GlcNAc (El Khoury et al., 2017). 
Downregulation of glutamine metabolism on treatment of S. pneumoniae 
cultures with penicillin has therefore been proposed to result from the 
accumulation of glutamine due to inactivity of the PG biosynthesis pathway 
(El Khoury et al., 2017). 
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Amidation has been suggested to play a role in determining the capacity of 
the cell wall to bind divalent cations, such that these can be stored and 
supplied for cellular function (Kern et al., 2010). NMR studies on B. subtilis 
peptidoglycan by Kern et al. (2010) found that the carboxyl groups of D-Glu 
and meso-DAP residues in the peptide stem mediated binding of Mg2+ by 
peptidoglycan to form an intermolecular complex with teichoic acids. 
Amidation of meso-DAP in B. subtilis has been considered to be responsive 
Figure 1.13 MurT/GatD amidase complex of S. aureus and S. 
pneumoniae. Amidation of the a-carboxylate of the stem peptide D-Glu residue is 
catalysed by the MurT/GatD complex, using L-glutamine as an amide donor, and 
ATP to activate the stem peptide Glu-carboxylate. The GatD subunit converts L-
glutamine to L-glutamate and ammonia. Ammonia is then transferred to the MurT 
active site, for catalysis of ATP-dependent amidation. Lipid II (iGln), Lipid II with g-
D-isoglutamine at the second position of the peptide stem. 




to growth conditions, and so Kern et al. (2010) suggested that this 
modification could be involved in allowing the supply of metal ions to be tuned 
to the needs of the cell.  
  
1.6.2.2 Branched muropeptides 
A second modification observed in pneumococcal PG is the linkage of 
additional amino acid residues to the e-amino group of the lysyl residue of the 
stem peptide, yielding branched stem peptides (Severin & Tomasz, 1996; 
Filipe & Tomasz, 2000). When incorporated into peptidoglycan, these 
branched precursors generate indirect cross-links (consisting of L-Ser-L-Ala 
or L-Ala-L-Ala) in the PG structure (Garcia-Bustos et al., 1987). Indirect cross 
linking has also been identified in Gram-positive bacteria including S. aureus 
and E. faecalis (Schleifer & Kandler, 1972; Vollmer, Blanot, et al., 2008) 
(Figure 1.14). The composition of indirect cross links is considered a species-
level characteristic, according to the diverse interpeptide bridges identified in 
other streptococci (Schleifer & Kandler, 1972). 
The glycyl side chain on Lipid II in S. aureus is an essential part of the 
peptidoglycan precursor. FemX, the enzyme responsible for addition of the 
first glycine, is an essential protein, and depletion of FemX protein decreases 
the extent of cross linking and also sensitises the strain to methicillin (Rohrer 
Figure 1.14 Branched muropeptides in Gram positive pathogens. The 
interpeptide bridge of S. pneumoniae is L-X-L-Ala, where X is L-Ala or L-Ser; in E. 
faecalis is L-Ala-L-Ala; and in S. aureus is an invariant pentaglycyl bridge.  
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et al., 1999). By contrast, in pneumococci the extent and composition of 
indirect cross linking is variable between pneumococcal strains (Severin & 
Tomasz, 1996), in a manner shown to be dependent on the particular allele 
of MurM present (Filipe et al., 2000; Filipe et al., 2001). Whilst the MurMN 
operon is non-essential (Filipe & Tomasz, 2000), branching of muropeptides 
is, similarly to S. aureus, linked to b-lactam resistance. Both MurMN (Lloyd 
et al., 2008) and FemXAB (Schneider et al., 2004) have been demonstrated 
to use Lipid II and tRNAs as their substrates (Lloyd et al., 2008; Schneider et 
al., 2004). Homologues of these proteins in other organisms generate indirect 
cross-linking in the peptidoglycan structure, such as BppA1 and BppA2 in 
Enterococcus faecalis (generating an L-Ala-L-Ala cross-link) (Bouhss et al., 
2001; Bouhss et al., 2002). 
Whilst the physiological role of branched muropeptides in pneumococci has 
not been confirmed, Greene et al. (2015) demonstrated that the extent of 
branching has been shown to impact the PG hydrolase-dependent release of 
pneumolysin.  
 
1.6.3 Pneumococcal b-lactam resistance 
In the case of S. pneumoniae, high-level resistance to β-lactams involves 
both alteration of PBPs by homologous recombination, producing enzymes 
with decreased affinity for the antibiotic; and production of branched 
peptidoglycan intermediates.  
In order for pneumococci to develop resistance to penicillin, amino acid 
alterations conferring low affinity to β-lactams on three of the six penicillin-
binding proteins – PBP1a (a bifunctional class A PBP); and PBP2x and 
PBP2b (both of which are monofunctional class B PBPs) are required 
(Hakenbeck et al., 1999, Goffin and Ghuysen, 2002). This process is enabled 
by the natural genetic competence of pneumococci (Hakenbeck et al., 1999). 
Transformation of pneumococci by exogeneous DNA in the pharynx has 
been experimentally demonstrated (Ottolenghi-Nightingale, 1972), and 
longitudinal study of pneumococcal isolates has also indicated that multiple 
horizontal gene transfer events occur between strains (Hiller et al., 2010). 
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Particular low-affinity variants have arisen by homologous recombination of 
PBP alleles (Dowson et al., 1989), utilising exogenous DNA from related 
species such as Streptococcus mitis which the pneumococcus encounters 
within the oropharynx (Dowson et al., 1993, Dowson et al., 1994; Reichmann 
et al., 1997; Chi et al., 2007). Within the recombined blocks, particular 
mutations confer the b-lactam resistance phenotype. A genome-wide 
association study using large datasets of genome sequence and resistance 
phenotype from American and Thai pneumococcal isolates identified a 
common set of 71 non-synonymous single-nucleotide polymorphisms 
(SNPs), many within linkage blocks, associated with b-lactam non-
susceptibility (Chewapreecha et al., 2014). Amino acid changes were 
identified within the GT, TP and PASTA domains (as applicable) of each 
resistance-linked PBP, and those in the TP domain included previously-
identified, phenotype-linked changes such as the T574SQF to N574TGY. In 
addition, amino acid alterations were identified in genes including ciaH, 
encoding a histidine kinase sensor; and gpsB, a cell cycle protein. The 
biochemical impact of particular amino acid alterations in pneumococcal 
PBP1a is discussed in Section 4.1.3. 
The combination of asymptomatic carriage of pneumococci, and the selective 
pressure of b-lactam treatment, has likely contributed to the emergence of 
resistant pneumococcal clones (Dagan et al., 1998). Nasopharyngeal 
colonisation in children with penicillin-resistant streptococci has been 
reported (Farber et al., 1983; Yagupsky et al., 1998; Leiberman et al., 1999; 
Petrosillo et al., 2002), which may act as a reservoir for progression to 
invasive pneumococcal disease (Gray et al., 1980). In addition, treatment 
with b-lactams has been associated with selection of penicillin non-
susceptible pneumococci in the nasopharyngeal flora (Dagan et al., 1998; 
Yagupsky et al., 1998). 
Branched muropeptides are found in β-lactam-susceptible pneumococci, as 
a result of the activity of MurM and MurN. However, it has been found that 
the extent of peptidoglycan indirect interpeptide cross-linking generally 
increases in pneumococcal strains with decreased β-lactam susceptibility 
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(Garcia-Bustos & Tomasz, 1990), with the exception of the laboratory strain 
R6, which is an example of a penicillin-susceptible strain with a high degree 
of indirect cross linking (Smith & Klugman, 2000). In addition, the ability to 
synthesise branched muropeptides has been demonstrated to be an 
essential β-lactam resistance determinant in pneumococci; in knockout 
mutants of the MurMN operon, there is an increase in susceptibility to β-
lactam antibiotics, as measured by minimal inhibitory concentrations (MIC) 
(Filipe & Tomasz, 2000; Smith & Klugman, 2000).  
Based on the association of cross-linking and b-lactam resistance, J. Garcia-
Bustos and Tomasz (1990) proposed that the active site remodelling that 
caused decreased affinity for penicillin was responsible for a shift in substrate 
preference for branched muropeptides. Filipe and Tomasz (2000) further 
suggested that branching of muropeptides was beneficial in competition for 




1.7 Aims of this thesis 
Whilst the link between the requirement for both PBP modification and 
branched muropeptides in the pneumococcal b-lactam resistance 
mechanism has been well documented, it has not been possible to confirm 
the suspected mechanistic basis for the link between these two factors, due 
to challenges in obtaining the natural substrates. We aim to address the 
hypothesis that branching of precursors is beneficial for competition against 
b-lactams, by the use of a chemo-enzymatic synthesis of branched 
pneumococcal Lipid II variants, and the development of an in vitro assay for 
transpeptidase activity of pneumococcal PBP1a. 
In order to demonstrate the impact of factors such as branching on the usage 
of Lipid II substrates as transpeptidase substrates, we must also analyse the 
impact upon glycosyltransferase activity of PBP1a. We therefore also aim to 
further characterise the GT activity of PBP1a under the conditions used for 
assays of TP activity. 
Finally, key environmental factors such as the lipid environment of the 
enzymes could provide further links between MurMN and PBPs. An 
increasing body of evidence suggests that lipid environment, and particularly 
interaction with cardiolipin, impacts the activity of the enzymes of the 
peptidoglycan biosynthesis pathway. Of particular interest is the stimulation 
of pneumococcal MurM by cardiolipin (Dr. A.J. Lloyd, University of Warwick, 
unpublished). We therefore sought to compare previous observations of the 




Chapter 2: Materials and Methods 
 
2.1 Chemicals, Buffers and Solutions 
 
Chemicals were supplied by Sigma-Aldrich (UK) or Fisher Scientific (UK) 
unless otherwise stated. Buffers and solutions were prepared using MilliQ 
purified water, and filtered using a 0.22 µm MF-Millipore Membrane Filter 
(Merck). Buffer solutions were adjusted to the correct pH with use of a 
SevenEasy pH meter (Mettler Toledo), which was calibrated at ambient 
temperature with pH 4.0, 7.0 and 10.01 buffer standards. 
 
2.2 Growth and Maintenance of Escherichia coli strains 
 
2.2.1 Growth Media 
The following growth media were used throughout this project. All media were 
sterilised by autoclaving at 121 ˚C for 20 minutes (mins). Antibiotic selection 
was with 100 µg.mL-1 ampicillin, 50 µg.mL-1 kanamycin or 35 µg.mL-1 
chloramphenicol. Agar plates were cooled and dried in a flow cabinet, and 
stored at   4 ˚C. Media containing glucose were made up and sterilised by 
autoclaving without the glucose, and glucose was then added from a separate 
autoclaved stock solution, to prevent charring. 
 
2.2.1.1 Lysogeny broth (LB) medium (Bertani, 1951) 
LB medium consisted of 1 % (w/v) tryptone, 0.5 % (w/v) sodium chloride, 0.5 
% (w/v) yeast extract. 
 
2.2.1.2 LB agar plates 
LB medium with 1.5 % (w/v) bacto-agar was sterilized by autoclaving at 121 
˚C for 20 mins. The solution was cooled to 50 ˚C, the appropriate antibiotics 




2.2.1.3 ZY medium (Studier, 2005) 
The medium was composed of 1 % (w/v) N-Z amine, 0.5 % (w/v) yeast extract. 
 
2.2.1.4 Autoinduction medium (ZYP-5052) (Studier, 2005) 
ZYP-5052 comprised ZY medium; 1 x NPS (25 mM ammonium sulfate, 50 mM 
potassium dihydrogen phosphate, 50 mM disodium hydrogen phosphate); and 
1 x 5052 (0.5 % (v/v) glycerol, 0.05 % (w/v) D-glucose, 0.2 % (w/v) a-lactose); 
1 mM magnesium sulfate. Components of the medium were mixed from 
autoclave-sterilised stock solutions. 
 
2.2.1.5 Super Optimal broth with Catabolite repression (SOC) outgrowth 
medium 
The medium was composed of 2 % (v/v) peptone, 0.5 % (w/v) yeast extract, 
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose. 
 
2.2.1.6 Tryptic soy broth (TSB) 
The medium was composed of 17 g.L-1 casein peptone (pancreatic), 2.5 g.L-1 
dipotassium hydrogen phosphate, 2.5 g.L-1 glucose, 5 g.L-1 NaCl, 3 g.L-1 soya 
peptone. 
 
2.2.1.7 TSB agar plates 
TSB medium with 1.5 % (w/v) bacto-agar was sterilized by autoclaving. The 
solution was cooled to 50 ˚C and plates prepared by pouring 25 mL per sterile 
Petri dish.  
 
2.2.1.8 Blood agar plates 
Nutrient agar was sterilized by autoclaving, cooled to 50 ˚C and 5 % (v/v) 
defibrinated horse blood was added. Plates were prepared by pouring 25 mL 




2.2.1.9 Cation-adjusted Mueller-Hinton Broth (Mueller et al., 1941) 
The medium was composed of 17.5 g.L-1 casein acid hydrolysate, 3.0 g.L-1 
beef extract, 1.5 g.L-1 starch, 20-25 mg.L-1 Ca2+ and 10-12.5 mg.L-1 Mg2+ 
(both from chloride salts), pH 7.3. 
 
2.2.2 Bacterial Strains 
The strains used for DNA procedures and over-expression of proteins are 
given in Table 2.1. 
 
Table 2.1 E. coli strains used for DNA manipulation and protein over-
expression 
 







fhuA2 Δ(argF-lacZ)U169 phoA 
glnV44 Φ80Δ (lacZ)M15 gyrA96 




(Studier & Moffatt, 
1986) 








F– ompT hsdSB (rB–, mB–) gal 
dcm (DE3) and pRosetta to supply 




2.2.3 Preparation of Chemically Competent Cells for DNA Transformation 
An overnight culture was prepared by inoculating 5 mL sterile LB medium 
(Section 2.2.1.1), plus appropriate antibiotic selection, with the required E. coli 
strain. The culture was incubated at 37 ˚C overnight with shaking at 180 rpm. 
2.5 mL of the overnight culture was then used to inoculate 250 mL of sterile 
LB medium plus antibiotic selection and 20 mM MgSO4. The 250 mL culture 
was incubated at 37 ˚C with shaking at 180 rpm. When the optical density 
(OD600nm, absorbance at 600 nm) was in the range 0.4 – 0.6, the culture was 
 
 45 
harvested by centrifugation at 4500 x g for 10 mins. The cells were washed by 
gentle resuspension in 100 mL ice cold TFB1 buffer (30 mM potassium 
acetate, 10 mM calcium chloride, 50 mM manganese chloride, 100 mM 
rubidium chloride, 15 % (v/v) glycerol, pH 5.8) and the suspension was 
incubated for 5 mins on ice, and then pelleted by centrifugation as before. The 
pellet was resuspended in 10 mL TFB2 buffer (10 mM MOPS pH 6.5, 75 mM 
calcium chloride, 10 mM rubidium chloride, 15 % (v/v) glycerol) and incubated 
on ice for 1 hour (h). Competent cells were stored in 50 µL aliquots flash-frozen 
in liquid nitrogen and subsequently stored at -80 ˚C. 
 
2.2.4 DNA Transformation of E. coli strains 
50 µL aliquots of competent cells were thawed on ice and then incubated with 
2 µL of plasmid stock containing 50 - 100 ng of plasmid DNA for 30 mins on 
ice. The cells were then heat-shocked at 42 ˚C for 30 seconds (sec), and then 
returned to ice for 5 minutes (mins). Outgrowth was performed by addition of 
950 µL SOC medium (Section 2.2.1.5), with incubation at 37 ˚C for 1 h with 
shaking at 180 rpm. 100 µL of the culture was then spread on an LB agar plate 
with the appropriate antibiotic selection, and incubated overnight at 37 ˚C. 
 
2.3 DNA Manipulation and Cloning Techniques 
 
2.3.1 Oligonucleotides 
Oligonucleotides for cloning (Table 2.2) and for sequencing of vectors (Table 
2.3) were purchased from Integrated DNA Technologies (Belgium). 
 
2.3.2 Polymerase Chain Reaction (PCR) 
PCR amplification (Mullis et al., 1986) for cloning procedures was completed 
using Phusion High-Fidelity DNA polymerase (NEB) in accordance with the 
manufacturer’s instructions, with use of a SureCycler 8800 thermocycler 
(Agilent Technologies). Annealing temperatures were determined using the 




2.3.3 Agarose gel electrophoresis 
1 % (w/v) agarose gels were used for separation of DNA fragments. 1 g 
agarose (Cleaver Scientific) per 100 mL 1 x TAE buffer (Tris-acetate EDTA: 
40 mM Tris pH 8.3, 20 mM acetic acid, 1 mM EDTA) was dissolved by heating 
in a microwave. The solution was cooled to approximately 50 ˚C before 
addition of 10 µL GelRed stain (Biotium), and the solution was then poured 
into a gel cast to set. The gel was submerged in 1 x TAE buffer in a MultiSUB 
Midi Horizontal Gel System (Cleaver Scientific). 6 µL samples were made up 
in 1 x DNA Gel Loading Dye (NEB) and loaded into the wells. 5 µL of 1 kb or 
100 bp DNA ladder (NEB) as appropriate were loaded as a size reference for 
sample lanes. Electrophoresis was conducted at 100 V for 1 h, and gels were 
visualised under ultraviolet light using a GeneSnap G:Box gel illuminator 
(Syngene). 
 
2.3.4 Gel Extraction of PCR products 
PCR products were purified following agarose gel electrophoresis using the 






2.3.5 Cloning by Gibson Assembly 
Primers for cloning by Gibson Assembly (Gibson et al., 2009) were designed 
using the NEBuilder Assembly Tool (Version 1.12.13). Phusion High-Fidelity 
DNA polymerase (NEB, USA) was used (as previously described) for 
amplification of the target gene and linearization of the plasmid (see Table 2.2 
for primer sequences). The NEBuilder HiFi DNA Assembly Cloning Kit (NEB, 
USA) was then used in accordance with the manufacturer’s instructions for the 
assembly reaction, following which the ligated construct was transformed into 
NEB 5-alpha competent cells.  
 
Table 2.2 Oligonucleotide primers used in cloning by Gibson Assembly 
 


















2.3.6 Preparation of plasmid DNA 
NEB 5-alpha competent cells were transformed with the required plasmid 
(Section 2.2.4). 5 mL overnight cultures in LB medium with the appropriate 
antibiotic selection were inoculated with a single colony from the 
transformation plate. Overnight cultures were incubated at 37 ˚C with shaking 
at 180 rpm. Cells were pelleted by centrifugation at 1,800 x g for 10 mins 
(Eppendorf Centrifuge 5810R). Plasmid DNA was then purified using the 





2.3.7 Quantification of DNA 
DNA samples were quantified by absorbance at 260nm using an N60 
Nanophotometer (Implen), with the appropriate buffer as a blank. 
 
2.3.8 DNA sequencing of constructs 
Sanger sequencing, conducted by GATC Biotech (Germany), was used to 
confirm that inserts in plasmid constructs were in frame with the affinity tag, 
and that there were no PCR-induced mutations. Samples consisted of 500 ng 
plasmid DNA and 5 pmol.µL-1 of the relevant sequencing primer (Table 2.3). 
The quality of sequence reads (as shown by sequence chromatograms) was 
analysed using SnapGene Viewer (GSL Biotech LLC), and the clipped 
sequence read was translated using the ExPASy Translate tool (Artimo et al., 
2012). The translated sequence reads were then aligned to the desired 
construct amino acid sequence using the Clustal Omega Multiple Sequence 
Alignment program (Sievers et al., 2011), to confirm the sequence of the vector 






Table 2.3. Oligonucleotide primers used for sequencing of vectors for 
PBP1a expression 
 
Primer Sequence (5’-3’) 
T7 promoter TAATACGACTCACTATAGGG 
















2.3.9 Protein expression constructs used in this project 
Details of the constructs used, and the source of each, are given in Table 2.4. 
Table 2.4. Protein expression constructs used in this project 
 
Construct Description (strain of origin) Selection Source Expression cell 
line 






As above, but with mutation of the active site 
serine to alanine – S370A 
Ampicillin K. Abrahams 
(Warwick) 
pET46a::pbpa_Pn16 N-ter. His12-tagged PBP1a (S. pneumoniae 
Pn16) 
Ampicillin Cloned for this project 
pET46a::pbpa_159 N-ter. His12-tagged PBP1a (S. pneumoniae 159) Ampicillin Cloned for this project 
pET30::pbp2a Untagged PBP2a (S. pneumoniae D39) Kanamycin A. Zapun (Grenoble) 
pET28::MurA C-ter. His6-tagged MurA (E. coli) Kanamycin El Zoeiby et al. (2001) BL21 (DE3) 
pET26a::MurB C-ter. His6-tagged MurB (Pseudomonas 
aeruginosa PAO1293) 
Kanamycin El Zoeiby et al. (2001) 
BL21 (DE3) 
pRosetta 
pET30a::MurC C-ter. His6-tagged MurC (P. aeruginosa PAO1) Kanamycin El Zoeiby et al. (2000) 
pET21b::MurD C-ter. His6-tagged MurD (P. aeruginosa 
PAO1293) 
Ampicillin El Zoeiby et al. (2001) 
pET21b::MurE C-ter. His6-tagged MurE (S. pneumoniae Pn16) Ampicillin Blewett et al. (2004) 
pPROEX-HTa::MurF N-ter. His6-tagged MurF (S. pneumoniae 159) Ampicillin Lloyd et al. (2008) 
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2.4 Expression and Purification of Recombinant Proteins 
Expression and purification of PBP1a constructs was conducted as described 
by Zapun et al. (2013), unless otherwise stated. Expression and purification of 
MurA-F was as described by Lloyd et al. (2008). MurG, IDH, and DacB 
proteins used in this project were kindly provided by Julie Tod and Anita 
Catherwood (University of Warwick).  
 
High-speed centrifugation steps used a Beckman Coulter AvantiÔ J-20 XPI 
centrifuge, and ultracentrifugation steps used a Beckman Coulter Optima L-
90K ultracentrifuge. Both were run at 4 ˚C. 
 
Purification columns were washed in 10 column volumes (CV) of water 
followed by equilibration with 10 CV of the appropriate wash buffer. For 
immobilised metal affinity chromatography (IMAC), the resin was washed 
following sample loading with 10 CV of wash buffer, to remove unbound 
protein (with collection of the flow-through). At completion of the purification 
procedure, all columns or resins were washed with 10 CV water and 10 CV 20 
% (v/v) ethanol, and stored at 4 ˚C. 
 
2.4.1 Expression by autoinduction 
All PBP1a constructs were expressed by autoinduction, as described by 
Studier (2005). Overnight cultures in 2 mL ZYP-0.8G medium (ZY medium, 1 
mM MgSO4, 0.8 % (w/v) glucose, 1 x NPS) with ampicillin and chloramphenicol 
selection were inoculated with a single colony from a fresh transformation. 
Overnight cultures were incubated at 37 ˚C with shaking at 180 rpm. 1 mL of 
overnight culture was used to inoculate 1 L autoinduction medium (Section 
2.2.1.4) plus antibiotic selection. Cultures were incubated at 25 ̊ C for 22 h with 
shaking at 180 rpm. Cells were harvested at 10,000 x g for 20 mins and the 
pellet stored at -80 ˚C. 
 
2.4.2 Expression by Isopropyl-b-D-thiogalactopyranoside (IPTG) induction 
MurA-F and PBP2a were expressed by IPTG induction. 10 mL overnight 
cultures in LB medium plus antibiotic selection were inoculated with a single 
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colony from a fresh transformation. Overnight cultures were incubated at 37 
˚C with shaking at 180 rpm. The entire overnight culture was used to inoculate 
1 L LB medium plus 0.8 % (w/v) glucose and antibiotic selection. Cultures were 
incubated at 37 ˚C with shaking at 180 rpm. Cultures were induced with 1 mM 
IPTG. Cultures expressing MurA-F were induced at an OD600nm of 0.6 and 
incubated at 25 ̊ C, with shaking at 180 rpm, for 4 h before harvesting. Cultures 
expressing PBP2a were induced at an OD600nm of 2.0 and incubated overnight 
with shaking at 180 rpm. Cells were harvested at 10 000 x g for 20 mins and 
the pellet stored at -80 ˚C. 
 
2.4.3 Purification of N-ter. His12-PBP1a 
 
2.4.3.1 Preparation of membranes containing N-ter. His12-PBP1a 
Cell pellets were thawed on ice and resuspended in 3 mL.g-1 cell weight of 
cold phosphate buffered saline (PBS), 20 µg.mL-1 DNase and 1 mM MgCl2. 
The cell suspension was incubated with agitation at 4 ˚C for 1 h. Cells were 
then lysed by passing twice through a continuous cell disrupter (Constant Cell 
Disruption Systems) at 28 kpsi at 4 ˚C. Cell debris was pelleted by two 
consecutive centrifugation steps at 24,000 x g for 12 mins at 4 ˚C. Membranes 
were then pelleted by ultracentrifugation at 150,000 x g for 1 h at 4 ˚C. The 
membrane pellet was resuspended in 10 mL of cold phosphate buffered saline 
(PBS, pH 7.4) per litre of original culture using a glass homogeniser (Scientific 
Laboratory Supplies) and stored at -20 ˚C overnight.  
 
2.4.3.2 Solubilisation of N-ter. His12-PBP1a 
The suspension was thawed on ice, and sodium deoxycholate added to a 1 % 
(w/v) final concentration to solubilise membrane proteins. This step was 
carried out with incubation at 4 ˚C for 3 h with agitation. The suspension was 
then diluted 7-fold into cold PBS with 0.1 % (w/v) N-dodecyl b-D-maltoside 
(DDM), and insoluble material was pelleted by ultracentrifugation at 150,000 x 




2.4.3.3 Immobilised metal affinity chromatography (IMAC) purification 
The supernatant from Section 2.4.3.2 was incubated for 3 h at 4 ˚C with 5 mL 
of TALON Metal Affinity Resin (Clontech) pre-equilibrated in 10 CV Buffer A 
(PBS with 0.1 % (w/v) DDM and 150 mM NaCl). The resin suspension was 
poured into an Econo-Pac Chromatography Column (BioRad) to form a 
column, and the unbound material washed from the resin in Buffer A, 
developed by gravity flow. The purification was then conducted by stepwise 
elution in PBS with 0.1% (w/v) DDM and 150 mM NaCl plus the relevant 
concentration of imidazole. The elution steps were 100 mL of 15mM imidazole, 
collected as 10 mL fractions; 50 mL of 50 mM imidazole, collected as 5 mL 
fractions; and 50 mL of 250 mM imidazole, collected as 5 mL fractions. 
 
2.4.3.4 Gel filtration and final storage 
Fractions containing PBP1a (as determined by sodium dodecyl sulfate -
polyacrylamide gel electrophoresis (SDS-PAGE), Section 2.5.1) were pooled 
and concentrated to 20 mg.mL-1 (see protein concentration determination 
Section 2.5.2.1) using a 20 mL Vivaspin 100 kDa molecular weight cut-off 
(MWCO) centrifugal concentrator (Sartorius) at 3,000 x g at 4 ˚C in a bench-
top centrifuge (Eppendorf Centrifuge 5810R). 500 µL samples were purified 
by gel filtration using a Superose 6 10/300 GL column (GE Healthcare) pre-
equilibrated in 1.5 CV 20 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic 
acid (HEPES) pH 7.5, 150 mM NaCl and 0.03 % (w/v) DDM, on an AKTA 
10/100 system (GE Healthcare) in a cold cabinet at 4 ˚C. The column was 
developed in 1 CV of the same buffer at 0.4 mL.min-1, with collection of 0.5 mL 
fractions. Protein elution was followed by absorbance at 280 nm, and fractions 
containing PBP1a at high purity (as determined by SDS-PAGE) were pooled 
and concentrated to 16 mg.mL-1 using a 100 kDa MWCO centrifugal 
concentrator (as previous). Stocks were then diluted with equal volume 100 % 
glycerol to give a final stock at 8 mg.mL-1 in 10 mM HEPES pH 7.5, 75 mM 
NaCl, 0.015 % (w/v) DDM and 50 % (v/v) glycerol. Aliquots of protein were 




2.4.4 Purification of MurA-F 
Frozen cell pellets were thawed on ice and resuspended in 3 mL.g-1 cell weight 
of resuspension buffer (50 mM HEPES pH 7.5, 1 mM MgCl2, 2 mM b-
mercaptoethanol, 2.5 mg.mL-1 lysozyme, 1 µM pepstatin, 1 µM leupeptin and 
0.2 mM phenylmethane sulfonyl fluoride (PMSF)). Following incubation at 4 ˚C 
for 10 mins, cells were lysed by sonication on ice using a Bandelin Sonoplus 
sonicator, with 10 bursts of 15 sec at 70 % power. Cell debris was pelleted by 
centrifugation at 10,000 x g for 15 mins, and the supernatant clarified by a 
further centrifugation step at 50,000 x g for 45 mins. The supernatant was 
loaded to a 5 mL HisTrap HP (GE Healthcare) IMAC column at 2 mL.min-1 
using a P-1 peristaltic pump (Pharmacia Biotech). The column was then 
connected to an AKTA Pure system (GE Healthcare) and washed with 10 CV 
Buffer A (50 mM HEPES pH 7.5, 1 mM MgCl2, 500 mM NaCl, 5 % (v/v) 
glycerol, 10 mM imidazole, 1 µM pepstatin, 1 µM leupeptin and 0.2 mM PMSF) 
at 3 mL.min-1 to remove unbound material. The column was then developed 
over a linear gradient of 10 mM to 1 M imidazole (100 % Buffer A to 100 % 
Buffer B. Buffer B: 50 mM HEPES pH 7.5, 1 mM MgCl2, 500 mM NaCl, 5 % 
(v/v) glycerol, 1M imidazole, 1 µM pepstatin, 1 µM leupeptin and 0.2 mM 
PMSF) over 40 mins, with collection of 5 mL fractions. The A280nm was 
continuously monitored to identify protein peaks eluted from the column. 
Fractions were analysed by SDS-PAGE, and those containing the protein of 
interest were dialysed into 50 mM HEPES pH 7.5, 1 mM MgCl2, 50 mM NaCl, 
3 mM DTT, 50 % (v/v) glycerol, 1 µM pepstatin, 1 µM leupeptin and 0.2 mM 
PMSF, overnight at 4 ̊ C (dialysis tubing: 15.9 mm diameter, 12-14 kDa MWCO 
(Medicell International)). Protein stocks were then quantified by BioRad assay 
(Section 2.5.2.2) and stored as aliquots at -80 ˚C. 
 
2.4.5 Purification of untagged S. pneumoniae PBP2a 
 
2.4.5.1 Isolation of solubilised membrane proteins 
PBP2a was purified based upon the method described in Helassa et al. (2012) 
with modifications. Cell pellets were thawed on ice and resuspended in 40 
mL.L-1 original culture of resuspension buffer (50 mM HEPES pH 7.5, 100 mM 
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NaCl, 10 mM MgCl2, 20 µg.mL-1 DNase and one cOmplete Protease Inhibitor 
Cocktail tablet (Roche)). The cell suspension was incubated at 4 ˚C with 
agitation for 10 mins, followed by lysis by passage twice through a continuous 
cell disrupter (Constant Cell Disruption Systems) at 28 kpsi at 4 ˚C. Membrane 
proteins were solubilised by addition of 1 % (w/v) Triton X-100, with incubation 
at 4 ˚C with agitation for 2 h. Insoluble material was then pelleted by 
centrifugation at 20,000 x g for 30 mins at 4 ˚C. 
 
2.4.5.2 Purification of PBP2a by cation and anion exchange chromatography 
A 5 mL HiTrap SP HP cation exchange column (GE Healthcare) was washed 
with 10 CV water, 10 CV cation-Buffer BPBP2a (50 mM Tris pH 8.0, 10 mM 
MgCl2, 0.2 % (w/v) Triton X-100, 1 M NaCl) and finally equilibrated in cation-
Buffer APBP2a (50 mM Tris pH 8.0, 10 mM MgCl2, 0.2 % (w/v) Triton X-100). 
The membrane suspension was then loaded to the column at 3 mL.min-1 via 
a 150 mL Superloop (GE Healthcare) on an AKTA 10/100 system (GE 
Healthcare) in a cold cabinet at 4 ˚C. The column was developed at the same 
flow rate on a gradient from 0 – 1 M NaCl (in the buffers previously described) 
over 10 CV, with collection of 2.5 mL fractions. Elution of protein was followed 
by A280nm. Fractions containing PBP2a (as determined by SDS-PAGE) were 
diluted 10-fold for loading to a 6 mL RESOURCE Q anion exchange column 
(GE Healthcare). The column was prepared as described for the cation 
exchange column, though with alternative buffers (anion-Buffer APBP2a: 50 mM 
HEPES pH 7.5, 10 mM MgCl2, 0.2 % (w/v) Triton X-100, cation-Buffer BPBP2a: 
Buffer A plus 1 M NaCl). The sample was loaded as described previously, and 
the column developed using a linear gradient from 0 – 100 % cation-Buffer 
BPBP2a (in the buffers previously described) over 10 CV at a flow rate of 6 
mL.min-1, with collection of 1 mL fractions. Fractions containing PBP2a (as 
determined by SDS-PAGE) were concentrated using a 20 mL Vivaspin 50 kDa 
molecular weight cut-off (MWCO) centrifugal concentrator (Sartorius) at 3000 
x g in a bench-top centrifuge (Eppendorf Centrifuge 5810R). Stocks of PBP2a 





2.5 Analysis of purified recombinant proteins 
 
2.5.1 Sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-
PAGE) 
Protein samples were visualised under denaturing conditions by sodium 
dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) in a 
discontinuous Tris-glycine buffer system (Laemmli, 1970). Protein samples 
were mixed with 1 x protein loading dye (6 x stock contained 63.5 mM Tris pH 
6.8, 0.4 % (w/v) sodium dodecyl sulfate (SDS), 5 % (v/v) b-mercaptoethanol, 
20 % (v/v) glycerol and 2.5 % (w/v) bromophenol blue) and heat-denatured at 
60 ˚C for 10 mins using an Aviso Mechatronic Systems Primus thermocycler. 
12 % acrylamide:bis-acrylamide (37.5:1) gels were cast using a Mini-
PROTEAN Tetra System gel kit (Bio-Rad). 5 mL resolving gel (375 mM Tris 
pH 8.8, 12% acrylamide:bis-acrylamide (37.5:1), 0.4 % (w/v) SDS) was 
polymerised with 100 µL of 10 % (w/v) ammonium persulfate (APS), and 10 
µL N,N,N',N'-tetramethylethane-1,2-diamine (TEMED). The gel was overlaid 
with 100 % ethanol to create a level top, and the ethanol was poured off once 
the gel had set. 2 mL stacking gel (125 mM Tris pH 6.8, 4 % acrylamide:bis-
acrylamide (37.5:1), 0.1 % (w/v) SDS) was polymerised with 50 µL of 10 % 
(w/v) APS and 10 µL TEMED, and was then poured on top of the resolving 
gel, with insertion of a plastic comb to create wells.  
Samples were pipetted into the wells, with a control lane containing Color 
Prestained Protein Standard, Broad Range (NEB) molecular weight markers 
to estimate molecular weight of the protein bands. Gels were run in SDS-
PAGE running buffer (25 mM Tris pH 8.3, 0.19 M glycine, 0.1 % (w/v) SDS) at 
180V until the dye front reached the bottom of the gel (or until the relevant 
protein markers showed sufficient separation). Protein bands were stained 
using InstantBlue Protein Stain (Expedeon), and gels were then washed in 






2.5.2 Protein quantification 
 
2.5.2.1 Quantification by A280nm 
Protein concentrations were quantified using an N60 Nanophotometer 
(Implen). The appropriate buffer was used as a blank, and then a 1 µL sample 
was analysed. The A280nm reading (path length (l) of 1 cm) was used to 
calculate the protein concentration using the formula: 
!"#$%&'	)#')%'$"*$&#'	(,-	. ,/01) = 456789 × ;<=>? 
Where eprot is the protein factor, calculated by: 
;<=>? =
,#@%)A@*"	B%&-ℎ$	(D*)
E#@*"	%F$&')$&#'	)#%GG&)&%'$	*$	280',	(E01),01) × @	(),) 
Parameters of molecular weight and extinction coefficient at 280nm were 
derived for each protein using the ExPASy ProtParam online tool (Artimo et 
al., 2012).  
 
2.5.2.2 Bio-Rad protein assay 
The Bio-Rad protein assay was used for quantification of MurA-F protein 
stocks. In triplicate, 10 µL of protein sample was mixed with 990 µL Protein 
Assay Dye Reagent Concentrate (Bio-Rad) diluted to working concentration 
in water, and the mixture incubated at room temperature for 5 mins. The 
absorbance of each sample was read at 595nm using a Jenway 7305 UV-





0.1 × 1.95 ×
1000
R*,L@%	S#@A,%	(K/) × T&@A$&#'	G*)$#" 
Where an absorbance of 0.1 was realised by 1.95 µg protein within the 
absorbance range of 0 – 0.6 at 595 nm, as derived from a calibration curve 
constructed using bovine serum albumin. 
 
2.5.2.3 Bicinchoninic acid (BCA) assay 
Protein stocks containing detergents were quantified using the Micro BCA 
Protein Assay Kit (Thermo Scientific) in accordance with the manufacturer’s 
 
 58 
instructions. Reactions were assembled in a clear 96-well plate, and A562nm 
was read using a CLARIOstar plate reader (BMG LABTECH).  
 
2.6 Synthesis of Peptidoglycan Intermediates 
Dansylated lipid II variants were kindly provided by Julie Tod (University of 
Warwick). 
 
2.6.1 UDP-MurNAc peptides 
UDP-MurNAc peptide intermediates were synthesised enzymatically as 
described by Lloyd et al. (2008), although with inclusion of D-isoGln for 
incorporation into the second position of the peptide stem. This allowed 
generation of 100 % amidated UDP-MurNAc peptides. 
 
2.6.1.1 Synthesis of UDP-MurNAc peptides 
2 mL reactions contained 50 mM HEPES pH 7.5, 10 mM MgCl2, 200 mM PEP, 
1 mM dithiothreitol (DTT), 50 mM KCl, 8.22 mM uridine 5’ diphospho-N-
acetylglucosamine (UDP-GlcNAc), 1.2 µM MurA, 57.3 µM MurB, 0.2 mM 
NADP+, 1.47 units.mL-1 isocitrate dehydrogenase (Sigma-Aldrich), 26 mM DL-
isocitrate, 6 mM ATP, 5.53 units.mL-1 pyruvate kinase (Sigma-Aldrich), 4.3 µM 
MurC, 35 mM L-Ala, 1.1 µM MurD, 105 mM D-isoGln, 4.0 µM MurE, 35 mM L-
Lys, 8.5 µM MurF, 35 mM D-alanyl-D-alanine. Syntheses were incubated at 
37 ˚C overnight, and then diluted with 5 mL of sterile water prior to filtration 
using a 20 mL Vivaspin 10 kDa MWCO centrifugal concentrator. Filtered 
samples were diluted into 100 mL sterile water. 
 
2.6.1.2 Synthesis of UDP-MurNAc 3P (iGln) 
UDP-MurNAc 3P (iGln) was synthesised as described for UDP-MurNAc 5P 
(iGln), but with omission of MurF and D-alanyl-D-alanine. 
 
2.6.1.3 Purification of UDP-MurNAc peptides 
UDP-MurNAc peptides were purified by anion exchange using a 75 mL column 
of Source30Q resin (GE Healthcare) on an AKTA Pure system (GE 
Healthcare). The column was washed with 10 CV water, cleaned with 1 M 
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ammonium acetate pH 7.6, and finally equilibrated in 10 mM ammonium 
acetate pH 7.6. The synthesis reaction was loaded on to the column and 
unbound material washed off with 100 mL of 10 mM ammonium acetate. The 
column was developed at 10 mL.min-1 by a linear gradient of 10 mM to 1 M 
ammonium acetate (both at pH 7.6) over 120 mins, with collection of 10 mL 
fractions. Elution of the desired products was followed by monitoring 
absorbance at 280 nm, 254 nm and 218 nm. Fractions containing the desired 
product were pooled and lyophilised 5 times in a 500 mL round-bottomed flask 
to remove ammonium acetate. 6 mL of sterile water was used to transfer the 
lyophilised, powdered product to a 15 mL falcon tube, followed by 2 further 
rounds of freeze drying. The product was finally resuspended in 1 mL sterile 
water and stored at -80 ˚C.  
 
2.6.2 Synthesis of UDP-MurNAc 4P (iGln) using DacB 
UDP-MurNAc 4P (iGln) was synthesised from UDP-MurNAc 5P (iGln) by 
cleavage of the terminal D-Ala using the D,D-carboxypeptidase DacB. In a 
final volume of 2 mL, 10 mg UDP-MurNAc 5P (iGln) was incubated with 2 mg 
purified recombinant DacB in 50 mM HEPES pH 7.6, 10 mM MgCl2 overnight 
at 37 °C. Reactions were then purified as described by in Section 2.6.1.3. 
 
2.6.3 Acid hydrolysis for synthesis of MurNAc peptides 
MurNAc peptides were synthesised from UDP-MurNAc peptides by acid 
hydrolysis to remove the UDP group. To 10 mg of UDP-MurNAc peptide, 1 M 
HCl was added for 0.1 M final concentration (pH 1). The sample was boiled at 
99 °C for 30 mins, and then neutralised to pH 7.5 by addition of 1M NaOH.  
The reactions were purified by anion exchange chromatography using a 
MonoQ HR 10/10 column (GE Healthcare). The column was washed with 10 
CV water, cleaned with 1 M ammonium acetate pH 7.6, and finally equilibrated 
in 10 mM ammonium acetate pH 7.6. Elution of the desired products was 
followed by monitoring absorbance at 280 nm, 254 nm and 218 nm, and 500 
µL fractions were collected. The acid hydrolysis reaction was diluted to 5 mL 
and loaded on to the column via a 5 mL loop. MurNAc peptide compounds 
eluted in the column flow through. The column was then developed at 3 
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mL.min-1 by a linear gradient of 10 mM to 1 M ammonium acetate (both at pH 
7.6) over 16 mins, with collection of 500 µL fractions. Fractions containing the 
desired product were pooled and lyophilised 5 times in a 15 mL falcon tube to 
remove ammonium acetate. The product was finally resuspended at 0.2 mM 
in sterile water and stored at -80 ˚C.  
 
2.6.4 Synthesis of Donor-only UDP-MurNAc Pentapeptides 
Donor-only UDP-MurNAc pentapeptides were made either enzymatically or 
chemically, and the products of both reaction schemes were purified as 
described in Section 2.6.1.2. Enzymatic synthesis was by the reaction 
described in Section 2.6.1.1, but with inclusion of 35mM L-arginine or e-
dimethyl-L-lysine for incorporation into the third position of the pentapeptide 
stem by MurE.  
Chemical synthesis of donor-only UDP-MurNAc pentapeptide was by 
acetylation of iGln UDP-MurNAc pentapeptide with acetic anhydride. A stock 
of iGln UDP-MurNAc pentapeptide was first buffer exchanged into sodium 
hydrogen carbonate using a 75 mL column of Source30Q resin (GE 
Healthcare) on an AKTA Pure system (GE Healthcare). The column was 
washed with 10 CV of water, cleaned with 500 mM sodium hydrogen 
carbonate, and finally equilibrated in 10 mM sodium hydrogen carbonate. The 
iGln UDP-MurNAc pentapeptide stock was loaded to the column via a 1 mL 
loop, and the column was washed with 300 mL of 10 mM sodium hydrogen 
carbonate to ensure removal of residual ammonium acetate. The compound 
was eluted in a single step at 500 mM sodium hydrogen carbonate, with 
collection of 10 mL fractions. Fractions containing iGln UDP-MurNAc 
pentapeptide were distributed into 6 mL aliquots in glass bijoux tubes and 
incubated overnight with a 40-fold molar excess of acetic anhydride, at room 
temperature with stirring. Each 6 mL aliquot was diluted into 100 mL and 
purified as described in Section 2.6.1.2. 
 
2.6.5 Desalting of iGln UDP-MurNAc pentapeptide 
Residual ammonium acetate was removed from iGln UDP-MurNAc 
pentapeptide stocks by gel filtration on a Biogel P2 resin (Bio-Rad) column (89 
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cm length x 2.6 cm diameter). The column was equilibrated with 2 CV of sterile 
water at 1 mL.min-1, and then the sample was loaded via a 500 µL injection 
loop. The column was developed over 1 CV in sterile water, with collection of 
10 mL, where the eluate was monitored by absorbance at 280 nm, 254 nm 
and 218 nm. Fractions containing the desired product were concentrated by 
lyophilisation, resuspended in a small volume of sterile water and stored at -
80 ˚C. 
 
2.6.6 Synthesis of branched iGln UDP-MurNAc peptides  
UDP-MurNAc (iGln) compounds with branched stem peptides were 
synthesized in a carbodiimide coupling reaction as described by De Pascale 
et al. (2008). 90 µmol 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 
60 µmol N-hydroxysuccinimide (HOSu) and 24 µmol of the relevant 9-
fluorenylmethyloxycarbonyl (Fmoc)-protected amino acid or dipeptide were 
combined in 2 mL of 80% (v/v) acetonitrile and stirred at room temperature for 
1 h. The pH was then adjusted to 10 with 0.5 M sodium bicarbonate buffer, 
followed by addition of 2 µmol of iGln UDP-MurNAc Lys5P. After stirring for 3 
h, the product was deprotected with 100 µl piperidine with incubation for 1 h, 
and the reaction was then quenched by addition of 20 mL of water. The 
reaction mixture was filtered through a Minisart syringe filter (Sartorius), and 
solvents were removed by rotary evaporation using a Buchi R-210 Rotavapor. 
The dried product was then resuspended in 20 mL of water and freeze-dried 
overnight, then resuspended in 200 mL of 10 mM ammonium acetate buffer 
adjusted to pH 7.6 and purified on a gradient up to 1 M ammonium acetate 
over 80 mins at 4 mL.min-1 using a MonoQ HR 10/10 column (GE Healthcare), 
with collection of 4 mL fractions. Fractions containing the desired product were 
pooled and lyophilised 5 times in a 500 mL round-bottomed flask to remove 
ammonium acetate. 6 mL sterile water was used to transfer the lyophilised, 
powdered product to a 15 mL falcon tube, followed by 2 further rounds of 
freeze drying. The product was finally resuspended in 0.5 mL sterile water and 




2.6.7 Synthesis of Fmoc-dipeptides by solid-phase peptide synthesis 
Dipeptides were synthesized by solid phase peptide synthesis. 500 mg Fmoc-
amino acid-Wang resin (Sigma Aldrich) was swollen in 10 mL 
dimethylformamide (DMF) (Fisher) in an Econo-Pac Chromatography Column 
(BioRad) for 1 h. After removal of the DMF by vacuum, the amino acid on the 
resin was deprotected by addition of 10% (v/v) piperidine in DMF, with 
incubation for 5 mins at room temperature. The resin was washed twice with 
DMF, and the deprotection step repeated. Following the second deprotection, 
the resin was washed 4 times with 10 mL of DMF and 4 times with 10 mL 
dichloromethane (DCM). For coupling of L-Alanine to the amino acid of the 
resin, 1 mmol of Fmoc-Ala-OH (Sigma), 1 mmol of N-[(Dimethylamino)-1H-
1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium 
hexafluorophosphate N-oxide (HATU) and 350 µL of N,N-
Diisopropylethylamine (DIPEA) were added to the resin and incubated at room 
temperature overnight with agitation. 
The resin was then washed with 40 mL each of DMF, DCM and methanol 
(using 10ml volumes at each step). The dipeptide product was cleaved from 
the resin by two rounds of incubation in 4.5 mL of 90 % (v/v) trifluoroacetic 
acid (TFA) for 1 h at room temperature with shaking, where the cleaved 
product was decanted after each incubation into a 50 mL round bottomed 
flask. The product was then precipitated (with chloroform in the case of Fmoc-
L-Ala-L-Ser, and diethyl ether in the case of Fmoc-L-Ala-L-Ala), and the 
solvent was removed by rotary evaporation on a Buchi R-210 Rotavapor. 
Finally, the product was dissolved in a minimal volume of 3:1 methanol:water 
and transferred to a 7 mL universal tube. The stock was desiccated to yield 
dry product, which was stored at -20 ˚C. 
 
2.6.8 Analysis of UDP-MurNAc Peptides 
 
2.6.8.1 Quantification by A260nm 
UDP-MurNAc peptide stocks were quantified by absorbance at 260 nm, using 
a Jenway 7305 UV-visible spectrophotometer. 198 µL of sterile water was 
used as a blank, to which 2 µL of the sample, was subsequently added, mixed 
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by pipetting and A260nm (with 1 cm path length) was determined. The mean 
value from triplicate readings was used to calculate the concentration of the 
UDP-MurNAc peptide stock using the following formula, where the molar 
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2.6.8.2 Analysis of purity by analytical anion exchange chromatography 
Purity of UDP-MurNAc peptides was assessed by analytical anion exchange, 
using a MonoQ HR 5/50 column (GE Healthcare). The column was washed 
with 10 CV water and 10 CV 1 M ammonium acetate pH 7.6 and then 
equilibrated in 10 CV 10 mM ammonium acetate pH 7.6. A 1000-fold diluted 
sample in 500 µL was loaded onto the column via a 1 mL loop, and 
chromatographed on a gradient of 10 mM to 1 M ammonium acetate buffer pH 
7.6. Purity was estimated from integration of the peaks observed (using the 
Unicorn analysis software) by absorbance at 254 nm (the absorbance 






2.6.9 Synthesis of Lipid-linked Peptidoglycan Intermediates 
Lipid (undecaprenyl phosphate)-linked peptidoglycan intermediates were 
synthesized as described by Breukink et al. (2003), using Micrococcus flavus 
membranes to supply MraY and MurG for assembly of Lipid II from UDP-
MurNAc pentapeptide, undecaprenyl phosphate, and UDP-GlcNAc.  
 
2.6.9.1 Isolation of M. flavus membranes 
A sample of M. flavus from a glycerol stock was streaked to allow isolation of 
single colonies on a TSB agar plate and incubated overnight at 37 ̊ C. Cultures 
of 15 mL TSB medium were inoculated with a single colony each from the 
plate, and were incubated overnight at 37 ̊ C with shaking at 180 rpm. Cultures 
of 800 mL TSB medium were supplemented with 4 mL of 20 % (w/v) glucose 
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and were inoculated with 15 mL of overnight culture and incubated at 37 ˚C 
with shaking at 180 rpm. Cultures were harvested at 10,000 x g for 20 mins at 
4 ˚C when the OD600 reached 8.0, or if they appeared to be exiting log phase. 
Cell pellets were washed by resuspension in 100 mL of resuspension buffer 
(20 mM Tris.HCl pH 7.5, 1 mM MgCl2, 2 mM b-mercaptoethanol) per litre of 
original culture, followed by a further centrifugation step at 15,000 x g for 20 
mins at 4 ˚C. The cell pellets were then stored at -20 ˚C. 
Cell pellets were thawed on ice and resuspended in 3 mL.g-1 of resuspension 
buffer, followed by addition of 2.5 mg.mL-1 lysozyme. The cell suspension was 
incubated at 4 ˚C for 20 mins with agitation. Cells were then lysed by passing 
twice through a continuous cell disrupter (Constant Cell Disruption Systems) 
at 30 kpsi at 4 ˚C. Cell debris was pelleted by centrifugation at 10,000 x g for 
1 h. The membranes were then pelleted by ultracentrifugation at 75,000 x g 
for 1 h. Membranes were resuspended in a minimal volume of the supernatant 
and stored as 2 mL aliquots at -80 ˚C. 
 
2.6.9.2 Synthesis of Lipid II  
A 3.5 mL Lipid II synthesis reaction (of Lipid II (iGln) or Lipid II 3P (iGln)) 
contained 0.1 M Tris pH 8.0, 5 mM MgCl2, 1 % (w/v) Triton X-100, 6 mM UDP-
GlcNAc, 4mM UDP-MurNAc peptide, 4.5 µmol undecaprenyl phosphate 
(Larodan), and 0.57 mg.mL-1 MurG. Analytical scale Lipid II synthesis 
reactions were conducted in 200 µL. Reactions were incubated overnight at 
37 ˚C. 
 
2.6.9.3 Purification of iGln Lipid II (L-Lys) 
The reaction was transferred to a test tube and mixed with 1 volume 6 M 
pyridinium acetate and 2 volumes N-butanol, followed by centrifugation at 
3,000 x g for 10 mins at 4 ˚C. This resulted in partition of the suspension into 
organic and aqueous phases. The organic upper phase was transferred to a 
fresh test tube and mixed with 1 volume sterile water, followed by 
centrifugation at 3,000 x g for 10 mins at 4 ˚C. The organic upper phase of this 
separation was then transferred to a 50 mL round-bottomed flask, and 
solvents removed by rotary evaporation (Buchi R-210 Rota-vapor). The dried 
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mixture was resuspended in 6 mL of Solvent A (2:3:1 (v/v) 
chloroform:methanol:water). 
The synthesis reaction was then chromatographed by anion exchange on a 
DEAE Sephacel resin (GE Healthcare) column. The column was formed in a 
glass burette with glass wool as a filter at the spout. A 4 mL bed volume of 
resin was used for 3.5 mL reactions, and this was scaled as defined in the text 
for smaller-scale reactions. The resin was prepared by washing with 10 CV 1 
M ammonium acetate and 15 CV water, and then equilibrated in 10 CV Solvent 
A. The sample was then loaded to the column, followed by a wash of 3 CV 
Solvent A. The column was then developed over a stepwise elution in 12 mL 
washes of 8.3, 9.2, 10.0, 10.8, 11.7, 12.5, 13.3, 14.2, 15.0, 15.8, 16.7, 25.0, 
33.3, 41.7, 50.0, 83.3 and 166.7 mM ammonium bicarbonate in Solvent A. 400 
µL samples of each fraction were desiccated overnight and were then 
resuspended in 25 µL of fresh Solvent A. These samples were analysed by 
thin-layer chromatography (TLC) using silica 60-coated ALUGRAMÒ Xtra SIL 
G plates (Macherey-Nagel) run in 44:88:10:1 (v/v) 
chloroform:methanol:water:ammonia mobile phase at room temperature, until 
the solvent front was within 1 cm of the top of the plate. TLC plates were 
stained in iodine vapour and imaged using a scanner. 
Fractions containing the desired lipid product were pooled in a 50 mL round-
bottomed flask and dried by rotary evaporation (Buchi R-210 Rota-vapor), 
followed by 5 rounds of lyophilisation against water to remove ammonium 
bicarbonate. The product was then resuspended in 1.5 mL of Solvent A and 
stored at -80 ˚C. 
 
2.6.9.4 Quantification of Lipid II stocks by phosphate release 
Lipid II stocks were quantified based on cleavage and assay of the phosphate 
moiety. Two 50 µL samples were taken of the Lipid stock, and one of the 
Solvent A used to resuspend the Lipid II. Samples were dried in 0.5 mL low-
binding Eppendorf tubes under nitrogen gas, and resuspended in 50 µL 50 




propanesulfonate (CHAPS). One Lipid sample was then set aside as a non-
hydrolysed control. To the other Lipid sample and the Solvent A sample were 
added 50 µL 1 M HCl, and the samples were boiled at 100 ˚C for 30 mins. 1 
M NaOH was then used to adjust the samples to pH 7.6.  
The inorganic phosphate in the samples (released by acid hydrolysis) was 
then quantified by use of a phosphate release assay. In a crystal quartz 
cuvette, 200 µL reactions were assembled comprising 50 mM HEPES, 10 mM 
MgCl2, 5 U.mL-1 purine nucleoside phosphorylase (PNP), 5 U.mL-1 inorganic 
pyrophosphatase (IPP), 200 µM 7-methyl-6-thioguanosine (MESG) (Berry and 
Associates) and monitored at 360nm using a Varian Cary 100 
spectrophotometer at 37 ˚C. After establishing a stable baseline (3 mins), 10 
µL of the sample was added and the DA360nm was recorded until the reaction 
reached completion.  
IPP releases phosphate from inorganic pyrophosphate generated by the acid 
hydrolysis of the samples. PNP catalyses the Pi-dependent conversion of 
MESG to ribose-1-phosphate and 7-methyl-6-thioguanine. The latter product 
absorbs strongly at 360nm, with a D molar extinction coefficient of 10,000 M-
1.cm-1 relative to MESG which has a residual absorbance at this wavelength. 
This parameter was therefore used to convert the mean DA360nm readings from 
triplicate samples into µM lipid concentrations by first calculating the 









Where the total volume of sample refers to that following pH adjustment. The 
lipid concentration in the stock was then calculated, with correction for 
background phosphate and the presence of two Pi per Lipid II molecule, using 
the formula: 
[/&L&T]	KE =
[!̀ ]	ℎYT"#@YR%T − [!̀ ]	A'ℎYT"#@YR%T − [!̀ ]	X#@4
2  
 
2.6.10 Mass Spectrometry 
All peptidoglycan intermediates were analysed by negative ion nano-spray 
time of flight (TOF) mass spectrometry using a SYNAPT G2-Si instrument 
(Waters), to verify the compounds synthesised by comparison of observed and 
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expected masses. The instrument was calibrated in negative ion mode with 
sodium iodide over a mass to charge ratio range of 200-2500. Samples were 
diluted into 70 % (v/v) methanol and 30 % (v/v) 25 mM ammonium acetate for 
lipid-linked intermediates; and 50 % (v/v) acetonitrile for UDP-MurNAc and 
MurNAc-peptides. Sample injection was via a thin wall nanoflow capillary 
(Waters) at a capillary voltage of 2.0 kV.  Data were collected and analysed 
using Waters Mass Lynx software, by Dr. Adrian Lloyd, Julie Tod or Anita 
Catherwood (all University of Warwick). 
 
2.7 Biochemical Assays 
 
2.7.1 SDS-PAGE analysis of glycosyltransferase activity 
Glycosyltransferase activity was monitored by use of gel electrophoresis as 
described by Galley (Thesis, 2015) whose method built upon those of Helassa 
et al. (2012) and Barrett et al. (2007). Assay detergent and concentrations of 
enzyme and substrate varied between experiments, and are described in the 
text. Reactions were made up in low-binding 0.5 mL eppendorf or PCR tubes, 
in a buffer consisting of 50 mM HEPES pH 7.6, 10 mM MgCl2, 150 mM NaCl, 
25 % (v/v) DMSO, and the chosen concentrations of PBP1a (from a 10 x 
stock), 100 % dansylated Lipid II in assay detergent (from a 100 µM stock), 
and assay detergent to make up the desired concentration (relative to the 
critical micelle concentration (CMC)). Where possible, master-mixes were 
used to reduce the impact of pipetting error on liquid handling. Reactions were 
initiated by addition of the enzyme, and incubated at 30 ˚C in an Aviso 
Mechatronic Systems Primus thermocycler, with the time period of incubation 
dictated by the experiment. Reactions were terminated by addition of 1 µL 
moenomycin and 1 µL 0.5 M EDTA. Samples were then mixed with loading 
dye (6 x stock: 100 mM Tris pH 8.8, 4 % (w/v) SDS, 40 % (v/v) glycerol, 0.05 
% (w/v) bromophenol blue).  
Polyacrylamide gels were made by the method of Barrett et al. (2007) using a 
Mini-PROTEAN Tetra System gel kit (Bio-Rad). 7.5 mL of 9 % Tris-Tricine gel 
(0.42 M Tris pH 8.45, 0.13 % (w/v) SDS, 9 % acrylamide:bis-acrylamide 
37.5:1) was polymerised by addition of 30 µL 10 % (w/v) APS and 15 µL 
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TEMED, and poured into a gel casting tray with insertion of a 10 well plastic 
comb to form the wells. Electrophoresis was completed with anode (0.1 M Tris 
pH 8.8) and cathode (0.1 M Tris, 0.1 M Tricine, 0.1 % (w/v) SDS, pH 8.25) 
buffers at 100 V, 50 mA for 1 h 15 mins.  
As specified in the text, some experiments made use of Criterion 16.5 % Tris-
Tricine Precast gels (Bio-Rad). Such gels were run at 100 V, 50 mA for 3 h, in 
buffers as previously described. 
Fluorescence was imaged using an ImageQuant LAS 4000 instrument (GE 
Healthcare) on the Ethidium bromide fluorescence setting (transmitted light at 
312 nm, 605DF40 filter; to allow imaging of glycan strands based on dansyl 
group fluorescence: λabs 340 nm; λem 520 nm). 
2.7.2 SDS-PAGE analysis of transpeptidase activity 
Transpeptidase activity was monitored in the same gel-based system 
described in 2.7.1, but with use of Lipid II (iGln, Dans) and an additional 
substrate that could behave as a transpeptidase acceptor. Controls with 1 mM 
ampicillin and 200 µM moenomycin were run alongside. 
Double-volume reactions were made for these experiments, such that half 
could be analysed by SDS-PAGE, and half by mass spectrometry as 
described in Section 2.7.4. 
 
2.7.3 Amplex Red assay for D-Ala release 
Transpeptidase and D,D-carboxypeptidase activity was monitored in a 
coupled continuous assay system developed by Dr. A. J. Lloyd (University of 
Warwick).  
Reaction buffer, assay detergent and substrates were as dictated by the 
experiment, but all contained the coupling system of 33.51 mM.min-1 
Rhodotorula gracilis DAAO, 14.82 mM.min-1 horseradish peroxidase and 50 
µM Amplex Red, allowing D-Ala release to be followed by the generation of 
resorufin (l(max) 555 nm). 
Reactions were assembled, minus the initiating component, in crystal quartz 
cuvettes and performed in a Varian Cary 100 spectrophotometer monitoring 
A555nm at 30 ˚C. Reactions were then initiated once a stable baseline had been 
reached (5 mins).  
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2.7.4 Mass spectrometry analysis of transpeptidase reaction products 
Reactions for analysis of transpeptidase activity (by either of the methods 
described in Section 2.7.2 or 2.7.3) were digested with Streptomyces 
globisporus mutanolysin (prepared in 10 mM HEPES pH 7.6 and 25 mM 
MgCl2) to allow detection of cross-linked products by mass spectrometry. 
Volumes are given for a 200 µL transpeptidase reaction, but these were scaled 
accordingly for processing of smaller reaction volumes. 
To each 200 µL reaction, 20 µL 2.2 M bis.Tris pH 6.2 was added, followed by 
20 µL of 10mg.mL-1 mutanolysin. The digestion was incubated for 2 h at 37 
˚C, a further 20 µL aliquot of mutanolysin added and the incubation repeated. 
The reaction was boiled at 100 ˚C for 10 mins, and proteins were then pelleted 
by centrifugation at 16,000 x g for 10 mins in a bench-top centrifuge 
(Eppendorf 5415 R). 150 µL was added from a fresh stock of 10 mg.mL-1 
NaBH4 followed by incubation at room temperature for 30 mins. The final step 
was then addition of 17.5 µL 20 % (v/v) phosphoric acid.  
Mass spectrometry analysis was by liquid chromatography mass spectrometry 
(LCMS) using an ACQUITY UPLC Peptide BEH C18 column (Waters), which 
was equilibrated at 50 mL.min-1 in 99:1 water + 0.1 % (v/v) formic acid (solvent 
A): acetonitrile + 0.1 % (v/v) formic acid (solvent B). The column was 
developed over a gradient of 1 to 37 % solvent B in 30 mins; followed by a 
step to 90 % solvent B in 1 min, with a 3 mins wash at 90 % solvent B; and 
finally restoration of the original 1 % B condition over 1 min with a 6 min wash. 
After the first minute, the elution entered the mass spectrometer (calibrated as 
described in Section 2.6.7, but run in positive mode) at a capillary voltage of 
2.5-3.0 kV. Further analysis of selected ions was by LCMSMS using collision-
induced fragmentation, with argon flow at 2 mL.min-1 at a constant trap 
collision energy of 40 eV. Data were collected and analysed using Waters 
Mass Lynx software, by Dr. Adrian Lloyd, Julie Tod or Anita Catherwood (all 
University of Warwick). 
 
2.7.5 Electrophoretic analysis of BOCILLIN FL binding 
Interaction of PBP1a with Bocillin FL (fluorescently labelled BODIPY penicillin) 
was analysed by SDS-PAGE. Unless otherwise stated, 6 µM PBP1a was 
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incubated with 2 mM ampicillin, 200 µM moenomycin (or other test inhibitor) 
or water for 30 mins at room temperature. Bocillin FL was then added to give 
a final concentration of 60 µM (or the equivalent volume of 100 % dimethyl 
sulfoxide (DMSO)) and samples were incubated at 37 ˚C for 1 h in the dark. 
Samples were mixed with protein loading dye and run on 12 % SDS-PAGE 
gels (Section 2.5.1), though without the heat denaturing step to avoid 
disruption of the PBP-BOCILLIN FL interaction. A lane each of protein ladder 
(Color Prestained Protein Standard, Broad Range (NEB)) and fluorescent 
protein ladder (BenchMark Fluorescent Protein Standard (ThermoFisher 
Scientific)) were loaded for sizing of the bands. Fluorescence was detected by 
imaging on a Typhoon FLA 9500 laser scanner (GE Healthcare) with a Y510 
filter and laser at 473 nm, and exposure setting on 100 µm pixel size. Gels 
were then stained using InstantBlue Protein Stain (Expedeon) and imaged 
using an ImageQuant LAS 4000 instrument (GE Healthcare). 
 
2.7.6 Continuous fluorescence assay for glycosyltransferase activity 
Rates of glycosyltransferase activity by pneumococcal PBPs were analysed 
using a continuous fluorescence assay for glycosyltransferase activity 
(Schwartz et al., 2002), with conditions as described by Galley (2015). 50 uL 
reactions consisted of 50 mM HEPES pH 7.5, 10 mM MgCl2, 150 mM NaCl, 
25 % (v/v) DMSO, 0.0116 % (w/v) E6C12, 0.1 mg.mL-1 hen egg lysozyme, and 
concentrations of PBP1a and Lipid II (iGln, Dans) as determined by the 
experiment. Where cardiolipin and phosphatidylglycerol were included in the 
reactions, these phospholipids were dried down under N2 gas from stocks in 
2:3:1 chloroform:methanol:water, and resuspended in 0.039 % (w/v) E6C12. 
Reactions were run in a FLUOTRACT 600 high binding 96-well plate (Greiner), 
and initiated by addition of 5 uL PBP1a at 10 X final concentration. 
Fluorescence was monitored at 30 °C for 100 mins on a Clariostar platereader 
(BMG Labtech) with excitation at 340 nm and emission at 521 nm. 
Progress curves were exported using MARS Data Analysis Software (BMG 





2.8 Determination of Minimal Inhibitory Concentration (MIC) by 
microbroth dilution 
MIC values for S. pneumoniae strains Pn16 and 159 were determined by 
microbroth dilution according to CLSI guidelines (CLSI, 2014). Cell 
suspensions of S. pneumoniae were made in PBS to match turbidity with a 0.5 
McFarland standard. These cell suspensions were then diluted 100-fold in 
PBS to produce the working stock of S. pneumoniae. In a 96-well plate, 2-fold 
serial dilutions of antibiotics (at 2 x the required concentration for each well) 
were made in 100 µL per well of cation-adjusted Mueller-Hinton Broth with 5 
% (v/v) lysed horse blood. Each well was then inoculated with 100 uL of the 
diluted cell suspension. Controls with PBS in place of inoculum and broth in 
place of antibiotic were included. Plates were incubated in anaerobic jars for 
18 h, following which growth was assessed based on turbidity. MIC values 
were read as the lowest concentration of antibiotic at which no growth was 
observed. 
MICs were determined in parallel for S. pneumoniae strain ATCC46919. The 
observed MIC values were compared to published values to validate the 




Chapter 3: Synthesis of Pneumococcal Peptidoglycan 
Precursors and Substrate Analogues 
3.1 Introduction 
In order to address the research questions of this thesis relating to activity of 
pneumococcal penicillin binding proteins (PBPs), a necessary first step was 
the synthesis of a variety of substrates for these enzymes, to represent the 
naturally occurring variations in pneumococcal peptidoglycan. The necessity 
of different kinds of substrates for the assay systems to be used will be 
discussed further in Section 3.1.4. 
 
Reviews encompassing the synthesis of peptidoglycan precursors and 
substrate analogues have been published by Lazar and Walker (2002), Welzel 
(2005), Narayan and VanNieuwenzhe (2007), and Egan et al. (2015). The 
various methodologies for obtaining or synthesising PBP substrates can be 
broadly categorised as the accumulation and purification of native substrates 
(hereafter referred to as bioaccumulation); biosynthesis with purified 
recombinant enzymes or bacterial membrane preparations; and chemical 
methods. Many published methods, however, combine a few of these 
approaches to reach the final product. A summary diagram of published 




Figure 3.1: Summary of the published pathways for synthesis of peptidoglycan precursors. Chemical, enzymatic and 
bioaccumulation methods of various stages of peptidoglycan precursor synthesis have been described. Numbering refers to the 
relevant Sections of this Chapter. 
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3.1.1 Purification of native precursors and bioaccumulation 
3.1.1.1 Bioaccumulation of UDP-MurNAc peptides 
The earliest methods for obtaining peptidoglycan precursors were based on 
their purification from natural sources, in pursuit of chemical characterisation 
of the peptidoglycan precursor (Park, 1952). The estimated pool of Lipid II in 
E. coli is a maximum of 2000 molecules (Van Heijenoort et al., 1992). 
Consequently, Park (1952) and others have used antibiotics such as penicillin 
(Hammes & Neuhaus, 1974), vancomycin (Reynolds, 1961) and D-cycloserine 
(Izaki et al., 1968; Neuhaus & Struve, 1965) to accumulate UDP-MurNAc 
peptides in vivo by inhibition of peptidoglycan biosynthesis, in organisms such 
as Bacillus cereus. In general, these methods involved treatment of cultures 
with chloramphenicol, to increase the availability of amino acids for 
incorporation into the peptide stem (Ishiguro & Ramey, 1978); followed by 
vancomycin/penicillin or D-cycloserine to accumulate UDP-MurNAc 
pentapeptide or -tripeptide respectively. Kohlrausch and Höltje (1991) built 
upon previous methods by use of a one-step HPLC purification followed by 
desalting, to give high purity and yield of UDP-MurNAc pentapeptide (5P) from 
B. cereus culture. This method was adapted to supply soluble precursor for 
many of the enzymatic Lipid syntheses described in Section 3.1.2. 
 
3.1.1.2 Bioaccumulation of Lipid II 
Guan et al. (2005) isolated Lipid II from E. coli in sufficient yield and purity for 
mass spectrometry analysis. However, Qiao et al. (2017) were the first to 
publish the use of cell wall synthesis inhibition to accumulate and then purify 
sufficient lipid-linked peptidoglycan precursors for biochemical studies. 
Moenomycin treatment was used to accumulate Lipid II in Staphylococcus 
aureus cultures. Cultures were then lysed and the Lipids extracted using a 
chloroform:methanol mixture. This method was subsequently employed with 
femA and femB deletion strains, to obtain Lipids with monoglycyl- and triglycyl- 




3.1.1.3 Considerations for use of bioaccumulation 
Bioaccumulation to obtain peptidoglycan precursors allows the generation of 
authentic substrates for cell wall synthesis enzymes. In addition, the methods 
of Qiao et al. (2017) and Srisuknimit et al. (2017) are, at the time of writing, 
the only published methods for generation of the pentaglycyl-Lipid II precursor 
of S. aureus peptidoglycan.  
The limitations of bioaccumulation include the limit in yield unless large 
volumes of culture are handled; possible contamination of the product with 
other cellular constituents; and unsuitability for application to organisms with 
variation in the final peptidoglycan structure, such as the variety of interpeptide 
bridges found in pneumococci (Garcia-Bustos et al., 1987), if a uniform final 
product is desired. Such a mixture may however be desired, depending on the 
assay system to be used. Furthermore, bioaccumulation is comparably poorer 
in flexibility to that afforded by biosynthetic or chemical methods, whereby 
altered amino acids may be incorporated or certain groups functionalized.  
 
3.1.2 Biosynthesis methods 
 
3.1.2.1 Bacterial membranes for linkage of UDP-MurNAc pentapeptide to 
undecaprenyl phosphate 
The bioaccumulation method of Kohlrausch and Höltje (1991) was used by a 
variety of investigations seeking to synthesise and purify Lipid II. Membranes 
from organisms such as S. aureus had been used to investigate the pathway 
of incorporation of MurNAc 5P into the cell wall (Anderson et al., 1965). These 
methods demonstrated the utility of membrane preparations for synthesis of 
lipid-linked precursors. Anderson et al. (1967) described the purification of 
Lipid II synthesised using this method, by solvent extraction followed by anion 
exchange chromatography. N-butyl alcohol was found to perform well as a 
quenching agent and for extraction of lipid product from the reaction mixture. 
Subsequent uses of similar methods include Umbreit et al. (1972), and van 
Heijenoort et al. (1992), who described an additional sialic acid column 
chromatography step.  
Breukink et al. (2003) described synthesis of Lipid I and Lipid II intermediates 
with enzymatic activity provided by M. flavus vesicles. In this case, shorter 
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polyprenyl chain lipids (geranyl or farnesyl -pyrophosphate) were used in the 
synthesis.  
 
3.1.2.2 Purified recombinant enzymes in synthesis of UDP-MurNAc peptides 
Lipid substrates have also been synthesised from UDP-MurNAc 5P provided 
by enzymatic biosynthesis. Reddy et al. (1999) described the first preparative-
scale enzymatic biosynthesis of UDP-MurNAc 5P from UDP-GlcNAc by use 
of purified recombinant Mur-ligases. The progress of the reactions was 
followed by ADP accumulation, as reported by NADH consumption in a 
pyruvate kinase/lactate dehydrogenase coupled assay. At completion, the 
product of each step was purified by anion exchange chromatography. Each 
intermediate in the pathway could be synthesised via this enzymatic method, 
at quoted yields of 10 – 100 mg. Limitations of the enzymatic synthesis 
included the impact of substrate and product inhibition on MurB, as well as 
NADPH oxidase activity by this enzyme (necessitating high concentrations of 
MurB and NADPH to overcome respectively); and the need for multiple rounds 
of anion exchange chromatography to resolve ADP accumulated by the 
activity of MurC-F from the desired peptidoglycan intermediate products.  
 
Liu et al. (2001) included glucose dehydrogenase (GDH) to recycle NADPH in 
their chemoenzymatic synthesis of UDP-MurNAc 5P, thus maintaining a low 
concentration of NADP+ to alleviate product inhibition of MurB, and simplify 
the purification of the desired product. The method of Liu et al. is further 
discussed in Section 3.1.3. Lloyd et al. (2008), in addition to utilising isocitrate 
dehydrogenase (IDH) to recycle NADPH, included pyruvate kinase in their 
one-pot enzymatic synthesis reaction from UDP-GlcNAc to UDP-MurNAc 5P, 
both to limit the starting concentration of ATP required, and to remove the ADP 
by-product which had complicated the purification of Reddy et al. (1999). 
 
Huang et al. (2014) described an enzymatic Lipid II synthesis method 
analogous to that of Lloyd et al. (2008), but with differences in starting 
materials, MraY and MurG sources, and the cofactor recycling system. The 
undecaprenol kinase activity of Streptococcus mutans diacylglycerol kinase 
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(DGK) was used to generate undecaprenyl phosphate, in addition to 
enzymatic synthesis of UDP-GlcNAc from GlcNAc using Bifidobacterium 
longum NahK and E. coli GlmU. Purified recombinant Bacillus subtilis MraY 
and E. coli MurG were employed in place of a bacterial membrane preparation 
to provide these activities. Purified recombinant enzymes are advantageous 
as the impact of batch-to-batch variation can be controlled by using the specific 
activity of each batch to calculate the final concentration of enzyme to use in 
the assay. Limitations of the use of purified recombinant enzymes include the 
more time-intensive preparation required (in particular with specific activity 
determination), and the possible expense incurred by the requirement for 
detergent solubilisation of the enzymes. Phospholipid interactions have been 
found to affect the activity of enzymes in the cell wall biosynthesis pathway 
(Section 5.1.3.4), and so this is an additional concern for preserving the activity 
of purified enzymes. 
 
Figure 3.2: Comparison of the energy recycling systems of Lloyd et al. 
(2008) and Huang et al. (2014). The pathways of enzymatic biosynthesis of 
Lipid II published by a) Lloyd et al. (2008) and b) Huang et al. (2014) are 
presented to illustrate differences in the cofactor recycling enzymes used. 
ADP, Adenosine 5’-diphosphate; ATP, Adenosine 5’-triphosphate 
; C55P, undecaprenyl phosphate; GDH, glucose dehydrogenase; IDH, 
isocitrate dehydrogenase; NADP+, nicotinamide adenine dinucleotide 
phosphate; NADPH, dihydronicotinamide adenine dinucleotide phosphate; 
PEP, phospho-enol pyruvate; Pi, inorganic phosphate; PK, pyruvate kinase; 






A comparison of the reaction pathways for the Lloyd et al. (2008) and Huang 
et al. (2014) Lipid II syntheses, with annotation of cofactor recycling enzymes, 
is depicted in Figure 3.2. In both methods NADPH and ATP were recycled. 
Whilst both used pyruvate kinase (PK) for recycling of ATP, different enzymes 
were used for reduction of NADP+; isocitrate dehydrogenase (IDH) by Lloyd et 
al. (2008), and glucose dehydrogenase (GDH) by Huang et al. (2014). In 
addition, Huang et al. (2014) used PK, NahK, GlmU and IPP to recycle UDP 
liberated by the activity of MurG to generate more UDP-GlcNAc from GlcNAc. 
This would be expected to significantly reduce the cost of UDP-MurNAc 
peptide synthesis in terms of starting materials (as of 23.10.18, UDP-GlcNAc 
was priced at £870.00 per gram, compared to GlcNAc at £16.90 per gram from 
Sigma-Aldrich, UK). However, the preparation of the enzymes required for the 
enzymatic synthesis and regeneration of UDP-GlcNAc will incur its own costs. 
 
3.1.2.3 Considerations of biosynthesis methods 
Biosynthetic methods offer benefits including stereospecificity, and the 
potential for flexibility (although this depends upon the substrate specificity of 
the enzyme). Limitations can include the impact of substrate or product 
inhibition on yield and purity (Koeller & Wong, 2001).  
Though, in general, greater flexibility in synthesis is afforded by chemical 
methods, there are published examples whereby enzymatic synthesis routes 
have been used to incorporate modifications to peptidoglycan precursors. 
Fonvielle et al. (2018) used MurE to incorporate meso-cystine into an 
enzymatically-prepared Lipid II molecule. This modified amino acid allowed 
subsequent functionalisation of the side chain of residue 3 in the peptide stem 
with an RNA moiety to mimic the acceptor arm of tRNAGly. The molecule 
generated was used to assess the impact of D-Ala-D-Lac peptide stem 
terminus on the activity of FemX. Whilst it may have been possible to have 
synthesised the intermediate chemically, as stated by Liu et al. (2001), 
enzymatic synthesis negates the requirement for handling of varied protecting 




3.1.3 Chemical synthesis methods 
Chemical synthesis has been used to generate the entire Lipid II molecule; to 
functionalise certain parts of Lipid II such as the peptide stem; and often in 
combination with enzymatic techniques where a wholly enzymatic approach 
would have been otherwise limited in flexibility. 
 
3.1.3.1 Chemical synthesis of UDP-MurNAc 5P 
Hitchcock et al. (1998) are credited with the first total chemical synthesis of 
UDP-MurNAc 5P. A muramyl-phosphate sugar was synthesised from N-acetyl 
glucosamine, and then coupled to a pentapeptide stem constructed by 
carbodiimide coupling (see further discussion of this method in Section 
3.3.4.1). The Khorana-Moffatt procedure (Roseman et al., 1961) was then 
used to couple the protected peptidomuramyl phosphate to uridine 5’-
monophosphomorpholidate. Global deprotection was then achieved using 
sodium hydroxide.  
 
A key limitation of the method of Hitchcock et al. (1998) was the time taken for 
the coupling of peptidomuramyl phosphate and uridine 5’-
monophosphomorpholidate (14 days). Liu et al. (2001) addressed this issue 
by the inclusion of 1H-tetrazole as a catalyst, achieving a reaction time of 2 
days and ‘nearly quantitative’ yield, compared to the 32 % yield quoted by 
Hitchcock et al. (1998). The pentapeptide or depsipentapeptide (with C-
terminal D-Ala-D-Lac, rather than D-Ala-D-Ala) stem was constructed by 
peptide coupling based on the method of Men et al. (1998).  
 
Liu et al. (2001) also described a chemoenzymatic method for synthesis of 
UDP-MurNAc penta- and depsipentapeptide, whereby UDP-MurNAc was 
synthesised enzymatically from UDP-GlcNAc using purified recombinant 
MurA-B, with glucose dehydrogenase to recycle the cofactor NADPH as 
previously discussed (Section 3.1.2). The pentapeptide or depsipentapeptide 
stem was synthesised and then coupled to the UDP-MurNAc as before. The 
authors obtained a lower yield for UDP-MurNAc 5P synthesised by the 
chemoenzymatic route (70 %) compared to the wholly chemical route (nearly 
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quantitative). No yield was quoted for the depsipentapeptide compound by the 
chemical route, but that quoted for the chemoenzymatic route was 56 %. The 
authors note, however, that the chemoenzymatic synthesis was simplified due 
to fewer steps in the procedure, and the need for protecting groups only in the 
synthesis of the peptide stems.  
 
3.1.3.2 Chemical synthesis of Lipid-linked substrates 
Men et al. (1998) prepared a citronelloyl-anchored Lipid I substrate analogue. 
The first step was synthesis of a phospho-MurNAc peptide precursor, by 
coupling a dibenzyl phosphate-derivatised MurNAc sugar to a protected 
pentapeptide. The product was then deprotected, and linked to the citronelloyl 
lipid by pyrophosphate exchange with diphenyl citronelloyl pyrophosphate. 
The authors also described biotinylation of the e-amino group of L-lysine at the 
3rd position of the peptide stem, to facilitate the downstream use of the 
compound in activity assays for MurG.  
The Lipid I synthesis described by Men et al. (1998) was later used to generate 
starting material for Lipid II synthesis. This method used purified recombinant 
MurG to append GlcNAc to Lipid I variants with prenyl chains of varying 
lengths (Ye et al., 2001), necessitating a change in the coupling chemistry for 
Lipid I synthesis. 
 
VanNieuwenzhe et al. (2001) described a similar chemical synthesis method 
for Lipid I to that of Men et al. (1998). In both methods, the phosphate moiety 
was first coupled to a MurNAc derivative. A peptide stem constructed by 
solution-phase peptide synthesis was then coupled to the MurNAc phosphate. 
The two pathways differed in choice of protecting groups, and in the timing of 
the removal of the 4,6 benzylidene moiety of the starting material in each case. 
VanNieuwenzhe et al. (2001) then generated the final product via formation of 
an activated phosphoimidazolidate intermediate from the phospho-MurNAc 





Schwartz et al. (2001) chemically synthesised Lipid II by first assembling a 
disaccharyl-monopeptide, which was then phosphorylated. The remainder of 
the peptide stem was coupled to the phosphorylated disaccharyl-monopeptide 
as a tetrapeptide. Finally, the phosphoryl group was activated using 1,1′-
carbonyldiimidazole (CDI) to allow coupling to undecaprenyl phosphate. 
 
A similar synthetic route to that of Schwartz et al. (2001) was employed by 
VanNiewenzhe et al. (2002) to achieve total chemical synthesis of Lipid II. The 
starting material was the disaccharyl monopeptide moiety, synthesised using 
a published protocol (Saha et al., 2001). The phosphate and then the 
tetrapeptide moieties were introduced to the molecule in similar fashion to the 
Lipid I synthesis protocol of the same group (VanNieuwenzhe et al., 2001), in 
addition to the same phosphoroimidazolidate protocol for coupling of 
undecaprenyl phosphate to the intermediate. Despite the similar routes to 
synthesis employed by VanNieuwenhze et al. (2001) and Schwartz et al. 
(2001), the yield is much lower for the latter (24 % vs 0.7 %). However, it is 
unclear whether the yield calculated by VanNieuwenzhe et al. encompasses 
the steps to make the disaccharyl monopeptide, which may account for the 
difference. 
 
Nakamura et al. (2013) generated Lipid II depsipentapeptide 
chemoenzymatically, though in contrast to the approach of Liu et al. (2001), 
the route to the phospho-MurNAc depsipentapeptide moiety was by linking 
tetradepsipeptide to phospho-MurNAc L-Ala (Schwartz et al., 2001; 
VanNieuwenhze et al., 2002). Tetradepsipeptide was synthesised by solution-
phase peptide synthesis, and then coupled to protected phospho-MurNAc L-
Ala. Following deprotection of the phospho-MurNAc moiety (but retaining 
protecting groups on the peptide stem), the phospho-sugar was activated by 
CDI and coupled to undecaprenyl or heptaprenyl -phosphate, followed by 
deprotection and purification. Heptaprenyl-Lipid II was then synthesised 
enzymatically from heptaprenyl Lipid I using purified recombinant MurG and 
UDP-[14C]-GlcNAc. The authors stated that undecaprenyl Lipid II synthesis 
was not attempted due to aggregation of undecaprenyl Lipid I in solution, 
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though published methods have achieved synthesis of such products by 
inclusion of detergent in the reaction mixture (Breukink et al., 2003). 
 
3.1.3.3 Synthesis of branched UDP-MurNAc peptides by carbodiimide 
coupling 
 A common technique throughout the chemical syntheses discussed has been 
peptide coupling, using activating agents such as carbodiimides, to assemble 
the peptide stem of peptidoglycan precursors. The chemoenzymatic method 
of De Pascale et al. (2008) utilised carbodiimide coupling to synthesise 
branched pneumococcal peptidoglycan precursors. UDP-MurNAc 5P was 
synthesised enzymatically as described by Lloyd et al. (2008) and the branch 
was then appended by coupling of N-terminally 9-fluorenylmethyloxycarbonyl 
(Fmoc)-protected amino acids to the e-amino of the third position L-lysine in 
the stem peptide. The mechanism of this carbodiimide coupling method is 
further discussed in Section 3.3.4.1. M. flavus membranes were then used to 
generate branched Lipids from the UDP-MurNAc peptides according to the 
method described by Breukink et al. (2003). This chemoenzymatic method 
offered flexibility in the amino acids that could be incorporated into the branch, 
such that the pentaglycyl-Lipid II precursor of S. aureus could be prepared in 
the same way. 
 
3.1.4 Use of variety of substrates 
A variety of pneumococcal peptidoglycan intermediates were desired for this 
project in order to address the central research question; how does the 
availability of linear and branched pneumococcal peptidoglycan precursors 
relate to expression of resistance to b-lactam antibiotics?  
Indirect cross links in the pneumococcal cell walls consist of dipeptide 
branches with either L-Ala or L-Ser in the first position, and an invariant L-Ala 
residue in the second (L-X-L-Ala) (Filipe et al., 2000). The extent of indirect 
cross-links in pneumococcal cell walls varies by strain, as a consequence of 
variation in the activity level of the MurM enzyme that is responsible for 
branching of Lipid II (Filipe & Tomasz, 2000; Lloyd et al., 2008). A range of 
branched PBP substrates were therefore sought to allow characterization of 
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the kinetics of usage for each, to shed light on how the variety in 
pneumococcal cell wall peptide stems affects transpeptidation, and thereby 
influences the b-lactam resistance mechanism.  
The use of defined donor and acceptor substrates offers two main benefits in 
analysis of transpeptidase activity in our case; firstly, this makes possible the 
distinction of D,D-carboxypeptidation (the removal of the terminal D-Ala of the 
pentapeptide stem) from transpeptidation in assays that follow D-Ala release 
(Section 2.7.3). This is of particular use in the optimisation stage of assay 
development, as the effect of different conditions on the ratio of D,D-
carboxypeptidation to transpeptidation can be assessed. Secondly, the use of 
defined donor and acceptor substrates allows the substrate requirements and 
other important chemical features of either the donor or acceptor site to be 
investigated independently.  
  
Figure 3.3 Summary of the uses for different kinds of substrates for 
pneumococcal PBPs.  
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3.2 Experimental Aims 
• To synthesise UDP-MurNAc 5P (iGln) and Lipid II (iGln) using 
published methods 
• To use the published carbodiimide synthesis method to synthesise 
amidated branched UDP-MurNAc peptides 
• To develop a carbodiimide coupling synthesis method for synthesis of 
UDP-MurNAc heptapeptide intermediates 
• To test the synthesis of branched Lipid II intermediates from branched 
UDP-MurNAc peptides 
• To develop a method for synthesis of donor-only pneumococcal PBP 
substrates 
• To synthesis a range of acceptor-only pneumococcal PBP substrates, 
including polymerisable and non-polymerisable variants 
3.3 Results 
3.3.1 Synthesis of UDP-MurNAc 5P (iGln) 
The starting material for the majority of the syntheses described in this chapter 
was an amidated variant of the UDP-MurNAc 5P “cytoplasmic” peptidoglycan 
precursor, giving the peptide stem L-Ala-g-D-iGln-L-Lys-D-Ala-D-Ala. The 
chosen synthesis method was by use of purified recombinant Mur ligases to 
assemble UDP-MurNAc 5P from UDP-GlcNAc (Section 2.6.1), as described 
by Lloyd et al. (2008). The methodology has been used extensively in our 
group for the synthesis of a variety of native and modified peptidoglycan 
precursors.  
 
The energy recycling system, as depicted in Figure 3.2, enabled ongoing 
supply of the ATP required for the catalytic activity of Mur ligases C to F, and 
also simplified the purification procedure. Byproducts of the reaction without 
the energy recycling enzymes would include ADP and PEP, which would 
coelute with UDP-MurNAc peptide at the anion exchange purification step 




Amidated UDP-MurNAc 5P (UDP-MurNAc 5P (iGln)) was synthesized 
enzymatically in an overnight reaction, with UDP-GlcNAc as the starting 
material. Amidation of the second position was achieved by inclusion of D-
isoglutamine for incorporation into the peptide stem by MurD. This method 
ensures 100 % amidation of the final product, which is crucial if the product is 
to be used for Lipid II synthesis. Whilst non-amidated and amidated UDP-
MurNAc pentapeptide can be resolved by the anion exchange procedure used 
to chromatograph the reaction (Appendix 3.1), separation of amidated and 
non-amidated Lipid II would likely require an additional chromatography step, 
with associated losses of material. A technique has been described for 
separation of radiolabeled amidated and non-amidated Lipid II (Siewert & 
Strominger, 1968). However, detection of Lipid II on HPLC in the absence of 
radiolabelling or a chromophore is challenging, in addition to the limited 
column choice owing to the difficulty in handling of C55 lipid.  By contrast, a 
limitation of our method is the decreased efficiency with which MraY catalyses 
the linkage of the amidated substrate to undecaprenyl phosphate (Siewert & 
Strominger, 1968), resulting in consistent lower yields of Lipid II (iGln) in 
comparison to non-amidated Lipid II. 
 
The UDP-MurNAc 5P (iGln) synthesis reaction was purified by anion 
exchange chromatography on Source30Q resin (GE Healthcare) as described 
in Section 2.6.1.3 (Figure 3.4). The chromatogram appeared as depicted in 
Figure 3.4.a, with peaks corresponding to (i) the desired product; (ii) PEP; and 
Figure 3.4 Purification of UDP-MurNAc 5P (iGln). Chromatography of the 
synthesis reaction (a) by anion exchange chromatography, and analysis of final 
purity (b) by analytical anion exchange chromatography are presented. The 
product peak (i) was resolved from PEP (ii) and ATP (iii). Analytical anion 






(iii) ATP (Dr. A.J. Lloyd, University of Warwick, personal communication). 
Fractions containing the product were concentrated, and the ammonium 
acetate concentration reduced, by lyophilization. The final product was then 
quantified by A260nm, purity was established by analytical anion exchange 
chromatography (Figure 3.4b), and the identity of the product was confirmed 
by mass spectrometry (Appendix 3.2 – expected (m-2)/2 573.18; observed (m-
2)/2 573.18). 
 
3.3.2 Synthesis of Lipid intermediate 
Lipid intermediates were synthesized using the enzymatic method described 
by Breukink et al. (2003), wherein M. flavus membranes provide MraY and 
MurG activities. Purified recombinant MurG was used to supplement the 
membranes. The chromatography of such a synthesis reaction, as analysed 
by TLC, is presented in Figure 3.5. 
Figure 3.5 Thin-layer chromatography analysis of purification of Lipid II 
(iGln). The Lipid II synthesis reaction was purified by anion exchange 
chromatography using stepwise elution up to 166.7 mM ammonium 
bicarbonate in 2:3:1 chloroform:methanol:buffer. Fractions were analysed by 
thin-layer chromatography run in 44:88:10:1 chloroform: methanol: ammonia: 




Extensive wash steps were included between 8.3 and 16.7 mM ammonium 
bicarbonate, in contrast to purification of non-amidated Lipid II, whereby the 
wash steps across this range were 8.3, 12.5 and 100 mM only (Dr. A. York, 
University of Warwick, personal communication). The additional wash steps 
for purification of Lipid II (iGln) ensured adequate separation of the desired 
product from undecaprenyl phosphate (as shown in Figure 3.5), whereas non-
amidated Lipid II commonly elutes from the column approximately in the 16.7 
mM ammonium bicarbonate wash. The product was confirmed by mass 
spectrometry (expected (m-2)/2 936.03; observed (m-2)/2 936.03. See 
Appendix 3.3). 
 
3.3.3 Comparison of Lipid II synthesis method to a published method 
The method for synthesis of Lipid II published by Schneider et al. (2004) used 
enzymes supplied by M. flavus membranes. Their method was analogous to 
that described in this thesis, and quoted milligram yields of Lipid II, but had 
 
Table 3.1. Comparison of the Lipid II synthesis reactions of Lloyd et al. (2008) 
and Schneider et al. (2004). 
 
Reagent Lloyd et al.  
(2008)  
Schneider et al. 
(2004) 
Undecaprenyl phosphate (mM) 1.4 0.067 
Buffer 100 mM Tris-HCl 
pH 8 
10 mM MgCl2 
1 % (v/v) Triton X-
100 
60 mM Tris-HCl 
pH 8 
5 mM MgCl2 
0.5 % (v/v) Triton X-
100 
UDP-MurNAc 5P (mM) 4.0 0.67 
UDP-GlcNAc (mM) 6.0 0.67 
Purified recombinant MurG 
(mg.mL-1) 
0.57 N/A 
Incubation Overnight at 37°C 1 hr at 30°C 
M. flavus membranes  




various slight differences in composition of the synthesis reaction. A 
comparison of the two methods is given in Table 3.1. We sought to compare 
the yield of Lipid II (iGln) from the two methods, hereafter designated Lloyd et 
al. and Schneider et al., to determine the best choice of method for further 
syntheses. 
 
The Lloyd et al. Lipid II synthesis protocol was optimised to shift the equilibrium 
of the reversible reaction catalysed by MraY towards production of Lipid I. This 
was achieved using a 3:2 molar ratio of UDP-GlcNAc to UDP-MurNAc 
pentapeptide, and by supplementing the reaction with purified recombinant 
MurG, to ensure that MurG forces the equilibrium position of the system 
towards Lipid II synthesis. By comparison, Schneider et al. used equimolar 
concentrations of UDP-GlcNAc to UDP-MurNAc pentapeptide.  
 
Table 3.2 Analytical scale reactions for comparison of Lloyd et al. (2008) and 
Schneider et al. (2004) Lipid II syntheses. To compare the Lipid II (iGln) yield 
from the synthesis methods of Lloyd et al. (orange, reaction 1) and Schneider et 
al. (blue, reaction 2), 200 µL reactions with combinations of these conditions as 




1 2 3 4 
UDP-MurNAc 5P (mM) 4 0.67 4 0.67 
UDP-GlcNAc (mM) 6 0.67 6 0.67 
C55P (mM) 1.4 0.067 1.4 0.067 
MurG (mg.mL-1) 0.57 0 0.57 0 
M. flavus membranes (protein mass, mg) 2 2 0.4 0.4 
 
In the Lloyd et al. method, the reaction is made up to the required volume by addition 
of M. flavus membranes, and so the total protein concentration added to the reaction 
is over twice that quoted for the method used by Schneider et al.. 
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In order to compare the yields of Lipid II (iGln) from the methods of Schneider et al. 
and Lloyd et al., analytical scale (150 µL) syntheses combining different aspects of 
each method were used. In addition to comparing each method as described (Lloyd 
et al.: 4 mM UDP-MurNAc 5P, 6 mM UDP-GlcNAc, 1.4mM C55P – reaction 1, Table 
3.2; Schneider et al.: 0.67 mM UDP-MurNAc 5P, 0.67 mM UDP-GlcNAc, 0.067mM 
C55P – reaction 2, Table 3.2), the amount of M. flavus membranes was swapped 
1.6 4.2 1.0 0.2 5.0 0.4 1.2 1.2 8.4 0.3 Band intensity relative to C 
Figure 3.6. Thin-layer chromatography analysis of yield of Lipid II (iGln) 
from varied synthesis conditions. Reactions 1-4 correspond to the 
combinations set out in Table 3.2. Band intensity at the Rf expected for Lipid 
II was quantified using ImageJ software (Schneider et al., 2012), and is 
presented (in blue) as values relative to the Lipid II band in the control (C) 
lane. 
Reaction lanes 1-4. 1: 4 mM UDP-MurNAc 5P, 6 mM UDP-GlcNAc, 1.4mM 
C55P, 0.57 mg.mL-1 MurG, 2 mg protein from M. flavus membranes; 2: 0.67 
mM UDP-MurNAc 5P, 0.67 mM UDP-GlcNAc, 0.067 mM C55P, 2 mg protein 
from M. flavus membranes; 3: 4 mM UDP-MurNAc 5P, 6 mM UDP-GlcNAc, 
1.4mM C55P, 0.57 mg.mL-1 MurG, 0.4 mg protein from M. flavus membranes 
; 4: 0.67 mM UDP-MurNAc 5P, 0.67 mM UDP-GlcNAc, 0.067 mM C55P, 0.4 
mg protein from M. flavus membranes;  
Control lanes - C: Purified Lipid II and C55P; SolA: Solvent A only; 5: no 11P; 




between the reaction schemes to reveal the impact of the amount of MraY and MurG 
provided by M. flavus membranes (Table 3.2).  
Comparative analytical-scale (150 µL) syntheses were incubated at 37 °C overnight. 
These were then assessed by silica TLC, as presented in Figure 3.6. By this 
qualitative approach, there is an apparent greater yield of Lipid II with the Lloyd et al. 
synthesis protocol (Figure 3.6, Lane 1) compared to that for the protocol of Schneider 
et al. (Figure 3.6, Lane 4). Band intensities in the region of the TLC with the Lipid II 
bands was plotted using ImageJ software (Schneider et al., 2012), and the values 
presented in Figure 3.6 are relative to the intensity of the Lipid II (iGln) band in the 
control lane. 
The reactions with the same amount of C55P added, but differing in the amount of M. 
flavus membranes (Figure 3.6, Lane 1 vs 3, and Lane 2 vs 4), demonstrated similar 
apparent yield of Lipid II (iGln) with Lloyd et al. reagent concentrations (Lanes 1 and 
3; band intensities 5.0 and 4.2 respectively), but greater yield with the larger amount 
of M. flavus membranes (Lane 2) with Schneider et al. reagent concentrations (band 
intensities 1.6 and 0.4 respectively for lanes 2 and 4). Altogether, these results 
suggest that the synthesis protocol of Lloyd et al. gives greater yield of Lipid II than 
that published by Schneider et al.  
The double band observed running closest to the origin in lane 7 (marked *) would be 
expected to correspond to Lipid I, due to the omission of UDP-GlcNAc from this 
synthesis reaction. However, the migration of this band (*) is similar to bands in lanes 
1-4, and the Lipid II control. Syntheses of Lipid II described elsewhere in this Chapter 
were not found to contain Lipid I amongst the products, and so lanes 1-4 would be 
expect to correspond to Lipid II. The product in lane 7 warrants analysis by mass 




3.3.4 Synthesis of branched peptidoglycan intermediates 
Synthesis of branched peptidoglycan intermediates has been a key part of this 
project, to allow study of pneumococcal PBPs with relevant natural substrates. 
We therefore sought a reliable and flexible method for synthesis of such 
intermediates. 
 
3.3.4.1 Method choice 
The chosen route for synthesis of branched intermediates was by 
carbodiimide coupling (De Pascale et al., 2008). This method was used to add 
the amino acids of the branch to the e-amino group L-Lysine at residue 3 of 
the peptide stem in UDP-MurNAc 5P (iGln). The branched peptides thus 
obtained were then to be processed into Lipid intermediates as previously 
described (Section 3.3.2), or acid hydrolysed to generate branched acceptors 
for the transpeptidase reaction. The variety of branched UDP-MurNAc 
peptides sought (Figure 3.7) was devised to encompass the naturally 
occurring variation in the pneumococcal cell wall. 
The mechanism of carbodiimide coupling for synthesis of branched peptide 
intermediates is depicted in Figure 3.8: The carboxyl-terminus of an N-
Figure 3.7 The variety of branched UDP-MurNAc pentapeptide 
intermediates whose synthesis has been attempted. Amidation of the 
stem peptide at the a-carboxyl of D-isoglutamine is highlighted in green.   
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terminally Fmoc-protected amino acid (1) was activated by reaction with 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, (2)), generating an O-
acylisourea intermediate (3). Under the aqueous conditions necessary for 
handling of the UDP-MurNAc 5P starting material, the activated species is 
subject to hydrolysis (Staros et al., 1986). The efficiency of the reaction was 
therefore maintained by reacting the activated species with N-
hydroxysuccinimide (HOSu, (4)), generating a stable HOSu ester (6). Sodium 
bicarbonate buffer was used to adjust the pH of the solution to 10, and UDP-
MurNAc pentapeptide was then added. The e-amino group of L-lysine in the 
pentapeptide stem displaced HOSu by nucleophilic attack, with formation of a 
peptide bond (generating (8)). The reaction was then terminated by addition 
of ethanolamine, to quench excess HOSu esters remaining in the reaction 
mixture (Gestwicki et al., 2001). The final compound (10) was generated after 
deprotection using piperidine (9). The secondary amine of piperidine removed 
the acidic proton (9-position of Fmoc fluorene ring), following which a b-
elimination generated a dibenzofulvene intermediate (11) that formed a stable 






Figure 3.8 Mechanism of carbodiimide coupling for synthesis of branched intermediates. EDC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide, (2)) activates the carboxyl-terminus of N-terminally Fmoc-protected amino acids (1) generating an O-
acylisourea intermediate (3). HOSu (N-hydroxysuccinimide, (4)) reacts with the activated species to form a stable HOSu ester (6). UDP-
MurNAc pentapeptide was then added. The e-amino group of L-lysine in the pentapeptide stem displaced HOSu by nucleophilic attack, with 
formation of a peptide bond to generate 8. Compound 8 was deprotected using piperidine (9) to give the final product (10), with generation of 
an Fmoc-piperidine adduct as a by-product (11). 
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3.3.4.2 Desalting of UDP-MurNAc 5P 
The UDP-MurNAc 5P (iGln) to be used as the starting material for branched 
peptide synthesis was first desalted by gel filtration, using a Biogel P2 column 
(Bio-Rad) (Section 2.6.5). This step was incorporated to remove residual 
ammonium acetate from the starting material, which would otherwise have 
decreased the coupling efficiency (by reaction with the amino acid HOSu ester 
formed in the coupling reaction). Those fractions containing UDP-MurNAc 5P 
iGln (Figure 3.9, peak (i)) eluted separately from the salt peak (peak (ii)) were 
concentrated by lyophilization, and the concentration of the final stock was 
determined by A260nm.  
 
3.3.4.3 Synthesis of hexapeptide intermediates 
A published method (De Pascale et al., 2008) was initially followed for 
carbodiimide coupling synthesis of branched UDP-MurNAc peptides. In this 
protocol, ethanolamine was used to quench the reaction by consumption of 
excess HOSu ester, and piperidine was used to deprotect the compound. The 
reaction mixture was purified by anion exchange chromatography, using the 
same methodology as that previously described for purification of UDP-
MurNAc 5P (Section 2.6.1.3). 
Figure 3.9 Desalting of UDP-MurNAc pentapeptide by gel filtration. UDP-
MurNAc 5P (iGln) was desalted by gel filtration using a Biogel P2 column (Bio-
Rad). A 500 µL sample was loaded to the column via an injection loop, and 
the column was then developed over 2 column volumes. UDP-MurNAc 5P 




Upon analysis by mass spectrometry of the major peak from purification of 
branched UDP-MurNAc peptides, we identified the occurrence of multiple 
additions of L-Alanine to the e-amino group of L-Lys in the peptide stem (Table 
3.3), along with loss of amidation at the second position of the peptide stem 
(see Appendices 3.4 to 3.7). This finding necessitated both a change in the 
quenching technique, and a chromatography column affording higher 
resolution to allow separation of products with multiple additions.  
 
Table 3.3: Nanospray TOF mass spectrometry analysis of carbodiimide 
coupling reactions quenched using ethanolamine. Multiple alanylation was 
associated with loss of amidation of the 2nd position step peptide residue. Data 
collected and analysed by A.J. Lloyd. 
 
Compound 2nd posn Expected m/z Observed m/z Charge 
state 
UDP-MurNAc 6P iGln 608.70 608.71 
(m-2)/2 
iGlu 609.19 - 
UDP-MurNAc 9P iGln 715.25 - 
iGlu 715.74 715.76 
UDP-MurNAc 10P iGln 750.77 - 
iGlu 751.26 751.28 
UDP-MurNAc 11P iGln 786.29 - 
 iGlu 786.78 786.79 
UDP-MurNAc 12P iGln 821.81 - 
 iGlu 822.30 822.31 
 
The quenching agent used in the published method, ethanolamine, has itself 
been employed for deprotection of Fmoc-amino acids (Carpino & Han, 1972). 
The presence of this compound was therefore suspected to be the cause of 
the multiple addition observed, by deprotecting the intended product in the 
presence of reactive HOSu esters, allowing additional rounds of coupling to 
occur. Different agents for quenching of the reaction were therefore tested. 
The nucleophile hydroxylamine was chosen, which is weakly basic and should 




The products of UDP-MurNAc 6P (iGln, L-Ala) syntheses that were quenched 
with hydroxylamine were purified by anion exchange chromatography in the 
ammonium acetate buffer system previously described, but utilising a 
preparative-scale MonoQ column (GE Healthcare), which has greater 
resolution than the Source30Q (GE Healthcare) column previously used. The 
major peak from chromatography of reactions quenched by ethanolamine 
(Figure 3.10a) or hydroxylamine (Figure 3.10b) eluted at conductivity of ~15 
mS.cm-1 in each case. Based on the chromatographic analysis of reactions 
quenched with ethanolamine or hydroxylamine, the synthesis appeared 
cleaner with hydroxylamine; fewer products were detected by absorbance at 
280 nm and 254 nm. The major peaks from the reaction quenched with 
Figure 3.10. Anion exchange chromatography purification of iGln UDP-
MurNAc hexapeptide (L-Ala) from reactions quenched by ethanolamine 
or hydroxylamine. The efficacy of a) ethanolamine (with inset full 
chromatogram) and b) hydroxylamine as quenching agents in the synthesis of 




hydroxylamine were lyophilized, and analysed by mass spectrometry (Table 
3.4).  
Analysis of the products by mass spectrometry confirmed the synthesis of 
UDP-MurNAc 6P (iGln, L-Ala) (expected (m-2)/2, 608.69; observed (m-2)/2, 
608.71), but also identified minor ions corresponding to the products of 
multiple alanylation of UDP-MurNAc 5P (iGln). In addition, ions were detected 
corresponding to a loss of UMP from the molecule (Table 3.4), both co-eluting 
with the desired product and in a sample of the peak detected at                        
13.3 mS.cm-1 (for spectra, see Appendices 3.8 to 3.11). The alternate 
quenching agent tested therefore did not appear to aid in improvement in yield 
of the desired compounds. 
Quenching agents were therefore omitted completely from the coupling 
procedure. The desired UDP-MurNAc 6P (iGln, L-Ala) product was 
successfully synthesized under such conditions (expected (m-2)/2, 608.695; 
observed (m-2)/2, 608.695. See Table 3.5). A small degree of multiple 
alanylation was observed in the absence of quenching agent (up to UDP-
MurNAc 8P (iGln, L-Ala-L-Ala-L-Ala)). However, the omission of quenching 
agents avoided the loss of amidation and UMP that was associated with the 
use of ethanolamine and hydroxylamine respectively (Appendices 3.12 and 
3.13). Purification of UDP-MurNAc 6P (iGln, L-Ala) is illustrated in Figure 3.11. 
 
 
Table 3.4: Nanospray TOF mass spectrometry analysis of carbodiimide 
coupling reactions quenched using hydroxylamine. Ions detected in major 
peak eluting at 15.0 mS.cm-1. Data collected and analysed by A.J. Lloyd. 
 
Compound Expected m/z Observed m/z Charge state 
phospho-MurNAc 6P 912.37 912.39 (m-1)/1 
UDP-MurNAc 6P 608.69 608.71 (m-2)/2 
UDP-MurNAc 7P 644.21 644.23 (m-2)/2 
UDP-MurNAc 8P 679.74 679.74 (m-2)/2 
UDP-MurNAc 9P 715.25 715.26 (m-2)/2 
UDP-MurNAc 10P 750.77 750.78 (m-2)/2 
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3.3.4.4 Synthesis of heptapeptide intermediates 
Synthesis of heptapeptide (7P) intermediates was initially attempted by 
multiple rounds of the liquid phase coupling described in the previous Section 
(3.3.4.3). This method proved unsuccessful in obtaining any measurable 
heptapeptide products. 
 
An alternative method was therefore attempted whereby solid phase peptide 
synthesis (SPPS) (Fields & Noble, 1990) was used to generate the dipeptide 
‘branch’, which could then be coupled to the pentapeptide in a single step. The 
mechanism of this peptide coupling procedure is depicted in Figure 3.12. By 
using the SPPS method to supply dipeptide to be coupled to UDP-MurNAc 5P 
as before, detectable quantities of the L-Ala-L-Ala heptapeptide was 
synthesized, and purified using the same method as described for the 
hexapeptide intermediates (Figure 3.11c).  
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The SPPS method had not been the first choice of method for synthesis of 
heptapeptide intermediates. Cyclisation of the C-terminal amino acid, forming 
an oxazolone, can cause racemization within the dipeptide when it is activated 
(Figure 3.13). A branched UDP-MurNAc peptide with a D-X-L-Ala branch 
could therefore be produced if this occurs during the synthesis reaction. The 
use of HOSu to generate an active ester as an intermediate in the coupling  
Figure 3.11 Purification of branched UDP-MurNAc peptides. Chromatograms for 
purification of iGln UDP-MurNAc a) hexapeptide (L-Ala), b) hexapeptide (L-Ser), c) 
heptapeptide (L-Ala-L-Ala) and d) heptapeptide (L-Ser-L-Ala) respectively by anion exchange 
chromatography on a MonoQ HR 10/10 column (GE Healthcare). Peaks corresponding to the 
desired (or major) product (i) in each case are indicated, as identified by negative ion 
nanospray TOF mass spectrometry (a – expected m/z 608.695; observed m/z 608.695; b – 
expected m/z 616.69; major ion observed m/z 644.73; c – expected m/z 644.213; observed 
m/z 644.217; d – expected m/z 687.73; observed m/z 652.21), though in the case of the L-











Figure 3.12 Mechanism of solid phase peptide synthesis using N-HATU, for synthesis of Fmoc-dipeptides. N-terminally 
Fmoc-protected L-Ala (1) was activated at the carboxyl terminus for amide coupling using HATU (hexafluorophosphate N-
oxide) (2). The carboxylate terminus of Fmoc-L-Ala attacks (2), generating intermediate 3 and an HOAt (1-hydroxy-7-
azabenzotriazole) anion (4). 4 reacts with 3 to form an OAt-Fmoc-L-Ala activated ester (5). 5 was then subject to 
nucleophilic attack by the primary amine of L-Ser- or L-Ala-Wang resin (6). N-HATU was thus displaced (7) and the 
Fmoc-L-Ala coupled to the amino acid-Wang resin (8). Finally, Fmoc-dipeptide (9) was cleaved from Wang resin using 





reaction has been reported to suppress racemization (Kemp et al., 1970), and 
so this additive had been incorporated into the synthesis in original 
development of the method (De Pascale et al., 2008). 
 
Chiral chromatography by HPLC was used to assess whether racemization 
had occurred in the dipeptides. The glycopeptide class of antibiotics, which 
bind the terminal D-Ala-D-Ala moiety of Lipid II, can be used as chirally-
selective stationary phases for enantiomeric separation of amino acids, as 
proposed by Armstrong et al. (1994). In addition to this binding, other 
interactions between the analyte and a glycopeptide stationary phase may 
Figure 3.13 Mechanism of potential racemisation by oxazolone 
formation. Oxazolone formation could occur when activating Fmoc-
dipeptides.  The carbodiimide (EDC, denoted as ‘X’) provides a leaving group 
that allows cyclisation of the C-terminal amino acid, and upon reopening of 
this ring a switch in stereochemistry of this amino acid may occur. Made with 
reference to Scheme 2, El-Faham and Albericio (2011). 
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include hydrophobic, electrostatic and hydrogen bonding, as determined by 
the structural features of the chosen stationary phase (Ilisz et al., 2006). An 
attractive approach to generating enantiomerically pure branched 
muropeptides would be the enantioselective purification of Fmoc-dipeptide 
HOSu esters, prior to their use in the carbodiimide coupling procedure. This 
would give a good degree of certainty that diastereoisomerism would not be 
introduced into the final molecule by rearrangement during the amino acid 
activation. However, both vancomycin and teicoplanin, two of the antibiotics 
used in such columns, contain primary amines – and in the case of teicoplanin, 
the interaction between the ammonium group and a carboxylic acid moiety of 
the analytes has been demonstrated to be involved in the mechanism of 
separation (Ilisz et al., 2006). The addition of HOSu esters to such stationery 
phases would therefore carry a risk of covalent linkage of the analyte to these 
primary amines.  
The method chosen was therefore to hydrolyse a sample of each Fmoc-
dipeptide HOSu ester by the addition of water. These hydrolysed dipeptides, 
in addition to samples of the Fmoc-dipeptides before activation, were then 
analysed by R. Cain by chiral HPLC on a CHIROBIOTIC™ T column (Astec). 
The dipeptides were found by this method to be >98 % single stereoisomer. 
However, the analysis following hydrolysis of Fmoc-dipeptide HOSu esters 
proved more complicated owing to multiple peaks likely introduced by the 
presence of the activation reagents in the sample. In addition, this method 
introduced more complexity into the chromatographic resolution of 
pentapeptide and derivative molecules, as many more peaks were observed 
possibly due to the multitude of stereocenters in these molecules. Further 
experimentation will be required to achieve retention of the heptapeptides, to 




 The purity of branched intermediate stocks was tested by analytical anion 
exchange chromatography, as depicted in Figure 3.14. Whilst L-Ala branched 
variants were obtained to high purity (97 % and 95 % for hexapeptide and 
heptapeptide respectively), the final purity of the putative L-Ser-containing 
variants was lower particularly for the hexapeptide (62 % and 81 % for 
hexapeptide and heptapeptide respectively). The final product of the Ala 
 
Table 3.5: Nanospray TOF mass spectrometry analysis of Ala variant 












(m-1)/1 1218.40 1218.40 
Confirmed 
(m-2)/2 608.70 608.70 
UDP-MurNAc 7P 
(iGln, L-Ala-L-Ala) 
(m-1)/1 1289.43 1289.44 
Confirmed 
(m-2)/2 644.21 644.22 
Figure 3.14 Purity assessment of branched UDP-MurNAc peptides. 
Samples of branched UDP-MurNAc peptides were purified by analytical 
exchange chromatography, with purity assessed based on the area of peaks 
in absorbance at 254 nm. Purities: UDP-MurNAc 6P (iGln, L-Ala), 97 %; 
UDP-MurNAc 6P (iGln, L-Ser), 62 %; UDP-MurNAc 7P (iGln, L-Ala-L-Ala) 
95 %; UDP-MurNAc 7P (iGln, L-Ser-L-Ala), 81 %. 
 
 104 
variant syntheses was confirmed by nanospray mass spectrometry (Table 
3.5). Multiple alanylation beyond the desired product was observed in 
reactions with coupling of dipeptides to UDP-MurNAc 5P. It was unclear how 
products including UDP-MurNAc 8P (iGln, L-Ala-L-Ala-L-Ala) arose from 
dipeptide coupling. 
 
3.3.4.5 Challenges in synthesis of Ser-branch intermediate 
Analysis of Ser variants of branched UDP-MurNAc peptides (UDP-MurNAc 
hexapeptide (iGln, Ser) and UDP-MurNAc heptapeptide (iGln, L-Ser-L-Ala)) 
revealed that the product peaks were dominated by species including the 
products of multiple additions, and the un-deprotected branched peptides 
(Table 3.6, and Appendices 3.16 to 3.19). Due to these ongoing issues, further 
development was focused on the Ala variants. 
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3.3.4.6 Mass spectrometry analysis of branched UDP-MurNAc peptides 
To confirm the positioning of the amino acids added to UDP-MurNAc 5P (iGln) 
by carbodiimide coupling, UDP-MurNAc 6P (iGln, L-Ala) and UDP MurNAc 7P 
(iGln, L-Ala-L-Ala) were analysed by mass spectrometry using collision-
induced fragmentation. UDP-MurNAc 5P (iGln) was also fragmented to 
illustrate those fragments arising from the addition of the branch amino acids. 
For experimental details, see Appendices 3.20 to 3.23. 
The fragmentation patterns of UDP-MurNAc 6P (iGln, L-Ala) and UDP-
MurNAc 7P (iGln, L-Ala-L-Ala) revealed ions that were diagnostic of the 
Table 3.6: Nanospray TOF mass spectrometry analysis of Ser variant 
branched peptides. Ions detected in major peaks as indicated in Figure 3.11. Data 
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branch added to the e-amino group of the L-Lysine in the stem peptide in each 
case (Figure 3.15 to Figure 3.16). Fragmentation of UDP-MurNAc 6P (iGln, L-
Ala) generated Lactyl-L-Alanyl-D-isoglutaminyl-L-Lysyl-(L-Alanine)-D-Alanyl-
D-Alanine, (expected (m+1)/1 631.34, observed (m+1)/1 631.34), confirming 
position of branch on UDP-MurNAc 6P (iGln, L-Ala). Fragmentation of UDP-
MurNAc 7P (iGln, L-Ala-L-Ala) generated Lactyl-L-Alanyl-D-isoglutaminyl-L-
Lysyl-(L-Alanyl-L-Alanine)-D-Alanyl-D-Alanine, (expected (m+1)/1 702.38, 







Figure 3.15 Fragmentation pattern of UDP-MurNAc 5P (iGln). UDP-MurNAc 5P (iGln) was analysed by collision-induced 




Figure 3.16 Fragmentation pattern of UDP-MurNAc 6P (iGln, L-Ala). UDP-MurNAc 6P (iGln, L-Ala) was analysed by collision-




Figure 3.17 Fragmentation pattern of UDP-MurNAc 7P (iGln, L-Ala-L-Ala). UDP-MurNAc 7P (iGln, L-Ala-L-Ala) was analysed 
by collision-induced fragmentation. Data collected by A.J. Lloyd, and mass spectra generated using MassLynx software (Waters). 
 
 
3.3.4.7 Branched lipids 
Following success in obtaining branched UDP-MurNAc peptides, synthesis 
of lipid-linked branched intermediates was attempted by the enzymatic 
method previously described (Section 3.3.2). The syntheses were conducted 
in 400 µL reactions, in order to limit the mass of branched peptide starting 
material required, but provide sufficient volume for TLC and mass 
spectrometry analysis of the reaction products. Reactions were purified on a 
400 µL bed DEAE sephacel (GE Healthcare) column by stepwise elution in 
increasing concentrations of ammonium bicarbonate. Fractions were then 
analysed by TLC (Figure 3.18). For both Lipid II 6P and Lipid II 7P, two sets 
of spots were observed, referred to as ‘lower’ and ‘higher’ spots. For each 
purification, the fractions corresponding to each were pooled, dessicated to 
remove solvents, and lyophilised to remove the ammonium bicarbonate. 
These samples were then analysed by nanospray TOF mass spectrometry. 
A summary of the observed masses in each sample is presented in Table 3.7 
(see Appendices 3.24 to 3.27 for mass spectra).  
For both the Lipid II hexapeptide and Lipid II heptapeptide syntheses, a 
doubly-charged ion whose mass corresponded to that expected for the 
desired compound was detected in the ‘higher’ spots sample.  
 
Table 3.7 Summary of mass spectrometry data for analysis of branched lipid 
syntheses. Samples corresponding to the ‘higher’ and ‘lower’ spots observed on TLC 
analysis of the Lipid purifications were analysed by negative ion nanospray time-of-flight 






Observed m/z Compound 
Lipid II 6P (iGln, L-Ala) 
lower spot 
(m-3)/3  647.36 647.45 unknown 
Lipid II 6P (iGln, L-Ala) 
higher spot 
(m-2)/2  971.55 971.56 Confirmed 
Lipid II 7P (iGln, L-Ala-L-
Ala) lower spot 
(m-2)/2  971.55 971.55 (minor) Lipid II 6P 
(iGln, L-Ala) 
Lipid II 7P (iGln, L-Ala-L-
Ala) higher spot 
(m-2)/2  1007.07 1007.08 Confirmed 




Figure 3.18 Thin-layer chromatography analysis of purification of 
branched lipid syntheses. Analytical scale syntheses of amidated Lipid II a) 
hexapeptide (L-Ala) and b) heptapeptide (L-Ala-L-Ala) were purified by anion 
exchange chromatography through DEAE sephacel. Elution was performed 
by with incrementally increasing the ammonium bicarbonate concentration as 
depicted, in 2:3:1 chloroform:methanol:buffer, and the fractions analysed by 
thin-layer chromatography run in 44:88:10:1 
chloroform:methanol:water:ammonia and stained using iodine vapour. Two 
sets of apparent product spots were observed in each case, designated 
‘lower’ and ‘higher’ spots respectively. Purer fractions containing these spots 






Lipid II hexapeptide (iGln, L-Ala) was also detected in the ‘lower’ spot sample 
for the heptapeptide purification. 
 
3.3.5 Synthesis of donor-only PBP substrates 
Transpeptidase donor- and acceptor-only substrates were sought in order to 
allow the composite rate observed with Lipid II (iGln, L-Lys) (with 
pentapeptide stem) in the Amplex Red transpeptidase assay to be resolved 
into the D,D-carboxypeptidation rate (as observed in the presence of the 
donor-only substrate alone) and the composite rate with transpeptidation 
(observed in the presence of both a donor-only substrate and an acceptor-
only substrate). In addition, the use of defined substrates would allow the 
important chemical features of each substrate in the transpeptidase reaction 
to be investigated. Our intended methodology for synthesis of lipid-linked 
donor-only substrates was to first generate a modified UDP-MurNAc peptide, 
and to then link this precursor to undecaprenyl phosphate using M. flavus 
membranes. To render the peptide stem donor-only, the nucleophilic 




3.3.5.1 Enzymatic synthesis of donor-only substrates 
The first approach towards synthesis of donor-only substrate analogues for 
pneumococcal PBPs, was the enzymatic incorporation of non-canonical 
amino acids into position 3 of the pentapeptide stem by MurE. The amino 
acids tested for such incorporation were L-Arginine and e-dimethyl-L-Lysine 
(see structures of pentapeptide stems generated in Figure 3.20). The 
Figure 3.19 Features of donor- and acceptor-only substrates. a) The 
transpeptidase mechanism, illustrating involvement of the donor stem peptide 
carbonyl (green box) and the primary amine of the acceptor stem peptide (pink 
box). b) the key features determining whether particular substrate variants are 
donor- or acceptor-only. Donor-only substrates must be polymerisable (i.e. 
lipid linked) and retain the donor carbonyl. These substrates are made donor-
only by loss of the acceptor nucleophile (e.g. by acetylation, as depicted). 
Conversely, acceptor substrates retain the acceptor nucleophile, and are 
made acceptor-only by loss of the lipid linker or the donor carbonyl. 
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synthesis and purification were as described for UDP-MurNAc 5P (iGln) 
(Section 2.6.1) but with the relevant amino acid in place of L-Lysine (see 
chromatograms Figure 3.21). With both L-Arginine and e-dimethyl-L-Lysine, 
the incorporation by MurE was unsuccessful, as the syntheses appeared to 
have halted at the stage of the dipeptide. On each chromatogram (Figure 
3.21a and b), the peak (i) corresponding to a UDP-MurNAc substrate in the 
purification of these syntheses was freeze-dried and analysed by negative 
ion TOF mass spectrometry, which identified this compound as UDP-MurNAc 
dipeptide (iGln) (expected (m-2)/2, 438.1; observed, (m-2)/2,438.1. See 
Table 3.8 and Appendix 3.30).  
 
Figure 3.20. Synthesis of donor-only UDP-MurNAc pentapeptides. The 
pentapeptide precursors for donor-only substrates whose syntheses were 
attempted (a), with reaction schemes (b and c). For synthesis of e-dimethyl-
L-Lysine or L-Arginine -containing pentapeptides, the enzymatic biosynthesis 
method (b) was attempted, whereas acetylated pentapeptide (UDP-MurNAc 
5P (iGln, e-N-acetyl-L-Lysine) was synthesised by use of acetic anhydride 
((CH3CO)2O) to acetylate UDP-MurNAc Lys 5P (iGln) (c). All precursors were 
amidated variants (i.e. with L-isoglutamine at the second position, site of 
amidation indicated in green).  
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The failure of incorporation of non-canonical amino acids in these 
experiments by MurE is likely the result of alteration of both substrates for 
this enzyme. The in vivo substrates of S. pneumoniae MurE would be UDP-
MurNAc-L-Ala-D-Glu and L-Lysine (Barreteau et al., 2008), whilst in this 
enzymatic synthesis, the substrates for MurE were UDP-MurNAc-L-Ala-g-D-
isoGln and e-dimethyl-L-Lysine or L-Arginine. Both modified 3rd position 
amino acids can be utilized by S. pneumoniae MurE in an assay, but the Km 
with these substrates was at least 20-fold greater than that observed with L-
Lysine (Dr. A. York, unpublished, University of Warwick). The low affinity of 
Figure 3.21. Purification of potential donor-only substrates. Pentapeptide 
precursors for donor-only substrates were purified by anion exchange 
chromatography on a Source30Q column (a-c) using ammonium acetate 
buffers, followed by freeze drying to concentrate the product and decrease the 
salt concentration. In each case, the product peak is denoted by (i). These 
reaction products were analysed by negative ion nano-spray TOF mass 
spectrometry. For the reactions to synthesise iGln UDP-MurNAc L-Arg 5P (a) 
and iGln UDP-MurNAc e-diMe-L-Lysine 5P (b), peak (i) was found to contain 
iGln UDP-MurNAc dipeptide, indicating that the synthesis had halted at this 
stage. The synthesis of iGln UDP-MurNAc acetyl-L-Lys 5P (c) was successful, 
as peak (i) was found to contain the desired product (by analysis with negative 
ion nano-spray TOF mass spectrometry). This pentapeptide was therefore 
used to synthesise donor-only lipid (d) using M. flavus membranes (Breukink 
et al., 2003). 
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the MurE enzyme for both substrates in these syntheses was therefore the 
most likely cause of the synthesis not progressing beyond UDP-MurNAc 
dipeptide.  
 
Table 3.8: Summary of MS analysis of donor-only peptide syntheses. 
Samples were analysed by negative mode nanospray time-of-flight mass 
spectrometry. Data collected by A.J. Lloyd. 








UDP-MurNAc 5P  
(iGln, e-di-Me-Lys) 
(m-2)/2 587.19 438.10 
UDP-MurNAc 
2P (iGln) 
UDP-MurNAc 5P  
(iGln, L-Arg) 
(m-2)/2 587.18 438.09 
UDP-MurNAc 
2P (iGln) 
UDP-MurNAc 5P  
(iGln, e-N-acetyl-L-
Lys) 
(m-2)/2 594.18 594.20 Confirmed 
Lipid II  
(iGln, e-N-acetyl-L-
Lys) 
(m-2)/2 957.04 957.04 Confirmed 
 
3.3.5.2 Chemo-enzymatic synthesis of donor-only substrate 
Synthesis of donor-only UDP-MurNAc peptide was next attempted by 
acetylation of UDP-MurNAc 5P (iGln) using acetic anhydride (Figure 3.20c, 
and chromatography of reaction Figure 3.21c) was therefore attempted, 
using a method which has proven successful for synthesis of UDP-MurNAc 
D,L-e-N-acetyl-DAP pentapeptide (Anita Catherwood, personal 
communication, University of Warwick). The desired product was confirmed 
by negative-ion TOF mass spectrometry (expected (m-2)/2 594.18; observed 
(m-2)/2 594.20. See Table 3.8 and Appendix 3.28). 
Donor-only lipid was then synthesized from the acetylated pentapeptide 
precursor using M. flavus membranes (Section 3.3.2). The thin-layer 
chromatography analysis of the fractions from the purification is shown in 
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Figure 3.21d. The product was confirmed by mass spectrometry (expected 
(m-2)/2 957.04; observed (m-2)/2 957.04. See Table 3.8 and Appendix 3.29). 
3.3.6 Synthesis of acceptor-only PBP substrates 
As described in Section 3.3.5, the use of defined donor- and acceptor-only 
substrates enables the detailed analysis of transpeptidase kinetics. The 
requirements for a substrate analogue to be acceptor-only appear to be that 
the substrate is either non-polymerisable, such as a Lipid I or MurNAc peptide 
compound; or that the peptide stem is lacking one or both D-Ala residues that 
would ordinarily terminate the stem, preventing such an intermediate from 
acylating the transpeptidase active site serine (Figure 3.19). 
 
3.3.6.1 MurNAc peptide acceptors 
Acceptors were synthesised by acid hydrolysis of UDP-MurNAc peptides 
(with the desired peptide stem), followed by purification by anion exchange 
chromatography. The loss of the UDP group, which would be the primary 
portion of the molecule providing negative charges to bind the anion 
exchange chromatography column, abolished binding of the product to the 
anion exchange column. MurNAc peptides therefore instead eluted within 
one column volume (peak (i), Figure 3.22) from the anion exchange column. 
The removed UDP (iii) group, and further degraded UMP (ii), did bind the 




The MurNAc peptide compounds were collected from the column flow-
through and freeze dried to remove ammonium acetate. The mass of 
compound was determined gravimetrically, and identity confirmed by mass 
spectrometry (Table 3.9). This analysis confirmed that the correct product 
had been synthesised (expected (m-1)/1 761.37; observed (m-1)/1 761.37; 
see Appendix 3.31). The acid hydrolysis method as applied to synthesis of 
MurNAc 5P (iGln) gave > 95 % yield. 
This method was then extended to other substrate variants. In addition to 
MurNAc peptide acceptors, acceptor-only lipid (Lipid II 3P (iGln)) was also 
synthesised. The variety of linear MurNAc peptide acceptor-only substrates 









Figure 3.22 Chromatography of MurNAc 5P (iGln) synthesis. A sample 
of UDP-MurNAc 5P (iGln) was acid hydrolysed, neutralised and purified by 
anion exchange. Peaks were observed corresponding to (i) MurNAc 5P 










Table 3.9: Summary of MS analysis of linear acceptor-only substrate 
syntheses. Samples were analysed by negative mode nanospray time-of-flight 
mass spectrometry. Data collected by A.J. Lloyd. 








MurNAc 5P (iGln) (m-1)/1 761.37 761.37 Confirmed 
UDP-MurNAc 4P (iGln) 
(m-1)/1 1076.32 1076.33 
Confirmed 
(m-2)/2 537.66 537.66 
MurNAc 4P (iGln) (m-1)/1 690.33 690.34 Confirmed 
UDP-MurNAc 3P (iGln) 
(m-1)/1 1005.29 1005.30 
Confirmed 
(m-2)/2 502.14 502.15 
MurNAc 3P (iGln) (m-1)/1 619.29 619.30 Confirmed 
Lipid II 3P (iGln) 
(m-1)/1 1730.99 1731.00 
Confirmed 




3.3.6.1.1 Linear acceptors with truncated peptide stems 
Two linear acceptors with truncated peptide stems, MurNAc 4P (iGln) and 
MurNAc 3P (iGln) were synthesised by distinct synthetic routes (Figure 3.23).  
Figure 3.23. Synthesis of linear acceptor-only MurNAc pentapeptide 
substrates. The linear peptide acceptor-only substrates whose syntheses are 
described (a), with reaction schemes (b to d). For synthesis of MurNAc 
pentapeptide (MurNAc 5P (iGln)), UDP-MurNAc pentapeptide (UDP-MurNAc 
5P (iGln) was acid hydrolysed by incubation with 0.1M hydrochloric acid at 99 
°C. UDP-MurNAc tetrapeptide was synthesised from UDP-MurNAc 5P (iGln) 
using DacB for removal of the terminal D-Ala. UDP-MurNAc tripeptide was 
synthesised enzymatically. The two truncated UDP-MurNAc peptides were 
then acid hydrolysed as before. All precursors were amidated variants (i.e. 




MurNAc 4P (iGln) was synthesised using UDP-MurNAc 5P (iGln) as the 
starting material. MurNAc 4P (iGln) was made by incubating UDP-MurNAc 
5P (iGln) with purified recombinant DacB. The D,D-carboxypeptidase 
removed the terminal D-Ala of the pentapeptide stem.  
The reaction was purified by anion exchange (Figure 3.24a), and the product 
confirmed by nanospray TOF mass spectrometry (expected (m-1)/1 1076.32; 
observed (m-1)/1 1076.33. See Table 3.9 and Appendix 3.32). UDP-MurNAc 
4P (iGln) was acid hydrolysed as before to generate MurNAc 4P (iGln) 
(Figure 3.25). The product was confirmed by mass spectrometry (expected 
Figure 3.24 Chromatography of UDP-MurNAc 4P (iGln) synthesis. 
Chromatography of the synthesis reaction (a) by anion exchange 
chromatography (with product peak (i) indicated), and analysis of final purity 
(b) by analytical anion exchange chromatography (with full trace inset) are 
presented. Analytical anion exchange indicated purity of 94 %. 
Figure 3.25 Chromatography of MurNAc 4P (iGln) synthesis. A sample of 
UDP-MurNAc 4P (iGln) was acid hydrolysed, neutralised and purified by anion 
exchange. Inset, full chromatogram with zoomed area indicated in box. 
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(m-1)/1, 690.33; observed (m-1)/1, 690.34) The final yield was <30% due to 
losses at the two steps of the procedure.  
MurNAc 3P (iGln) was synthesised by first using a modified enzymatic UDP-
MurNAc peptide synthesis to generate UDP-MurNAc 3P. The synthesis of 
UDP-MurNAc 3P was as described for that of UDP-MurNAc 5P, but omitting 
MurF and D-Ala-D-Ala. The synthesis was purified by anion exchange 
chromatography (Figure 3.26) and the product identified by nanospray TOF 
mass spectrometry (expected (m-1)/1 1005.29 ; observed (m-1)/1 1005.30. 
See Table 3.9 and Appendix 3.34). UDP-MurNAc 3P was then hydrolysed as 
previously to generate MurNAc 3P (iGln). Chromatography of the acid 
(iii) 
Figure 3.26 Chromatography of UDP-MurNAc 3P (iGln) synthesis. 
Chromatography of the synthesis reaction (a) by anion exchange 
chromatography and analysis of final purity (b) by analytical anion exchange 
chromatography are presented. The product peak (i) was resolved from PEP 
(ii) and ATP (iii).  Analytical anion exchange indicated purity of 96 %. 
Figure 3.27 Chromatography of MurNAc 3P (iGln) synthesis. A sample of 
UDP-MurNAc 3P (iGln) was acid hydrolysed, neutralised and purified by anion 
exchange.  The compound was loaded to the column in two injections, 
resulting in the two peaks labelled (i). Further peaks were observed 





hydrolysed sample is depicted in Figure 3.27. The acid hydrolysed sample 
was loaded to the column in two injection steps. The two peaks from the 
column flow through were collected and lyophilised, and analysed as before. 
The desired product was confirmed by nanospray TOF mass spectrometry 
(expected (m-1)/1 619.29; observed (m-)/2 619.30. See Table 3.9 and 
Appendix 3.35). Purities were not determined for 4P and 3P acceptors. 
 
3.3.6.1.2 Branched acceptors 
Branched acceptor-only substrates were synthesised from the UDP-MurNAc 
peptide stocks whose syntheses were described in Section 3.3.4. As 
described for synthesis of linear MurNAc peptide acceptors, aliquots of 
branched UDP-MurNAc peptides were acid hydrolysed using hydrochloric 
acid. These reactions were purified by anion exchange (Figure 3.28a and b 
a) MurNAc 6P (iGln, L-Ala) purification 







Figure 3.28 Chromatography of MurNAc 6P (iGln, L-Ala) and MurNAc 7P 
syntheses (iGln, L-Ala, L-Ala). Samples of a) UDP-MurNAc 6P (iGln, L-Ala) 
and b) UDP-MurNAc 7P (iGln, L-Ala-L-Ala) peptides were acid hydrolysed, 
neutralised and purified by anion exchange. Peaks were observed 
corresponding to (i) putative MurNAc peptides (ii) UMP and (iii) UDP. The 




for MurNAc 6P (iGln, L-Ala) and MurNAc 7P (iGln, L-Ala-L-Ala) respectively). 
The profile of these purifications resembled those observed for linear peptide 
acid hydrolysis. The putative product peak for each of MurNAc 6P (iGln, L-
Ala) and MurNAc 7P (iGln, L-Ala-L-Ala) were lyophilised and analysed by 
nanospray TOF mass spectrometry.  
The mass spectra for both MurNAc 6P (iGln, L-Ala) and MurNAc 7P (iGln, L-
Ala-L-Ala) revealed two superimposed ion series, likely corresponding to a 
polymeric contaminant (Figure 3.29 and Table 3.10). The origin of this 
contaminant was unclear. There was therefore no evidence of successful 
synthesis of branched MurNAc peptide substrates. 
Table 3.10: Summary of MS analysis of branched acceptor-only 
peptide syntheses. Samples were analysed by negative mode nanospray 
time-of-flight mass spectrometry. Data collected by A.J. Lloyd. 





Observed m/z Compound 
MurNAc 6P  
(iGln, L-Ala) 




MurNAc 7P  
(iGln, L-Ala-L-
Ala) 
















Figure 3.29 Nanospray TOF mass spectrometry of branched MurNAc 
peptides. Full spectra of a) MurNAc 6P (iGln, L-Ala) peak (i) b) MurNAc 6P (iGln, 
L-Ala) peak (ii) c) MurNAc 7P (iGln, L-Ala-L-Ala) peak (i) d) MurNAc 7P (iGln, L-Ala-
L-Ala) peak (ii), showing polymeric ion series of m+(119.96)n. Data collected by A.J. 
Lloyd, and mass spectra generated using MassLynx software (Waters). 
a) MurNAc 6P (iGln, L-Ala) peak (i) 
b) MurNAc 6P (iGln, L-Ala) peak (ii) 
c) MurNAc 7P (iGln, L-Ala-L-Ala) peak (i) 
d) MurNAc 7P (iGln, L-Ala-L-Ala) peak (ii) 
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3.3.6.2 Polymerisable acceptor – Lipid II 3P (iGln) 
Polymerisable acceptor of Lipid II 3P (iGln) was synthesised by linkage of 
UDP-MurNAc 3P (iGln) to undecaprenyl phosphate using M. flavus 
membranes (Section 3.3.2). The reaction was purified by anion exchange as 
described for Lipid II (iGln), and the purification progress was analysed by 
TLC (Figure 3.30). The fractions containing Lipid II 3P (iGln) were pooled, 
lyophilised and resuspended in 2:3:1 chloroform:methanol:water for storage 
at -80 °C. 
The product of Lipid II 3P (iGln) synthesis was analysed by nanospray TOF 
mass spectrometry. Ions were detected corresponding to Lipid II 3P (iGln) 
(expected (m-1)/1 1730.99; observed (m-1)/1 1731.00. See Table 3.9 and 
Appendix 3.36). A second, unidentified compound was present in the sample, 
with both singly charged ((m-1)/1, 1295.90) and double charged ((m-2)/2, 
647.45) series observed.  
 
Figure 3.30 Thin-layer chromatography analysis of purification of Lipid 
II 3P (iGln). The Lipid II 3P (iGln) synthesis reaction was purified by anion 
exchange chromatography using stepwise elution up to 166.7 mM ammonium 
bicarbonate in 2:3:1 chloroform:methanol:buffer, and fractions were analysed 
by thin-layer chromatography run in 44:88:10:1 chloroform: methanol: 
ammonia: water, and stained using iodine vapour. Position of Lipid II 3P (iGln) 
spots is highlighted by circles due to poor image quality. C55P, undecaprenyl 
phosphate; LII 3P, Lipid II 3P (iGln); L, crude sample; FT, column flow through 
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3.4 Discussion  
A variety of substrates have been prepared for the study of pneumococcal 
PBPs by the methods described in this chapter. This is the first described 
synthesis of linear and branched defined substrates for pneumococcal 
penicillin binding proteins, and as such will allow assay of the activity of these 
enzymes with near-native substrates. Optimisation of the branched peptide 
syntheses will also pave the way for full-scale synthesis of branched lipids, 
further extending the capability to assay PBPs with native substrates. A 
chemo-enzymatic lipid synthesis for dipeptide branched lipids has also been 
demonstrated. From this work, larger scale lipid syntheses can be attempted, 
allowing the use of these substrates for pneumococcal PBP assays. 
 
3.4.1 Limitations of the current system 
Ongoing difficulties with the current methods of choice for synthesis of 
pneumococcal substrates include the low yield of amidated Lipid II; and the 
number of steps required for synthesis of branched substrates. In addition, 
the current work has so far not addressed the synthesis of defined donor-only 
branched substrates. 
 
3.4.1.1 Amidated lipid 
Studies of the importance of amidation to PBP activity have described in vitro 
amidation of Lipid II using the MurT/GatD amidase complex (Zapun et al., 
2013). This method allows for optimal activity of MraY in synthesising Lipid I, 
due to the absence of the amidation, which has very much limited the yield 
of lipid syntheses. This therefore may present a more optimal use of 
substrates for that reaction, including undecaprenyl phosphate which is 
expensive to buy. Several important pitfalls of enzymatic amidation using the 
purified GatD/MurT enzyme complex should be considered. There is the 
potential for incomplete amidation by the enzyme complex, thus giving rise 
to a mixture of amidated and non-amidated substrate. This would necessitate 
use of a method for separation of such a mixture, which is likely to prove 
difficult on the basis of such a minor chemical change in the current 
separation methodology. By contrast, the method currently used at Warwick 
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has the benefit of ensuring that all UDP-MurNAc pentapeptide will be 
amidated, so no such separation is necessary. Supplementation of M. flavus 
membranes with purified recombinant MraY may aid in overcoming the 
limited yields of this substrate. 
 
3.4.1.2. Branched substrates 
The main limitation of the procedure for synthesis of branched substrates is 
the number of steps taken in the procedure, and the resultant losses at each 
stage. Yields for the hexa- and heptapeptide syntheses were highly variable, 
and for both Lipid and peptide acceptor synthesis from these compounds, an 
additional purification step was required. Consequently, the scale of lipid 
synthesis that could be attempted was limited by how frequently UDP-
MurNAc 5P syntheses could be carried out. In the current work, synthesis of 
branched MurNAc peptide acceptors could not be conclusively 
demonstrated, and so further pursuit of this synthesis is a key next step. 
 
The use of N-[(Dimethlyamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-
ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (N-
HATU) as the activating agent for SPPS was intended to suppress 
racemization in peptide synthesis (Al-Warhi et al., 2012). However, N-HATU 
would hydrolyse in the aqueous buffer system used for coupling of the 
dipeptide to UDP-MurNAc 5P, and so there remains a risk of oxazolone 
formation with the EDC that is instead used as the activating agent. 
 
Assay of the S. aureus Fem ligases (Schneider et al., 2004) and E. faecalis 
BppA enzymes (Bouhss et al., 2002) with UDP-MurNAc peptides, Lipid I and 
Lipid II have found that the S. aureus enzymes are specific for the Lipid II 
intermediates (with the appropriate number of glycines added in the case of 
FemA and FemB), whilst the E. faecalis enzymes will catalyse addition to the 
UDP-MurNAc peptides. Each of these published methods could be scaled 
up, allowing their use for synthesis of branched intermediates. This would be 
more suitable in the case of the BppA enzymes, by nature of the greater 
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availability of UDP-MurNAc peptides for starting material (and comparative 
lower impact of losses at purification steps) compared to Lipid intermediates. 
Challenges of ensuring full deprotection, and limiting the occurrence of 
multiple addition, are ongoing in the synthesis of Ser-variant branched 
peptides. A separate deprotection procedure is required for the tert-Butyl 
protecting group of the serine side chain, which was omitted from these 
procedures. Multiple addition of serine during heptapeptide syntheses may 
have occurred due to deprotection of this group during the SPPS procedure. 
 
3.4.1.3 Acceptor and donor only substrates 
The substrate syntheses herein described offer methodologies that will 
greatly support the analysis of transpeptidase activity by S. pneumoniae and 
other Gram positive bacteria exhibiting similar peptidoglycan chemistry (i.e. 
possessing the amidated peptide stem). 
To improve the yield of MurNAc 4P (iGln) synthesis, the DacB step could be 
incorporated into the synthesis of UDP-MurNAc 5P (iGln), prior to anion 
exchange chromatography. This would decrease the number of purification 
steps required, and therefore mitigate the losses in this synthesis. 
 
3.4.2. Conclusions 
This work contributes to the field of peptidoglycan biosynthesis and study of 
antimicrobial resistance by providing methods that will facilitate the study of 
the activity of PBPs. This class of enzymes are a key target for antibiotics of 
multiple classes, and further characterization of their activity has the potential 




Chapter 4: Development of a transpeptidase assay for 
pneumococcal PBPs 
4.1 Introduction 
The resistance mechanism of pneumococci to b-lactams is based upon the 
alteration of the PBPs, and their interaction with a branched substrate. The 
development of a transpeptidase assay for pneumococcal PBPs using natural 
substrates would therefore provide insight into the resistance mechanism. 
 
4.1.1 Published assay technologies for transpeptidases 
Published assays for assessment of transpeptidation have classically relied 
upon substrate mimetics; the use of b-lactams as a proxy for study of acylation; 
and stopped assay methods involved chromatography or electrophoresis of 
reaction mixtures with labelled substrate. 
 
4.1.1.1 Chromogenic thioester substrate analogues 
Chromogenic thioester substrates for both D,D-transpeptidases and b-
lactamases were first synthesized by Adam et al. (1990). Thioester substrate 
analogues such as S2d (N-benzoyl-D-alanylmercaptoacetic acid thioester) 
mimic the D-Alanyl-D-Ala moiety at the terminus of the donor stem peptide 
(Macheboeuf et al., 2008). S2d can be used as a transpeptidase donor, with 
D-amino acid acceptors, for the study of in vitro transpeptidase activity. The 
thioester forms a covalent intermediate with the PBP (with release of 
thioglycolate), and upon hydrolysis the compound is released as N-Benzoyl-
D-Ala (Macheboeuf et al., 2008). Reaction of transpeptidases with thioester 
analogues has been followed directly by spectrophotometric assays, as well 
as by HPLC (Jamin et al., 1993), mass spectrometry and crystallography 
(Macheboeuf et al., 2008). 
 
Adam et al. (1991) demonstrated the hydrolysis of a range of thioester 
substrate analogues by soluble constructs of PBPs from E. coli, Enterococcus 
hirae and S. pneumoniae. In reactions containing E. hirae PBP3, there was an 
acceleration of S2d consumption above the rate with S2d alone upon addition 
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of D-Ala as an acceptor, and the consumption of S2d was inhibited by addition 
of benzylpenicillin. Reversed-phase HPLC chromatography of the reaction 
products allowed Adam et al. (1991) to establish the ratio of hydrolysis to 
transpeptidation products. Certain thioester analogues were also found to 
inhibit labelling of E. hirae PBP3 by benzyl-[35S]penicillin, with recovery of 
labelling in the presence of D-Ala as an acceptor. This was proposed to be the 
result of a decrease in the steady-state concentration of acyl-enzyme in the 
presence of acceptor (Adam et al., 1991). 
 
Macheboeuf et al. (2008) used crystallographic studies to reveal the structural 
details of the interaction of thioester analogues with S. pneumoniae PBP1b. 
As observed in PBP crystal structures in complex with b-lactams, the N-
Benzoyl-D-Ala moiety of S2d was covalently associated with the catalytic 
serine, with the D-Ala moiety positioned in the oxyanion hole and stabilised by 
a hydrogen bonding network. Additionally, a movement of the loop between 
b3 and b4 was observed in the PBP1b:S2d structure as compared to the apo 
structure. Macheboeuf et al. (2008) proposed that an activation, driven by 
substrate recognition, was responsible for ‘opening’ of the active site. 
 
Analysis of transpeptidation by the use of thioester substrate analogues has 
allowed the determination of acylation efficiency of transpeptidases, in addition 
to comparison of the ratio of hydrolysis and transfer rates in the presence of 
acceptors. A key limitation of the thioester substrate analogue method is the 
lack of coupling of transpeptidation with glycosyltransferase activity. Ongoing 
glycosyltransferase activity has been found to be a key requirement for in vitro 
transpeptidation of natural substrates (Section 4.1.2). The use of a substrate 
analogue also limits the possibility to analyse the substrate specificity of the 
transpeptidase donor, although a variety of amino acid and peptide acceptors 
have been used in thioester analogue assays (Adam et al., 1991; Macheboeuf 




4.1.1.2 HPLC methods 
Reversed-phase HPLC has been extensively used to follow in vitro 
transpeptidation. Detection of reaction products by HPLC was enabled by use 
of radiolabelled Lipid II substrate (Bertsche et al., 2005), with identification of 
the peaks by comparison to reference standards.  
 
Glauner (1988) published a method for the reproducible reversed-phase 
HPLC separation of muropeptides. Detection of muropeptides was based on 
absorbance at 205 nm, or radioactivity when peptidoglycan samples were 
labelled with [3H]-DAP. Bertsche et al. (2005) used the HPLC analysis 
described by Glauner (1988) to develop a method for following transpeptidase 
activity of E. coli PBP1b. This method has been used in applications such as 
determining the impact of protein interacting partners on the peptidoglycan 
synthesis activity of E. coli PBP1b (Müller et al., 2007). 
 
A distinct method for HPLC analysis of PG synthesis was described by 
Schwartz et al. (2001). This methodology involved post-reaction labelling with 
fluorescamine (via primary amines) to visualise glycan polymers, and to label 
D-Ala released by transpeptidation.  
 
HPLC-based analyses of peptidoglycan synthesis are suited to the use of 
natural substrates, thereby allowing comparisons of substrate usage that are 
not possible with thioester substrate analogues. The sensitivity of detection of 
the radiolabelled substrates allows the use of very limited quantities (in the 
nanomolar range) of substrate. Published uses of HPLC-based analysis are 
unclear on the mode of identification of particular substrate peaks, and would 
benefit from partnered analysis by mass spectrometry. In addition, the stopped 
format of HPLC assays is less favourable than a continuous assay system for 




4.1.1.3 Tris-tricine SDS-PAGE analysis 
Whilst the use of Tris-tricine SDS-PAGE has been primarily in the visualisation 
of glycan polymers generated by PG synthases (Section 5.1.1), the method 
has also been adapted to allow analysis of transpeptidase reaction products. 
Barrett et al. (2007) described the SDS-PAGE analysis of radiolabelled glycan 
polymers produced in vitro. This method was then adapted for the analysis of 
transpeptidase reaction products by Helassa et al. (2012), who used a mixture 
of fluorescently-labelled and unlabelled Lipid II to demonstrate putative in vitro 
synthesis of cross linked peptidoglycan by E. coli PBP1b. This observation 
was based upon the formation of high molecular weight material that was 
unable to enter the gel matrix, and which was not observed when penicillin 
was included in the reaction mixture. 
 
The SDS-PAGE analysis of labelled PG synthesis products allows qualitative 
analysis of peptidoglycan synthesis, and the determination of IC50 values in 
certain contexts (Qiao et al., 2017). However, this technique is not suited to 
the kinetic analysis of transpeptidation.  
A key criticism of the SDS-PAGE analysis method has been the difficulty in 
conclusive demonstration that the high molecular weight material corresponds 
to cross-linked polymer. Attempts to excise the material from acrylamide gels 
and detect the polymer by mass spectrometry have been unsuccessful 
(Galley, 2015). In addition, care must be taken in analysis of transpeptidase 
reaction products by mass spectrometry. Zapun et al. (2013) assigned a 
1842.743 Da product to the transpeptidase product, but this mass could also 
correspond to a GT dimer (see Section 4.3.2.1.1).  
 Qiao et al. (2017) validated the presence of cross-linked material using 
lysostaphin, which specifically hydrolyses pentaglycyl cross-links. Following 
lysostaphin hydrolysis, the high molecular weight material was lost, thereby 
illustrating that this material had been unable to enter the gel matrix due to the 




4.1.1.4 BOCILLIN FL binding 
BOCILLIN FL is a fluorescent b-lactam compound consisting of penicillin V 
with a BODIPY (boron-dipyrromethene) fluorophore conjugated to the phenyl 
side chain (Zhao et al., 1999). BOCILLIN FL offered a more convenient 
labelling method for PBPs than the previously used radiolabeled penicillins, 
which brought issues of hazard and experimental time (Zhao et al., 1999). 
BOCILLIN FL has been used in a variety of experiments to analyse PBPs and 
their interactions with other b-lactams, as reviewed by Stone et al. (2018).  
 
Zhao et al. (1997) reported the use of BOCILLIN FL to label PBPs prior to 
SDS-PAGE. This method allowed detection of the PBP profiles in bacterial 
membrane preparations. Binding affinities of competing b-lactams could also 
be determined with this method. Kocaoglu et al. (2015) used BOCILLIN FL 
labelling to define the selectivity of b-lactams for particular pneumococcal 
PBPs. 
 
An alternative technique for determination of binding affinities using BOCILLIN 
FL is based upon fluorescence anisotropy. Such assays measure the 
polarisation of incident light by the tumbling of BOCILLIN FL in solution, and 
the effect upon the signal by binding of the protein of interest (Shapiro et al., 
2013). 
 
BOCILLIN FL can be used to conduct similar experiments to those historically 
performed using radiolabelled b-lactams, but in a safer and less time-intensive 
manner. Fluorescence anisotropy assays with BOCILLIN FL are limited to use 
with soluble PBP constructs. Detergent micelles have been found to sequester 
BOCILLIN FL, resulting in high anisotropy signal (Shapiro et al., 2013). 
 
4.1.1.5 Chromogenic cephalosporins: nitrocefin and CENTA 
Assay systems developed for use with b-lactamases have shown utility in the 
study of PBPs. O'Callaghan et al. (1972) discovered the chromogenic 
properties of the cephalosporin analogue nitrocefin. Hydrolysis of nitrocefin to 
generate the corresponding cephalosporanoic acid could be followed 
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spectrophotometrically (lmax 482 nm). This phenomenon formed the basis of 
an extensively used assay for detection of b-lactamases (Livermore & Brown, 
2001). 
 
Nitrocefin hydrolysis has been used to analyse kinetics of PBP acylation with 
b-lactams. Roychoudhury et al. (1996) used nitrocefin to analyse the 
precipitation of S. aureus PBP2a when acylated by b-lactams.  
Interestingly, nitrocefin turnover by particular PBPs has been demonstrated. 
Calvez et al. (2017) demonstrated apparent turnover of nitrocefin by S. 
pneumoniae PBP2b5204, beyond the expected stoichiometric plateau. E. coli 
PBP5 has also been demonstrated to catalyse hydrolysis of the penicilloyl-
enzyme complex (Josephine et al., 2006).  
 
Similarly to nitrocefin, CENTA (7-β-thien-2-yl-acetamido-3-[(4-nitro-3-
carboxyphenyl)thiomethyl]-3-cephem-4-carboxylic acid) is a chromogenic 
cephalosporin used for the assay of b-lactamases (Jones et al., 1982). In 
contrast to nitrocefin, assay of CENTA hydrolysis relies upon detection of the 
leaving group, 2-nitro-5-sulfanylbenzoic acid (lmax 405 nm) that is expelled 
upon opening of the lactam ring (Fast & Sutton, 2013). In comparison with 
nitrocefin, CENTA offers the benefit of its solubility in aqueous solutions, whilst 
nitrocefin is soluble in DMSO and DMF (Bebrone et al., 2001). CENTA has 
also been used to demonstrate inhibition of PBPs (Bebrone et al., 2001). 
 
Chromogenic cephalosporins allow study of the interaction of PBPs with b-
lactams. Their suitability to analysis of transpeptidation is currently limited to 
those examples of PBPs that catalyse rapid hydrolysis of the b-lactam ring. 
 
4.1.1.6 Other assay technologies 
Fluorescent D-amino acids (FDAAs) are chemical probes that have been used 
to reveal a multitude of details of the in vivo cell division process. Building upon 
this technology, Hsu et al. (2019) designed novel fluorogenic amino acid 
probes for the study of transpeptidation both in vitro and in vivo. Rotor 
fluorogenic D-amino acid (RfDAA) assays were based upon the principle of 
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fluorescent molecular rotors, whereby the steric hindrance of the environment 
of the probe determines the emission intensity. High hindrance environments 
created an ‘on’ state whereby the excitation energy was converted into 
fluorescence emission, and incorporation of RfDAAs into peptidoglycan thus 
resulted in fluorescence emission, with low background from free probe. 
Transpeptidase activity of S. aureus PBP4 was followed using a peptide stem 
mimic as the acyl donor (diacetyl-L-lysyl-D-alanyl-D-alanine), and activity was 
inhibited by b-lactams known to bind PBP4. 
Other tool compounds for analysis of PBP activity are based on modified b-
lactams, allowing the analysis of acylation and deacylation parameters. 
Josephine et al. (2006) used penicillins with stem peptide-mimicking side 
chains to test the in vitro hydrolysis and aminolysis activity against such 
peptides. 
 
4.1.2 In vitro transpeptidase activity of pneumococcal PBPs 
A variety of authors have published analyses of the kinetics of b-lactam 
interactions with pneumococcal PBPs (Di Guilmi et al., 1998; Zhao et al., 
1997). Analysis of in vitro pneumococcal transpeptidase activity has been 
hindered by limited access to substrates. 
 
Poor correlation between pneumococcal PBP activity with substrate 
analogues and native substrates has been observed (Helassa et al., 2012). 
Helassa et al. (2012) found that whilst S2d hydrolysis could be catalysed by 
purified recombinant S. pneumoniae PBP2a, transpeptidase activity by PBP2a 
was not detected in the SDS-PAGE assay. However, the authors noted that 
this assay was performed with non-amidated Lipid II. 
 
The first unambiguous demonstration of in vitro transpeptidase activity by 
pneumococcal PBP1a using native substrate was shown by Galley (2015), 
using a continuous D-Ala release assay and with confirmation of the product 
formed by LC-MSMS analysis. These findings formed the basis for the assay 




4.1.3 b-lactam resistance-linked sequences in pneumococcal PBP1a 
Whilst in pneumococci the primary resistance determinants with respect to b-
lactam antibiotics are PBP2x and 2b, alterations to PBP1a are also required 
for high level pneumococcal penicillin resistance (Barcus et al., 1995; Coffey 
et al., 1995). A variety of studies have identified particular key motifs 
associated with b-lactam resistance in clinical pneumococcal strains. 
 
Smith and Klugman (1998) demonstrated the link with b-lactam resistance of 
the T371A/S and TSQF574-577NTGY mutations in pneumococcal PBP1a. PBP 
alleles originating from the resistant South African pneumococcal isolate 8303 
were transformed into the susceptible strain R6. R6 transformants showed 
approximately 3-fold reductions in MICs when either mutation was reverted, 
thus illustrating the link of these amino acid changes to the resistance 
mechanism. Various other authors have reported the T371A/S mutation in 
PBP1a alleles in b-lactam resistant strains (Davies et al., 2008; Kosowska et 
al., 2004; Nagai et al., 2002). 
 
The mechanistic basis of the importance of T371A/S and TSQF574-577NTGY in 
b-lactam resistance was analysed by Job et al. (2008), who compared the 
efficiency of acylation of PBP1a variants using intrinsic fluorescence. T371A 
and TSQF574-577NTGY were found individually to decrease the efficiency of 
acylation of PBP1a by cefotaxime and penicillin G, and an enhanced 
combined effect was also observed. Comparison of crystal structures from 
trypsinised PBP1aR6 and PBP1a5204 found that alterations to the active site in 
PBP1a5204 included the loss of a hydrogen bond between N430 and Y409; the 
appearance of a hydrogen bond between K373 and N430; rotation of the 
nucleophilic S370 to point away from the active site, with formation of an 
interaction with T560; loss of a hydrogen bond between T371 (mutated to A) and 
W368, suggested to be a factor in the 0.6 – 1.1 Å shift of the nucleophilic S370; 
and the F577Y mutation, whose modification of the properties of the 
hydrophobic wall at the lower portion of the active site cavity was hypothesised 




Contreras-Martel et al. (2006) found that mutations in PBP1a from a penicillin 
and ampicillin resistant clinical pneumococcal strain, 73311, mapped mainly 
to loop regions of the protein. There was additionally a mutational hotspot in 
the catalytic cleft region. Mutations in the ‘hotspot’ included TSQF574-577NTGY; 
L606I, N609D, L611F and T612L at a11; and N546G. These modifications were 
suggested to alter the surface polarity at the entrance to the active site, in 
addition to modification of the relevant loops by alterations of residues 546 and 
576. The proximity of these mutations to the interconnecting loop of b3 and b4 
enhances the flexibility of this region, in a feature common to both PBP1a and 
PBP2x variants from penicillin resistant strains (Contreras-Martel et al., 2009) 
and which was suggested to accommodate the branched substrates utilised 






The link between branched substrate synthesis and penicillin resistance of S. 
pneumoniae has been extensively documented. The mechanistic 
consequences of the alterations to pneumococcal PBPs, in combination with 
usage of branched substrates, has remained more obscure due to limitations 
in the available assays for transpeptidation, and supply of native substrates 
for these assays. Chapter 3 described efforts to address the latter issue; this 
Chapter focusses on experiments in pursuit of an assay for in vitro 





Figure 4.1 Chapter 4 experimental questions summary A visual summary 




4.2 Experimental aims 
• To clone PBP1a variants from S. pneumoniae Pn16 and 159 strains 
into pET46a vector 
• To express and purify PBP1a variants from S. pneumoniae D39, Pn16 
and 159 strains, and a transpeptidase active site serine mutant (S370A) 
of PBP1aD39 (PBP1aD39_S370A) 
• To establish observation of in-vitro transpeptidase activity of PBP1aD39 
in the continuous D-ala release assay 
• To determine the optimum concentration of E6C12 detergent for in vitro 
transpeptidase activity 
• To assess the contribution of transpeptidation and D,D-
carboxypeptidation to the D-ala release rate, by assay of the D-ala 
release activity of PBP1aD39 in the presence of donor- and acceptor-
only substrates  
• To assess TP activity by Tris-Tricine SDS-PAGE 
• To use mutanolysin digestion followed by liquid chromatography-
tandem mass spectrometry to analyse the products of putative in-vitro 
transpeptidation 
• To assess whether SDS-PAGE analysis of BOCILLIN FL binding can 





4.3.1 Expression and purification of pneumococcal PBP1a variants 
4.3.1.1 PBP1a construct progenitor strains 
This work made use of expression constructs of PBP1aD39 and PBP1aD39_S370A 
proteins that were generated by Abrahams (2011). Expression constructs of 
PBP1a variants from two clinical pneumococcal strains, Pn16 (PenS) and 159 
(PenR) were made in this work, to allow comparison of activity between PBP1a 
variants with different modifications to the amino acid sequence, and whose 
progenitor strains differed in b-lactam susceptibility. These strains were 
chosen to complement previous studies on the activity of MurM variants (Lloyd 
et al., 2008). 
 
Table 4.1 Penicillin G MIC values for pneumococcal strains of interest. 
Penicillin G (PenG) MICs were obtained from the relevant publications, or 
determed by microbroth dilution. 
 








Sources: a. this thesis; b. Sorg and Veening (2015); c. Job et al. (2008); d. du 
Plessis et al. (2002); e. Smith and Klugman (2003). 
 
Table 4.1 compares Penicillin G minimum inhibitory concentration (MIC) 
values of S. pneumoniae strains including the progenitors of the constructs 
discussed in this chapter (D39, Pn16 and 159), and some strains for which 
amino acid changes in PBP1a have been characterized (as discussed in 
Section 4.1.3.2). MIC values for Pn16 and 159 were determined by microbroth 
dilution (Section 2.8) in accordance with CLSI guidelines (CLSI, 2014). MIC 
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values would ideally be determined in-house for all strains, to ensure 
comparability of values, but this was limited by access to the strains. 
 
Figure 4.2 presents a comparison of the amino acid sequences of the 
corresponding PBP1a variants to the strains compared in Table 4.1. Notably, 
despite the high-level resistance of strain 159, PBP1a159 did not have the 
substitution T371S/A, whose association with b-lactam resistance by several 







Figure 4.2 Amino acid sequence comparison of transpeptidase 
domains of S. pneumoniae PBP1a variants. Amino acids are coloured 
according to properties and conservation (ClustalX scheme), with unconserved 
positions in white. Conserved motifs S370XXK, S428XN and K557TG are indicated by 
black boxes. Residue numbering corresponds to the position in the full-length 
protein. Alignments were performed using the Clustal Omega Multiple Sequence 
Alignment program (Sievers et al., 2011). Only regions of the PBP1a73311 and 
PBP1a3191 available in the GenBank entries are shown. 
SP_73311 Contreras Martel et al. (2006); Sp_5204 Job et al. (2008); Sp_3191 
Smith et al. (2003). 
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4.3.1.2 Gibson cloning of Pn16 and 159 PBP1a  
Expression constructs for the PBP1a variants of S. pneumoniae strains Pn16 
and 159 in pET46a vectors were generated using cloning by Gibson 
AssemblyÒ (Gibson et al., 2009) (Section 2.3.5). The vector pET46a was 
chosen for consistency with pET46::pbp_D39 and pET46a::pbpa_D39_S370A 
constructs, thus allowing comparison of activity between  purified recombinant 
proteins. Vector maps are depicted in Figure 4.3. Constructs were generated 
in which N-terminally (N-ter.) His12-tagged PBP1a from Pn16 and 159 (from 
pET46::pbp_Pn16 and pET46::pbp_159 respectively) were expressed from a 
T7 promoter, with regulation by a lac operator. Primers spanning the inserted 
genes were used to sequence across the length of the insert to confirm the 
vector sequences. Sequence alignment of the product plasmid sequence to 
Figure 4.3 Vector map of pET46a::PBP1a constructs generated in this 
thesis. A) Vector map and b) diagram of the coding region. Annealing sites 
of Gibson primers are highlighted in purple. Also indicated is the site of the 
tandem His6 tags (6xHis, pale purple arrows) Image generated using 







the desired sequence was used to ensure that the nucleotide sequence of 
pbpA_Pn16 and pbpA_159 were inserted in frame with the N. ter. His12 tag. 
The final constructs consisted of a protein expressed full length (i.e. with the 
transmembrane helix) and with an N- terminal 12-Histidine tag for immobilised 
metal affinity chromatography. In Class A PBPs, the TM anchor is considered 





4.3.1.3 Expression and purification of PBP1a variants  
The PBP1a variants presented in Table 4.2 were expressed and purified as 
described by Galley (2015), although with the omission of lysozyme for cell 
lysis (as discussed in Section 4.3.2.3.1) in later preparations.  
PBP1a variants were expressed in cultures of BL21 (DE3) pRosetta cells by 
autoinduction (Section 2.4.1) at 25 °C for 22 h.  
The membrane fraction was isolated from these cultures as described in 
Section 2.4.3.1, and membrane proteins were solubilised in phosphate-
buffered saline (PBS) buffer using 1 % (w/v) sodium deoxycholate. Following 
buffer-exchange into PBS supplemented with 0.1 % (w/v) N-dodecyl b-D-
maltoside (DDM), PBP1a was purified by Ni2+-immobilised metal ion affinity 
chromatography (IMAC). The IMAC peak was then further purified by gel 
filtration (Figure 4.4), and the final protein stocks were frozen at – 20 ˚C in 
aliquots at 8 mg.mL-1, in buffer containing 10 mM HEPES pH 7.5, 75 mM NaCl, 
0.015 % (w/v) DDM and 50 % (v/v) glycerol. Summary SDS-PAGE gels of the 
purification profile of each variant are depicted in Figure 4.4, where PBP1a 
was observed at ~80 kDa. Similar final purity was observed for all variants of 
PBP1a. 
 
Table 4.2 S. pneumoniae PBP1a variants expressed and purified for this 
thesis. All proteins were expressed as full length, membrane-anchored N-
terminally His12-tagged constructs. 
 
PBP1a variant Construct Source 
S. pneumoniae D39 pET46a::pbpA_D39 K. Abrahams 
(Warwick) 
S. pneumoniae D39 S370A  
(TP active site serine 
mutant) 
pET46a::pbpA_D39_S370A K. Abrahams 
(Warwick) 
S. pneumoniae Pn16 pET46a::pbpA_Pn16 Cloned for this project 
S. pneumoniae 5204 pET46a::pbpA_159 Cloned for this project 




Figure 4.4 Purification of PBP1a variants from 4 S. pneumoniae strains. PBP1a variants from strains D39 (and an active site 
serine mutant, D39 S370A), Pn16 and 159 were purified by immobilised metal ion affinity chromatography (IMAC) using TALONÒ Metal Affinity Resin 
(Clontech), followed by a gel filtration step (Superose 6 10/300 GL column (GE Healthcare)). Chromatograms illustrate the gel filtration step for each 
PBP1a variant. A small peak of aggregated material (i) was isolated from a large peak of PBP1a protein (ii) in each case. Summary analyses of each 
purification were performed by SDS-PAGE using a 12 % acrylamide gel.  
Lane loading was as follows: 1, cell suspension following lysis by cell disruption; 2, cell suspension following removal of insoluble material by 
centrifugation; 3, membrane fraction; 4, membrane proteins solubilised by 1 % (w/v) sodium deoxycholate and buffer exchanged into 0.1 (w/v) N-
dodecyl b-D-maltoside; 5, IMAC peak; Final, the final protein stock following gel filtration. kDa, kiloDaltons; mAU, milli-absorbance units; (i), 
aggregated material; (ii), PBP1a peak; Mr, Color Prestained Protein Standard, Broad Range (NEB) molecular weight marker. 
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Unless otherwise stated, the experiments in this chapter were undertaken 
using PBP1aD39. 
 
4.3.1.4 Protein mass spectrometry 
The mass of PBP1aD39 was experimentally determined by mass spectrometry, 
in an experiment conducted and analysed by Dr. A.J. Lloyd (University of 
Warwick). Samples of protein before and after incubation with ampicillin were 
desalted and analysed by positive ion time of flight (TOF) mass spectrometry 
(Figure 4.5).  
 
An increase in mass of 349.7 Da was observed in the presence of ampicillin, 
which was consistent with covalent modification of PBP1aD39 with ampicillin 
(expected mass change: 349.4 Da). The observed exact mass of PBP1aD39 
was 82348.09 Da, as compared to the expected mass of 82481.48 Da (as 
predicted from the protein sequence, using the ExPASy ProtParam online tool 
(Artimo et al., 2012)). This mass difference may have partially resulted from 
the removal of N-formylmethionine at the N-terminus of the protein by 
methionyl aminopeptidase (Ben-Bassat et al., 1987). Loss of the N-
formylmethionine would generate a polypeptide with an expected mass of 
82350.29, which was within 2.2 Daltons of the experimentally determined 
value (Figure 4.5). This experiment demonstrated the amenability of PBP1aD39 












Expected D mass due to 
ampicillin modification:  
349.4059 
Observed D mass due to 




Figure 4.5 Nanospray time of flight mass spectrometry of PBP1aD39 and its modification by a 10:1 molar excess of 
ampicillin. a) Mass spectrum of ampicillin treated PBP1a (red) superimposed upon the predicted (mock) mass spectrum for the protein 
(purple) based on its simplest interpretation on a mass scale (b). c) Mass spectrum of untreated PBP1a (red) superimposed upon the 
predicted (mock) mass spectrum for the protein (purple) based on its simplest interpretation on a mass scale (d). Experiment conducted 
and analysed by Dr. A.J Lloyd (University of Warwick). Mass spectra were acquired using Mass Lynx software and deconvoluted to a 





4.3.2 Continuous spectrophotometric assay for transpeptidation 
Purified recombinant PBP1aD39 was used in attempts to develop conditions for 
observation of in vitro transpeptidase activity of pneumococcal PBP1a. This 
work made use of the continuous assay for D-Ala release which was 
developed by Dr. A.J. Lloyd (University of Warwick). 
In the assay system, D-Ala released by transpeptidase or D,D-
carboxypeptidase activity is converted to a signal at 555 nm by the coupling 
enzymes, Rhodotorula gracalis D-amino acid oxidase (DAAO) and 
horseradish peroxidase (HRP). DAAO oxidises D-Ala to pyruvate, also 
Figure 4.6 Continuous assay for D-ala release using DAAO, HRP and 
Amplex Red. D-Ala (blue) released by transpeptidase or D,D-
carboxypeptidase activities of PBP1aD39 is converted to a signal at 555 nm by 
the coupling enzyme DAAO which oxidises D-Ala, generating hydrogen 
peroxide as a by-product. Horseradish peroxidase (HRP) uses hydrogen 
peroxide as an oxidizing agent to convert Amplex Red to Resorufin, which 
























generating hydrogen peroxide which is then used by HRP to convert Amplex 
Red to Resorufin, which absorbs strongly at 555 nm (Figure 4.6).  
 
4.3.2.1 Assay with iGln LII Lys 
In vitro transpeptidase activity of PBP1aD39 was previously observed in the D-
Ala release assay (Galley, 2015). Initial attempts at observation of 
transpeptidase activity were made using Lipid II (iGln) as a substrate. We 
observed D-Ala release activity that was dependent on the presence of both 
enzyme and substrate, and this activity was inhibited by 50 µM moenomycin 
and 2 mM ampicillin (Figure 4.7).  
 
The relation between D-Ala release and enzyme concentration was then 
established to find the linear range in rate. Enzyme concentration was varied 
at fixed (40 µM) concentration of Lipid II (iGln) (Figure 4.8). The range over 
which enzyme concentration could be varied was limited by the low reaction 
rates (precluding use of enzyme concentrations lower than 1 µM); and the 
precipitation of enzyme when added to the reaction mixture at concentrations 
Figure 4.7 Observation of S. pneumoniae PBP1aD39-catalysed D-alanine 
release in a continuous assay. Reaction mixes comprised 50 mM HEPES pH 
7.6, 10 mM MgCl2, 12 X CMC E6C12 (0.0464%), 2 µM PBP1aD39, 20 µM Lipid II (iGln), 
33.51 mM.min-1 R. gracalis D-amino acid oxidase, 14.82 mM.min-1 horseradish 
peroxidase, and 50 µM Amplex Red. Reactions were initiated (*) by addition of 2 µM 
PBP1aD39 (or enzyme buffer in control reactions omitting enzyme). Controls included 
the glycosyltransferase (GT) inhibitor moenomycin (Moe), to demonstrate that D-Ala 
release was dependent upon GT activity; and transpeptidase inhibitor ampicillin 
(Amp) to demonstrate that the signal relied upon transpeptidation to generate D-Ala 
release. Reaction progress was followed by absorbance at 555 nm. 
Moe, moenomycin (50 µM); Amp, ampicillin (2 mM); *, time point when reactions 




greater than 6 µM. There is an apparent linear relationship between enzyme 
concentration and the rate of D-Ala release over the concentration range 
tested. As a full saturation curve was not generated, the relation between 
enzyme concentration and rate of D-Ala release cannot reliably be inferred 
from these data.  
4.3.2.1.1 Mass spectrometry of transpeptidase reaction products 
The products of the transpeptidase reactions presented in Figure 4.7 were 
analysed by digesting the reaction products with Streptomyces globisporus 
mutanolysin, followed by mass spectrometry. The analysis of reaction 
products generated by PBP1aD39 when using Lipid II (iGln) as a substrate was 
complicated by the fact that the m/z of the transpeptidation product formed 
from one acceptor and one donor Lipid II (iGln) (structure (a), Figure 4.9) was 
identical to that if the two Lipid II (iGln) species were linked by glycosyltransfer, 
where one of the two pentapeptide stems had lost the C-terminal D-Alanine 
through D,D carboxypeptidation (structure (b), Figure 4.9). The ambiguity 
generated by the isobaric relationship of structures (a) and (b) in Figure 4.9 
therefore necessitated MSMS fragmentation pattern analysis of the ion to 
Figure 4.8 Relation between PBP1aD39 concentration and initial rate of 
D-Ala release, with Lipid II (iGln) as a substrate. Reaction mixes comprised 
50 mM HEPES pH 7.6, 10 mM MgCl2, 40 µM Lipid II (iGln), 33.51 mM.min-1 R. 
gracalis D-amino acid oxidase, 14.82 mM.min-1 horseradish peroxidase, 50 µM 
Amplex Red,12 X CMC E6C12 (0.0464%), and the relevant concentration of 
PBP1aD39. Data represent the mean rate from 3 replicates, except the 3 µM point 





conclusively assign it as a transpeptidase product. In contrast, digestion of 
reaction products by mutanolysin should yield carboxypeptidase products as 





Table 4.3 LC-MS analysis of TP reactions with Lipid II (iGln) Reactions were 
digested using S. globisporus mutanolysin and analysed by liquid chromatography-
mass spectrometry (LC-MS) by positive ion electrospray time of flight mass 
spectrometry, to detect ions corresponding to putative TP product. Data are 
representative of two samples. m/z, mass to charge ratio. Data collected by Dr. 











(m+1)/1 1842.87 - - 
(m+2)/2 921.94 - 921.41 
(m+3)/3 614.96 - - 
       
Figure 4.9 Structures of transpeptidase (TP) and D,D-
carboxypeptidase (CP) products formed by S. pneumoniae PBP1a 
using Lipid II (iGln) as a substrate, following digestion by an N-
acetylmuramidase. Products (a) and (b) are the products formed by TP and 
CP activities respectively of PBP1a, when using Lipid II (iGln) as a substrate and 
following digestion of the products by S. globisporus mutanolysin. Complete 




No species corresponding to the putative TP product was detected by positive 
mode LC-MS; analysis of the LC-MS chromatogram revealed only a species 
corresponding to the mass of the putative TP product minus 1 Da (Table 4.3, 
Appendices 4.1 and 4.3). There was thus no clear evidence of formation of a 
transpeptidase product between two Lipid II (iGln) molecules.  
 
4.3.2.2 Effect of detergent concentration 
To optimise the conditions of the D-Ala release assay of PBP1a, the impact of 
detergent concentration on the rate of D-Ala release activity was analysed by 
comparing the initial rate of D-Ala release across a range of concentrations of 
E6C12 detergent. The starting concentration of E6C12 detergent, of 12 X critical 
micellar concentration (CMC), was informed by the assay optimum for E. coli 
PBP1b (Dr. A.J. Lloyd, University of Warwick, personal communication). E6C12 
concentration was therefore varied between 12 X CMC and 1.7 X CMC (Figure 
4.11). The minimum concentration was dictated by the concentration when 
detergent was solely contributed by the enzyme dilution and lipid resuspension 
buffers only. Decreasing the concentration of detergent relative to CMC was 
found to be associated with an increase in the rate of D-Ala release.  
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It appears from the trend of the data presented in Figure 4.10 that the true 
optimum concentration of E6C12 may lie below 1.7 X CMC. However, at 
concentrations of detergent approaching CMC, the enzyme and its substrate 
may not be kept in solution. The detergent optimum for GT activity of PBP1aD39 
was similarly tested, and these data are presented in Section 5.3.1.1. 
To investigate whether transpeptidation or D,D-carboxypeptidation was being 
followed in the reactions presented in Figure 4.10, the reaction products at 
different concentrations of E6C12 were digested using S. globisporus 
mutanolysin and analysed by positive ion LC-MS as described previously. An 
ion was identified in samples at all detergent concentrations (observed 
(m+1)/1, 1842.868) that could have corresponded to either a transpeptidase 
product, or Lipid IV minus D-Ala (both expected (m+1)/1, 1842.87; see Table 
4.4 and Figure 4.9). This ion was not detected in control reactions from which 
the substrate was omitted.  
To resolve the identity of this ion, we employed collision-induced 
fragmentation as before. However, due to the low signal for the parent ion in 
this fragmentation experiment, a reliable fragmentation pattern could not be 
determined.  
Figure 4.10 Relation between detergent concentration and initial rate of 
D-Ala release. The concentration of E6C12 detergent was varied between 1.7 
and 12 X CMC. Reaction mixes comprised 50 mM HEPES pH 7.6, 10 mM 
MgCl2, 2 µM PBP1aD39, 20 µM Lipid II (iGln), 33.51 mM.min-1 R. gracalis D-
amino acid oxidase, 14.82 mM.min-1 horseradish peroxidase, 50 µM Amplex 
Red and the relevant concentration of E6C12 Data represent the mean rate 
from 3 replicates.  




Table 4.4 Summary of LC-MS analysis results from detergent titration TP 
reactions. Reactions were digested using mutanolysin and analysed by liquid 
chromatography-mass spectrometry (LC-MS) by positive ion electrospray time of 
flight mass spectrometry, to detect ions corresponding to putative TP product. Data 
are representative of two samples. m/z, mass to charge ratio. Data collected by Dr. 







Observed m/z at E6C12 multiple of CMC 
(X) 




(m + 1)/1 1842.87 1842.87 1842.87 1842.87 1842.87 
(m + 2)/2 921.94 921.94 921.94 921.94 - 
 
4.3.2.3 Troubleshooting variation in rate 
Difficulty was experienced in establishing reproducible activity of PBP1aD39, 
with certain enzyme preparations appearing inactive. The following section 
discusses the factors that were considered in addressing this issue. 
 
4.3.2.3.1 Use of lysozyme for cell lysis  
The purification protocol detailed by Galley (2015) included the use of 
lysozyme to aid cell lysis by cleavage of peptidoglycan. As PBP1a is a 
bifunctional PBP, the transpeptidase donor must be provided by ongoing 
glycosyltransferase activity (Bertsche et al., 2005). We therefore considered 
that lysozyme added during the purification procedure could be carried 
through to the final enzyme preparation, and may therefore cleave glycan 
polymers synthesized by PBP1aD39 and thus prevent transpeptidase activity 
from occurring. Due to the use of muramidases such as lysozyme in the 
continuous fluorometric assay for glycosyltransferase activity to mediate the 
fluorescence change (Schwartz et al., 2002), the impact of lysozyme carried 




We were interested in assessing whether the omission of lysozyme from the 
purification procedure would improve the activity of PBP1a. Published 
purification procedures for preparation of PBPs such as E. coli PBP1b (Biboy 
et al., 2013) do not make use of lysozyme to aid cell lysis.  
 
We therefore assessed whether omission of lysozyme would affect the 
purification of PBP1a. PBP1a purified with the use of lysozyme for cell 
disruption was enriched in the membrane fraction (obtained by centrifugation 
of the lysed cell suspension at 150 000 x g). The localization of PBP1aD39 with 
and without lysozyme treatment of cultures was compared by SDS-PAGE 
analysis of BOCILLIN FL binding. BOCILLIN FL is a penicillin analogue 
fluorescently-labelled by a BODIPY label. BOCILLIN FL will therefore 
covalently modify the active site serine of purified recombinant PBP1aD39, and 
allow sensitive detection of the protein throughout the purification. 
 
Cultures with and without lysozyme treatment were lysed using a cell disruptor 
(Constant Systems), and samples of the insoluble (24 000 xg pellet), soluble 
(150 000 x g supernatant) and membrane (150 000 x g pellet) fractions were 
incubated with BOCILLIN FL and analysed by SDS-PAGE (Figure 4.11). A 
control lane (P) was included, with purified recombinant PBP1aD39 that was 
incubated with BOCILLIN FL, for comparison to fluorescent bands in the 
control and sample lanes. The major band in lane P was observed at 63 kDa, 
which was unexpected compared to the experimentally determined mass of 
PBP1aD39 at approximately 82 kDa (Section 4.3.1.4). This phenomenon was 
further explored in the experiments detailed in Section 4.3.3.  
 
No fluorescent bands were observed in the control lanes, although there was 
some leakage of the bands from lane P (Figure 4.11a). Bands were observed 
in the sample lanes at 63 kDa, matching the major band of the purified 
PBP1aD39 in lane P for each gel. The fluorescent band detected in the induced 
samples could therefore be inferred to represent the overexpressed PBP1aD39. 
The apparent localization of PBP1aD39, based on bands observed under 
fluorescence detection, was unchanged by treatment of lysozyme, with the 
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majority of BOCILLIN FL-staining observed in the membrane fraction in each 
case (by comparison of Figure 4.11a, induced, lane 3; and 4.11b, induced, 
lane 3).  
 
Figure 4.11 Effect of lysozyme treatment on localisation of 
overexpressed PBP1aD39. Cultures of BL21 (DE3) pRosetta containing the 
plasmid pET46::pbpa_D39, with and without induction of expression of 
PBP1aD39, and then with (b) and without (a) cell lysis using lysozyme, were 
lysed by cell disruption and then centrifugation steps at 24 000 x g and 150 
000 x g were performed. Localisation of PBP1aD39 in each case was 
assessed by incubation with BOCILLIN FL, followed by analysis by SDS-
PAGE. A control lane (P) of purified PBP1aD39 incubated with BOCILLIN FL, 
was included to allow identification of PBP1aD39 in the sample lanes. 
Reactions were analysed by SDS-PAGE, with equal loading of based on 
protein concentration, using 12 % acrylamide gels and fluorescence was 
imaged (gels aii and bii) using a Typhoon FLA 9500 laser scanner (GE 
Healthcare). Gels were then stained using InstantBlueÔ Protein Stain 
(Expedeon) and imaged for total protein (gels ai and bi) using an ImageQuant 
LAS 4000 instrument (GE Healthcare).  
a), without lysozyme treatment; b), with lysozyme treatment; 1, insoluble (24 
000 xg pellet); 2, soluble (150 000 x g supernatant); 3, membrane (150 000 
x g pellet); P, purified recombinant PBP1aD39; Mr, Color Prestained Protein 
Standard, Broad Range (NEB) molecular weight marker; MrF, BenchMarkÔ 
Fluorescent Protein Standard (ThermoFisher Scientific); kDa, kilo-Daltons. 
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Despite omission of lysozyme, no transpeptidase activity of fresh preparations 
of PBP1aD39 was observed. The lack of in vitro activity could therefore not be 
ascribed to inclusion of lysozyme in the purification. 
 
4.3.2.3.2 Variation between Lipid II (iGln) stocks 
Subsequent experiments identified a variation between stocks of Lipid II (iGln), 
resulting in activity being detected with some batches of protein and not others. 
With Lipid II (iGln) from three separate synthesis (hereafter referred to as 
stocks 1, 2 and 3), transpeptidase activity was detected with Lipid stock 2 (with 
two separate batches of protein), but not with Lipid stock 1. A third Lipid stock 
appeared to be contaminated, as a response by the DAAO-HRP coupling 
enzymes was detected in the absence of PBP1aD39. The purity and 
concentration of the three stocks was compared by thin-layer chromatography 
analysis, with loading of 2.5 nmol of lipid based on quantification by phosphate 
release assay (Section 2.6.9.4). The abundance of Lipid II (iGln) detected in 
stock 1 by iodine staining appeared greatly reduced in comparison to that 
detected in stocks 2 and 3 (Figure 4.12, ‘1’ compared to ‘2’ respectively). The 
intensity of the Lipid II (iGln) band in stock 1 relative to stock 2 was 0.3 as 
analysed using ImageJ software (Schneider et al., 2012), compared to 0.7 for 
stock 3. A contaminant migrating close to the solvent front was detected in 
stock 3 (faintly visible in Figure 4.12, ‘3’, indicated by *). This contaminant was 
therefore considered as a possible cause of the stimulation of the coupling 
enzymes in the TP assay.  
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Lipid stocks 1, 2 and 3 were analysed by negative ion TOF mass spectrometry. 
Lipid II (iGln) was detected in stocks 1 and 2 (see Table 4.5, Appendices 4.5-
6), but not in stock 3. A polymeric species was detected in stock 3, which may 
correspond to the species (*) observed in Figure 4.12 (see Appendix 4.7).  
Figure 4.12 Analysis of quantity and purity of stocks of Lipid II (iGln). 
2.5 nmol of Lipid (iGln) was loaded to a thin-layer chromatography plate and 
run in 88:48:10:1 chloroform:methanol:water:ammonia buffer, followed by 
staining in iodine vapour. Numbering of lanes refers to the stock of Lipid II 
(iGln), whereby transpeptidase activity of PBP1aD39 was observed with stock 
2 only, and stock 3 gave rise to a PBP1a-independent D-Ala release signal. 
Band intensities of Stock 1 and 3 relative to 2 (as plotted using ImageJ 
software (Schneider et al., 2012)) were 0.3 and 0.7 respectively. 
2, Lipid II (iGln) stock 2; 1, Lipid II (iGln) stock 1; 3, Lipid II (iGln) stock 3; *, 
contaminant observed in stock 3. 
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Difficulties in establishing activity of PBP1aD39 may therefore have resulted 
from variation in the lipid stocks used. 
 
Table 4.5 Mass spectrometry data for analysis of Lipid II (iGln) stocks. 
Samples were analysed by negative ion time-of-flight mass spectrometry. 














Stock 1 (no activity) 1873.06 
Stock 2 (activity) 1873.06 




Stock 1 (no activity) 936.03 
Stock 2 (activity) 936.03 
Stock 3 (contaminant) 
Polymeric 
species 




4.3.2.5 In vitro activity of PBP1aD39 with donor- and acceptor-only substrates 
After having established D-Ala release activity of PBP1aD39 with Lipid II (iGln) 
as the substrate, we sought to test the activity with defined donor- and 
acceptor-only substrates. As previously discussed in Section 3.1.4, defined 
donors and acceptors were sought to attempt the resolution of the 
transpeptidase and D,D-carboxypeptidase rates of the PBP1a. Both of these 
activities would contribute to the D-Ala release signal in the presence of a 
Figure 4.13 Features of donor- and acceptor-only substrates. a) The 
transpeptidase mechanism, illustrating involvement of the donor stem 
peptide carbonyl (green box) and the primary amine of the acceptor stem 
peptide (pink box). b) the key features determining whether particular 
substrate variants are donor- or acceptor-only. Donor-only substrates must 
be polymerisable (i.e. lipid linked) and retain the donor carbonyl. These 
substrates are made donor-only by loss of the acceptor nucleophile (e.g. by 
acetylation, as depicted). Conversely, acceptor substrates retain the 
acceptor nucleophile, and are made acceptor-only by loss of the lipid linker 
or the donor carbonyl. 
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single substrate such as Lipid II (iGln). The D-Ala release rate in the presence 
of donor-only substrate alone can be ascribed to D,D-carboxypeptidase 






Figure 4.14 D-Ala release in the presence and absence of donor and 
acceptor-only substrates. The activity of PBP1aD39 was tested in the 
presence of donor-only (Lipid II (iGln, e-N-acetyl-Lys)) and acceptor-only 
(MurNAc 5P (iGln)) substrates. Reaction mixes comprised 50 mM HEPES pH 
7.6, 10 mM MgCl2, 2 µM PBP1aD39, 20 µM Lipid II (iGln, e-N-acetyl-Lys) or 
buffer, 20 µM MurNAc 5P (iGln) or buffer, 33.51 mM.min-1 R. gracalis D-amino 
acid oxidase, 14.82 mM.min-1 horseradish peroxidase, 50 µM Amplex Red 
and 3 X CMC (0.0116 %) of E6C12. All components apart from donor and 
acceptor substrates were present at zero time. The subsequent addition of 
donor and acceptor (in the order listed in the legend) are indicated as addition 
1 and 2 respectively. * indicates artefacts in the + donor + buffer trace due to 
a bubble. Absorbance at 555 nm at 30 °C was followed throughout. 




substrates, a higher rate comprising D-Ala release originating from catalysis 
of both transpeptidation and D,D-carboxypeptidation would be expected.  
 
The activity of PBP1aD39 was tested using Lipid II (iGln, e-N-acetyl-Lys) as the 
donor-only substrate and MurNAc 5P (iGln) as the acceptor-only substrate 
(Figure 4.14). The rates of D-Ala release observed in these experiments were 
slow. The difference in the background-corrected rates of D-Ala release in the 
presence of both donor and acceptor substrate (+ acceptor + donor reaction, 
0.0045 AU.min-1) and donor substrate alone (+ buffer + donor reaction, 0.0072 
AU.min-1) was therefore likely within the error of this experiment. Irrespective 
of the order of addition of donor-only and acceptor-only substrate (as 
compared between Figures 4.14a and b), the rate of D-Ala release appeared 
to be independent of the presence of acceptor substrate. 
 
The expected observation in these experiments, if in vitro transpeptidase 
activity of PBP1aD39 was detected, and the rate of transpeptidation was greater 
than that of D,D-carboxypeptidation, was that the rate would be greater in the 
presence of both donor and acceptor substrates compared to donor alone. 
The results presented in Figure 4.14 could therefore indicate either that the D-
Ala release activity observed could be entirely ascribed to D,D-
carboxypeptidation; or that transpeptidation was not associated with an 
increase in the rate of D-Ala release, which may occur if the acylation of the 
transpeptidase active site serine were the limiting step of the transpeptidase 
and D,D-carboxypeptidase reactions. 
 
To analyse the results further, samples from the assay were digested with S. 
globisporus mutanolysin and analysed by LC-MS. Such analysis is simplified 
by the use of defined donor-only and acceptor-only substrates, as 
fragmentation analysis is not required to deconvolute the mass of D,D-
carboxypeptidase and transpeptidase products (compared to when Lipid II 
(iGln) is the sole substrate; see Section 4.3.2.1.1). The LC-MS analyses of 
reactions shown in Figure 4.14a were scrutinised for the positively charged 
species associated with transpeptidation between the stem peptide of Lipid II 
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(iGln, e-N-acetyl-Lys) and MurNAc 5P (iGln), or carboxypeptidation of the Lipid 
II (iGln, e-N-acetyl-Lys), as depicted in Figure 4.15. 
 
The LC-MS analysis of the reactions in Figure 4.14a is summarised in Table 
4.6. No ions corresponding to the digested transpeptidase product was 
detected in any of the reaction samples. There was therefore no evidence of 
transpeptidase activity in these assays using donor-only and acceptor-only 
substrates. Based on these results, the D-Ala release rates observed in Figure 
4.14 were likely representative of solely D,D-carboxypeptidase activity. An ion 
corresponding to the digested D,D-carboxypeptidase product (expected 
(m+2)/2 469.22, observed (m+2)/2 469.22) was detected only in sample a, in 
which both donor-only and acceptor-only substrates were included. 
Further attempts were made to establish in vitro transpeptidase activity in the 
D-Ala release assay by use of D-Lactate as a substrate, to allow greater 
concentrations of acceptor to be used in the assay; by testing activity at pH 9 
in Bis.Tris propane buffer; and by increasing the concentration of E6C12 buffer 
to 12 X CMC, due to the possibility that the increase in rate with decreasing 
Figure 4.15 Expected products of transpeptidase and D,D-
carboxypeptidase activities using Lipid II (iGln, acetyl-Lys) and MurNAc 
5P (iGln) as substrates, following digestion by an N-acetylmuramidase. 
S. globisporus mutanolysin-digested products formed by transpeptidation (a) 
and D,D-carboxypeptidation (b) catalysed by PBP1aD39 using Lipid II (iGln, e-
N-acetyl-Lys and MurNAc 5P (iGln) as substrates. 
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detergent concentration (Figure 4.11) may reflect an increase in the ratio of 
D,D-carboxypeptidase to transpeptidase activity of PBP1aD39. Under each of  
 these conditions, the rate of D-Ala release was similarly limited, and was 
slowed slightly in the presence of acceptor.  
4.3.2.6 Analysis of TP activity under conditions of the GT assay 
We considered whether the slow rates observed in the D-Ala release assay, 
and the apparent lack of TP activity, were the consequence of rate-limiting, 
slow glycosyltransferase activity by PBP1aD39. Such slow GT activity would 
limit the supply of polymer to act as the TP donor. To test whether the apparent 
lack of transpeptidase activity was the result of limitation by poor GT activity, 
we sought to assay PBP1aD39-catalysed D-Ala release under conditions 
known to support GT activity.  
 
Previous results have suggested that DMSO is inhibitory to transpeptidase 
activity, but 25 % (v/v) DMSO was found to be optimal for in vitro 
glycosyltransferase activity in the continuous fluorometric assay with Lipid II 
(iGln, Dans) (Galley, 2015). Glycan polymer formation by PBP1aD39 using 
Lipid II (iGln, Dans) could be observed by Tris-tricine SDS-PAGE, and was 
accelerated in the presence of 25 % (v/v) DMSO (Appendix 4.9). We therefore 
 
Table 4.6 LC-MS analysis of TP reactions with donor- and acceptor-only 
substrates. Assignment of CP product or TP product putative ions was based on 
structures in Figure 4.11. Samples were analysed by positive-ion LCMS. Data 






Sample Observed m/z 
CP product  (m+2)/2 469.22 
a) acceptor + donor 469.224 
b) buffer + donor - 
c) acceptor + buffer - 
TP product (m+2)/2 841.40 
a) acceptor + donor - 
b) buffer + donor - 
c) acceptor + buffer - 
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used Lipid II (iGln, Dans) or Lipid II (iGln, e-N-acetyl-Lys) as the donor 
substrates in transpeptidase assays with and without 25 % (v/v) DMSO (Table 
4.6). 
 
 Under conditions shown to support extensive glycan polymer formation by 
PBP1aD39 using Lipid II (iGln, Dans) as a donor substrate, no transpeptidase 
rate was detected in the D-Ala release assay (Table 4.7, Appendix 4.10-11). 
As previously (Figure 4.14), the rate of D-Ala release was slowed or 
unchanged in the presence of MurNAc 5P (iGln) acceptor, indicating that the 
rate observed was likely to be solely attributable to D,D-carboxypeptidation. 
These results suggested that the lack of observation of TP activity in the 
continuous assay was not due to lack of GT activity under the conditions of 
the assay. No D-Ala release from Lipid II (iGln, Dans) was observed in the 
absence of DMSO, in agreement with the GT data. However, when Lipid II 
 
Table 4.7 D-Ala release activity under conditions suitable for GT activity.  D-
Ala release catalyzed by PBP1aD39 was followed in the presence and absence of 
25 % (v/v) DMSO, and using either Lipid II (iGln, Dans) or Lipid II (iGln, e-N-acetyl-
L-Lys) as a donor substrate. Reaction mixes comprised 50 mM HEPES pH 7.6, 10 
mM MgCl2, 2 µM PBP1aD39, 20 µM Lipid II (iGln, acetyl-Lys or Dans), 20 µM 
MurNAc 5P (iGln), 33.51 mM.min-1 R. gracalis D-amino acid oxidase, 14.82 
mM.min-1 horseradish peroxidase, 50 µM Amplex Red and 3 X CMC (0.0116 % 
(w/v)) of E6C12. D-Ala release rates were ascribed to transpeptidation if an elevated 
rate was observed in the presence of acceptor substrate compared to donor 
substrate alone; and rates were ascribed to D,D-carboxypeptidation if such 
elevation of rate was not observed. 
 
Lipid donor DMSO D,D-carboxypeptidation Transpeptidation 
Lipid II  
(iGln, Dans) 
+ ✔ ✖ 
- ✖ ✖ 
Lipid II  
(iGln, acetyl-
Lys) 
+ ✖ ✖ 
- ✔ ✖ 
    
 
 168 
(iGln, e-N-acetyl-Lys) was supplied as the donor substrate, D-Ala release 
activity was only detected in the absence of DMSO. These results suggested 
that the requirement for DMSO for optimal GT activity in the continuous 
fluorometric assay was related to the dansyl fluorophore rather than being a 
general requirement for GT activity. 
 
 4.3.3 Analysis of TP activity by SDS-PAGE 
Several published methods have used Tris-tricine gel electrophoresis to 
monitor transpeptidase activity, based on the inability of the cross-linked 
glycan polymer to enter the acrylamide gel matrix (Qiao et al., 2017; 
Srisuknimit et al., 2017; Zapun et al., 2013). We therefore attempted 
observation of transpeptidase activity using this technique. This discontinuous 
technique allowed transpeptidation to be followed on a longer time scale than 
was possible with the D-Ala release assay. The substrates for these reactions 
were a 1:1 mixture of Lipid II (iGln, Dans) as the transpeptidase donor-only 
substrate (allowing visualisation of glycan polymers based on the Dansyl 
fluorophore); and Lipid II 3P (iGln) (as the acceptor substrate for 
transpeptidation). Glycosyltransferase assays conducted prior to this work 
(and described in Section 5.3.1.2) identified that among the ethylene glycol 
detergents tested (including E6C12 used in previous work described in this 
Chapter), E8C10 supported optimal GT activity of PBP1aD39. The following 




4.3.3.1 Can TP activity be observed in the Tris-tricine gel system? 
We used the SDS-PAGE system to attempt to establish and compare the 
cross-linking activity of PBP1aPn16 and PBP1a159 (Figure 4.16). When the GT 
inhibitor moenomycin was included in the reaction mixture, only the Lipid II 
(iGln, Dans) starting material was observed, as a fluorescent band at the 
running front of the gel. With no inhibitor, a band at the top of the gel was 
observed, as expected for putative cross-linked material. When ampicillin was 
included in the reaction mixture, the high molecular weight band was lost with 
PBP1aPn16, but the band was still observed in the reaction with PBP1a159. This 
observation is consistent with the high molecular weight material being cross-
linked polymer, based upon the likely decreased affinity of PBP1a159 for the 
ampicillin compared to PBP1aPn16. In order to assess whether transpeptidation 
Figure 4.16 Analysis of putative transpeptidase activity of PBP1aPn16 and 
PBP1a159 by Tris-tricine SDS-PAGE. Reactions comprised 50 mM HEPES 
pH 7.6, 10 mM MgCl2, 0.5 µM PBP1a, 2.5 µM Lipid II (iGln, Dans), 2.5 µM Lipid 
II (iGln, tripeptide), 25 % (v/v) DMSO, 150 mM NaCl, 33.51 mM.min-1 R. 
gracalis D-amino acid oxidase, 14.82 mM.min-1 horseradish peroxidase, 50 µM 
Amplex Red and 3 X CMC of E8C10. Reactions without antibiotic, and control 
reactions incubated with 200 µM moenomycin (moe) to inhibit 
glycosyltransferase activity or 1 mM ampicillin (amp) to inhibit transpeptidase 
activity, were incubated for 30 mins. The reactions were then quenched with 
EDTA, mixed with loading dye and loaded to a CriterionÔ 16.5 % Tris-Tricine 
Precast gel (Bio-Rad). The gel was run at 100 V, 50 mA for 3 h, and then 
imaged using an ImageQuant LAS 4000 instrument (GE Healthcare).  
-, reaction with no inhibitors; moe, control reaction with moenomycin; amp, 
control reaction with ampicillin. 
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had occurred in these reactions, duplicate samples were digested using S. 
globisporus mutanolysin, and analysed by mass spectrometry.  
 
The compounds queried in the LC-MS data are depicted in Figure 4.17. As 
both the donor and acceptor in this experiment were polymerisable, the mass 
of a putative TP product (Figure 4.17a) would match that of an incompletely 
mutanolysin-digested heterodimer (Lipid IV) species of Lipid II (iGln, Dans) 
and Lipid II (iGln, tripeptide) with removal of the terminal D-Ala moiety of the 
Dansylated stem peptide (Figure 4.17b). Ions derived from a compound of that 
mass would therefore require collision-induced fragmentation to discriminate 
between these two possibilities. 
 
In the LC-MS analysis of the peptidoglycan assembly reactions with 
PBP1aPn16 and PBP1a159, insufficient signal was observed for ions derived 
from cross-linked material. We were therefore unable to confirm whether 
transpeptidase activity had occurred in these reactions.  
An ion associated with the D,D-carboxypeptidase product (expected (m+1)/1, 
1128.48; observed (m+1)/1, 1128.48) was detected in the reactions with 
PBP1aPn16 and no antibiotics, and PBP1a159 without inhibitors and with 
ampicillin (Table 4.8). The detection of a D,D-carboxypeptidase product in the 
Figure 4.17 Expected products of transpeptidase and D,D-
carboxypeptidase activities using Lipid II (iGln, Dans) and Lipid II (iGln, 
tripeptide) as substrates, following digestion by an N-
acetylmuramidase. Diagram of the S. globisporus mutanolysin-digested 
products formed by transpeptidation (a) and D,D-carboxypeptidation (b) 
catalysed by PBP1aPn16 or PBP1a159 using Lipid II (iGln, Dans) and Lipid II 
(iGln, tripeptide) as substrates. Full digestion of (b) by S. globisporus 
mutanolysin yields compound c). 
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reaction with PBP1a159 and ampicillin was consistent with the result in Figure 
4.16, where the high molecular weight band was still observed in the presence 
of ampicillin, and could be attributed to the comparative insensitivity of 
PBP1a159 to ampicillin. 
 
Table 4.8 LC-MS analysis of peptidoglycan assembly reactions of PBP1aPn16 
and PBP1a159. Reactions comprised 50 mM HEPES pH 7.6, 10 mM MgCl2, 0.5 µM 
PBP1a, 2.5 µM Lipid II (iGln, Dans), 2.5 µM Lipid II (iGln, tripeptide), 25 % (v/v) 
DMSO, 150 mM NaCl, 33.51 mM.min-1 R. gracalis D-amino acid oxidase, 14.82 
mM.min-1 horseradish peroxidase, 50 µM Amplex Red and 3 X CMC of E8C10. 
Following the reaction, samples were digested with mutanolysin and analysed by 
LC-MS. 
 




CP product (m+1)/1 1128.48 
Pn16 1128.48 
Pn16 amp - 
159  1128.48 
159 amp 1128.48 
159 moe - 




Pn16 amp - 
159  - 
159 amp - 
159 moe - 
     
4.3.4 BOCILLIN FL binding to assess substrate binding 
The major aim of this project was to investigate the impact of branched 
muropeptides on the inhibition of pneumococcal PBPs by b-lactams. As there 
were difficulties in establishing TP activity in the D-Ala release assay system, 
we looked to alternate techniques to compare the binding of b-lactams in the 
presence of linear and branched substrates. 
We therefore sought to establish whether BOCILLIN FL binding could be used 
to assess the interaction of PBP1a with its substrates. We hypothesised that 
the substrates of PBP1a may protect the active site serine from modification 
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with BOCILLIN FL, and that this protection may vary depending upon whether 
the substrate was donor or acceptor, and linear or branched. 
 
Interactions with BOCILLIN FL were assessed by incubating the protein with 
BOCILLIN FL (and any other molecules under investigation), and then 
analysing the samples by SDS-PAGE.  
 
4.3.4.1 BOCILLIN FL binding by different PBP1a variants 
The first step in the use of BOCILLIN FL binding for analysis of substrate 
interactions was to establish that each of the PBP1a variants could be modified 
by BOCILLIN FL. An active site serine mutant of PBP1a D39 (designated D39 
S370A) was used as a control enzyme, as the loss of the active site serine 
should prevent modification of this enzyme with BOCILLIN FL. For each 
enzyme, moenomycin and ampicillin were used in control reactions. 
Moenomycin binds PBP1a, but at the donor site of the glycosyltransferase 
active site, and as such this inhibitor should not prevent modification of PBP1a 
with BOCILLIN FL. Ampicillin was used to modify the active site serine of 
PBP1a prior to addition of BOCILLIN FL, thereby demonstrating that the 
modification by the latter is by interaction specifically with the active site serine. 
Also included was a negative control, with DMSO in place of BOCILLIN FL. As 
depicted in Figure 4.18, PBP1a variants from strains D39, Pn16 and 159 were 
all modified by BOCILLIN FL, but not PBP1aD39 S370A, as expected. The 
described control reactions were also broadly as expected, with no impact 
upon BOCILLIN FL binding by moenomycin, but competition of BOCILLIN FL 
binding by ampicillin. However, there was only partial competition of BOCILLIN 
FL binding of PBP1a159 by ampicillin. This was likely the consequence of 
reduced affinity of PBP1a159 for ampicillin. 
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The inclusion of the DMSO-only control allowed an additional observation from 
these gels; there was the shift in the bands of PBP1aD39 and PBP1aPn16 from 
the expected molecular weight of ~ 82 kDa, to 63 kDa when bound to 
BOCILLIN FL or ampicillin. This band shift was not observed with PBP1a159 or 
the PBP1aD39 S370A mutant, with binding of BOCILLIN FL or ampicillin. This 
observation was followed up in work described in Section 4.3.4.5. 
Figure 4.18 Analysis of BOCILLIN FL binding by S. pneumoniae PBP1a 
variants. Protein stocks (10 µM) were incubated with water, moenomycin 
(200 µM) or ampicillin (200 µM) for 30 mins at 25 °C, followed by incubation 
with 50 µM BOCILLIN FL or DMSO for 1 h at 37 °C. Reactions were analysed 
by SDS-PAGE using 12 % acrylamide gels and fluorescence was imaged (a)I 
and (b)i) using a Typhoon FLA 9500 laser scanner (GE Healthcare). Gels 
were then stained using InstantBlue Protein Stain (Expedeon) and imaged for 
total protein ((a)ii and (b)ii) using an ImageQuant LAS 4000 instrument (GE 
Healthcare).  
1, PBP1a, moenomycin and BOCILLIN FL; 2, PBP1a, water and BOCILLIN 
FL; 3, PBP1a, ampicillin and BOCILLIN FL; 4, PBP1a, water and DMSO; 
F.Mr, BenchMark Fluorescent Protein Standard (ThermoFisher Scientific); 
Mr, Color Prestained Protein Standard, Broad Range (NEB) molecular weight 
marker, kDa, kilo-Daltons. 
a)i Fluorescence scan a)ii Coomassie stain 
b)i Fluorescence scan b)ii Coomassie stain 
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4.3.4.2 Effect of donor-only substrate on BOCILLIN FL binding  
Interactions with the substrates were first investigated by using the donor-only 
substrate, Lipid II (iGln, e-N-acetyl Lys). The effect of the donor on BOCILLIN 
FL binding was tested by preincubating PBP1aD39 with Lipid, and then adding 
BOCILLIN FL (Figure 4.19). At the concentrations used (10:1 molar ratio of 
Lipid II (iGln, acetyl-Lys):PBP1aD39, with 5:1 molar ratio of BOCILLIN FL: 
PBP1aD39), no effect on BOCILLIN FL binding by the presence of Lipid II (iGln, 
e-N-acetyl Lys) was observed.  
 
4.3.4.3 Effect of MurNAc 5P (iGln) acceptor on BOCILLIN FL binding 
Acceptor-only substrates were then tested for their ability to alter the binding 
of PBP1a by BOCILLIN FL. Concentrations from 1 to 1000-fold the molar 
Figure 4.19 Analysis of BOCILLIN FL binding by PBP1aD39 in the 
presence of donor-only Lipid II. 6 µM PBP1aD39 was incubated with water, 
60 µM Lipid II (iGln, acetyl-Lys) or 200 µM ampicillin for 30 mins at 25 °C, 
followed by incubation with 30 µM BOCILLIN FL or DMSO for 1 h at 37 °C. 
Reactions were analysed by SDS-PAGE using 12 % acrylamide gels and 
fluorescence was imaged (left-hand gel) using a Typhoon FLA 9500 laser 
scanner (GE Healthcare). Gels were then stained using InstantBlue Protein 
Stain (Expedeon) and imaged for total protein (right-hand gel) using an 
ImageQuant LAS 4000 instrument (GE Healthcare).  
1, PBP1aD39, water, DMSO; 2, PBP1aD39, ampicillin, BOCILLIN FL; 3, 
PBP1aD39, water, BOCILLIN FL; 4, PBP1aD39, Lipid II (iGln, acetyl-Lys), 
BOCILLIN FL; F.Mr, BenchMark Fluorescent Protein Standard (ThermoFisher 
Scientific); Mr, Color Prestained Protein Standard, Broad Range (NEB) 
molecular weight marker, kDa, kilo-Daltons.  
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concentration of enzyme were used, with 5-fold BOCILLIN FL compared to the 
molar concentration of enzyme. The acceptor tested was MurNAc 5P (iGln) 
(Figure 4.20). 
No effect on BOCILLIN FL binding by the presence of MurNAc 5P (iGln) 
substrate was observed with PBP1aD39, based on band sizes observed under 
fluorescence imaging. This technique, under the conditions tested, could 
therefore not be used to compared the impact of different substrates (both 
donor- and acceptor-only) on acylation by BOCILLIN FL. 
 
  
Figure 4.20 Analysis of BOCILLIN FL binding by PBP1aD39 in the 
presence of MurNAc 5P (iGln) acceptor. 6 µM PBP1aD39 was incubated 
with water, varying concentrations of MurNAc 5P (iGln) acceptor or 200 µM 
ampicillin for 30 mins at 25 °C, followed by incubation with 30 µM BOCILLIN 
FL or DMSO for 1 h at 37 °C. Reactions were analysed by SDS-PAGE using 
12 % acrylamide gels and fluorescence was imaged (left-hand gel) using a 
Typhoon FLA 9500 laser scanner (GE Healthcare). Gels were then stained 
using InstantBlue Protein Stain (Expedeon) and imaged for total protein 
(right-hand gel) using an ImageQuant LAS 4000 instrument (GE Healthcare). 
1, PBP1aD39, water, DMSO; 2, PBP1aD39, ampicillin, BOCILLIN FL; 3, 
PBP1aD39, water, BOCILLIN FL; 4, 1:1 molar ratio PBP1aD39:MurNAc 5P 
(iGln), BOCILLIN FL; 5, 1:10 molar ratio PBP1aD39:MurNAc 5P (iGln) 
BOCILLIN FL; 6, 1:100 molar ratio PBP1aD39:MurNAc 5P (iGln), BOCILLIN 
FL; 7, 1:1000 molar ratio PBP1aD39:MurNAc 5P (iGln), BOCILLIN FL; F.Mr, 
BenchMark Fluorescent Protein Standard (ThermoFisher Scientific); Mr, 
Color Prestained Protein Standard, Broad Range (NEB) molecular weight 
marker; kDa, kilo-Daltons.  
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4.3.4.5 Shift in migration of PBP1a bands on SDS-PAGE upon binding of b-
lactams 
We observed a shift in the migration of BOCILLIN FL-PBP complexes with 
some variants of PBP1a (Figure 4.18). We therefore sought to assess whether 
acylation of PBP1a by other b-lactams would give the same result. We first 
established whether this effect upon PBP1aD39 was associated with binding of 
ampicillin and not specific to BOCILLIN FL; and whether the effect was 
observed with binding of Lipid II (iGln) (Figure 4.21).  
When incubated with Lipid II buffer (Figure 4.21, lane 1) or water (lane 4), a 
band of PBP1aD39 was observed at ~80 kDa, as expected based on the 
experimentally determined exact mass (82.3 kDa; see Section 4.3.1.4). No 
change in the observed molecular weight of this band was observed in the 
presence of Lipid II (iGln, e-N-acetyl Lys) (Figure 4.21, lane 2) or in the 
presence of Lipid II (iGln) (lane 3). However, as previously observed, in the 
presence of ampicillin the major band was observed between 58 and 80 kDa. 
The binding of ampicillin therefore appeared to be associated with a shift in 
the apparent molecular weight of PBP1aD39 on SDS-PAGE gels. Mass 
 
Figure 4.21 Analysis of PBP1aD39 band shift on SDS-PAGE in the 
presence of Lipid substrates and ampicillin. 6 µM PBP1aD39 was incubated 
with buffer (1), 60 µM Lipid II (iGln) (2), 60 µM Lipid II (iGln, e-N-acetyl Lys) 
(3), water (4) or 200 µM ampicillin (5) for 30 mins at 25 °C. Reactions were 
analysed by SDS-PAGE using a 12 % acrylamide gel. The gel was then 
stained using InstantBlue Protein Stain (Expedeon) and imaged using an 
ImageQuant LAS 4000 instrument (GE Healthcare).  
1, PBP1aD39 and buffer; 2, PBP1aD39 and Lipid II (iGln, e-N-acetyl Lys); 3, 
PBP1aD39 and Lipid II (iGln); 4, PBP1aD39 and water; 5, PBP1aD39 and 
ampicillin; Mr, Color Prestained Protein Standard, Broad Range (NEB) 
molecular weight marker, kDa, kilo-Daltons. 
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spectrometry analysis of this complex was only consistent with a change in 
mass resulting from the added mass of ampicillin (Section 4.3.1.4), and so this 
phenomenon was likely a consequence of conformation and not a genuine 
decrease in mass. 
 
We then sought to analyse whether the apparent shift in molecular weight (of 
PBP1aD39 bound to ampicillin or BOCILLIN FL) was a general property 
associated with acylation of PBP1aD39 by b-lactams. 
A variety of b-lactams, to represent the variation in structure of the different 
generations and chemical classes, was tested for the association with the 
change in band migration. Of particular interest were those inhibitors 
 
Table 4.9. Selectivity of b-lactams for pneumococcal PBPs, based on 
protection against labelling by BOCILLIN FL. Adapted from Kocaoglu et al. 
(2015). 
 
Class b-lactam Selectivity profile (PBP) 
1a 1b 2a 2x 2b 3 
Penicillins penicillin G 
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demonstrated by Kocaoglu et al. (2015) to be selective for PBP1a in an 
unencapsulated pneumococcal D39 strain (Table 4.9). It should be noted that, 
surprisingly, none of the inhibitors tested were designated as selective for 
PBP2b, despite the importance of this PBP in the pneumococcal resistance 
mechanism. 
 
Ampicillin, meropenem and cephalothin were therefore each incubated with 
PBP1aD39, and samples analysed by SDS-PAGE to analyse the observed 
molecular weight. In order to confirm the binding of PBP1aD39 by these 
inhibitors, a second set of reactions were run concurrently, with subsequent 
addition of BOCILLIN FL to establish whether ampicillin, meropenem and 
cephalothin protected against acylation of the TP active site serine by 
BOCILLIN FL. DMSO was added to reactions without BOCILLIN FL to control 
for the effect of this solvent.  
PBP1aD39 incubated with water and DMSO only migrated on SDS-PAGE as a 
major band at ~ 80 kDa (Figure 4.22). As previously, acylation of PBP1aD39 by 
BOCILLIN-FL was associated with a shift in the migration of the enzyme to ~ 
63 kDa. Very little fluorescence was detected in samples pre-incubated with 
Figure 4.22 b-lactam panel for analysis of shift in migration of PBP1aD39. 
6 µM PBP1aD39 was incubated with water or 600 µM b-lactam, followed by a 
further incubation with DMSO or 60 µM BOCILLIN FL. Reactions were analysed 
by SDS-PAGE using a 12 % acrylamide gel and fluorescence was imaged (left-
hand gel) using a Typhoon FLA 9500 laser scanner (GE Healthcare). The gel 
was then stained using InstantBlue Protein Stain (Expedeon) and imaged for 
total protein (right-hand gel) using an ImageQuant LAS 4000 instrument (GE 
Healthcare).   
-, PBP1aD39 and water; A, PBP1aD39 and ampicillin; M, PBP1aD39 and 
meropenem; C, PBP1aD39 and cephalothin; F.Mr, BenchMark Fluorescent 
Protein Standard (ThermoFisher Scientific); Mr, Color Prestained Protein 
Standard, Broad Range (NEB) molecular weight marker, kDa, kilo-Daltons.  
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ampicillin, meropenem or cephalothin, indicating that these inhibitors were 
able to acylate the active site serine and thereby prevent binding of BOCILLIN 
FL. Binding of PBP1aD39 by ampicillin, meropenem and cephalothin were all 
associated with a shift in the migration of the major band of PBP1aD39. This 
phenomenon appears to therefore be a general property among this subset of 
PBP1a-directed b-lactams. 
 
This experiment was then broadened to include b-lactams that were not 
reported to be PBP1a-selective by Kocaoglu et al. (2015), in addition to two 
peptidoglycan biosynthesis inhibitors unrelated to the b-lactams; moenomycin, 
as discussed previously; and vancomycin, a glycopeptide inhibitor. 
Vancomycin inhibits transpeptidation via binding of the D-Ala-D-Ala terminus 
of Lipid II, and should not therefore not be associated with the b-lactam 
mediated shift in band migration of PBP1a. Incubation with moenomycin or 
vancomycin in the absence of BOCILLIN FL was not associated with a shift in 
the migration of PBP1aD39 on an SDS-PAGE gel (Figure 4.23c), and these 
inhibitors did not prevent acylation of PBP1aD39 by BOCILLIN FL (Figure 
4.23b). These observations suggest that the shift in migration requires binding 
of PBP1aD39 at the transpeptidase active site, by a b-lactam. 
In agreement with the results from Figure 4.22, binding of PBP1aD39 by 
ampicillin or meropenem prevented acylation of the active site serine by 
BOCILLIN FL (Figure 4.23a), and was associated in a shift in the migration of 
the major band of protein. Such shift in migration was also observed with 
ceftazidime, though proportionally more protein remained at the expected 
molecular weight (Figure 4.23c), and protection against acylation by 
BOCILLIN FL (a) demonstrated acylation of the enzyme by ceftazidime. A shift 
in migration was observed with cephalexin, but the major band in this reaction 
remained at the expected molecular weight (Figure 4.23c). In addition, there 
was little effect on BOCILLIN FL labelling of PBP1aD39 when pre-incubated 
with cephalexin, suggesting poorer affinity of this antibiotic for the enzyme. 
Whilst pre-incubation with cefoxitin preventing labelling of PBP1a with 
BOCILLIN FL (Figure 4.23a), indicating binding of PBP1aD39 by this inhibitor, 
there was no shift observed in the migration of the major band (Figure 4.23b 
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and c). The migration-shift phenomenon was therefore not a general feature 
of acylation of PBP1a by b-lactams. 
 
Figure 4.23 Inhibitor panel for analysis of shift in migration of PBP1aD39. 
A range of peptidoglycan biosynthesis inhibitors (b-lactams: ampicillin (A), 
meropenem (M), cephalexin (L), cefoxitin (F), ceftazidime (T); moenomycin 
(M), a glycosyltransferase inhibitor; and vancomycin (V), a glycopeptide) at 600 
µM or water were incubated with 6 µM PBP1aD39, followed by addition of 60 
µM BOCILLIN FL (gels a) and b)) or DMSO (c) and a further incubation step. 
Reactions were analysed by SDS-PAGE using a 12 % acrylamide gel and 
fluorescence was imaged (left-hand gel) using a Typhoon FLA 9500 laser 
scanner (GE Healthcare). The gel was then stained using InstantBlue Protein 
Stain (Expedeon) and imaged for total protein (right-hand gel) using an 
ImageQuant LAS 4000 instrument (GE Healthcare).  
Gel a, reactions including BOCILLIN FL, and an inhibitor (abx) or water, and 
imaged for fluorescence; Gel b, reactions including BOCILLIN FL, and an 
inhibitor (abx) or water, and imaged for total protein; Gel c, reactions including 
DMSO, and an inhibitor (abx) or water, and imaged for total protein; A, 
ampicillin; M, meropenem; L, cephalexin; F, cefoxitin; T, ceftazidime; Mo, 
moenomycin; V, vancomycin; F.Mr, BenchMark Fluorescent Protein Standard 
(ThermoFisher Scientific); Mr, Color Prestained Protein Standard, Broad 






4.4.1 Difficulties in establishing in vitro transpeptidase activity of 
PBP1aD39 
The difficulty of establishing in vitro transpeptidase activity has limited 
progress in characterisation of the pneumococcal b-lactam resistance 
mechanism. The data presented in this Chapter indicated that slow D,D-
carboxypeptidase activity by PBP1aD39 could be detected, and that the rate of 
this activity (as measured by the rate of D-Ala release) was increased in near-
CMC concentrations of E6C12 assay detergent. 
 
4.4.1.1 Low activity of PBP1aD39 
Activity of PBP1aD39 was low in comparison to purified recombinant E. coli 
PBP1b (Dr. A.J. Lloyd, University of Warwick, personal communication). D-Ala 
release that was detected appeared to be composed near-entirely of D,D-
carboxypeptidation. This was based upon the apparent independence of D-
Ala release to presence of acceptor substrate; along with lack of detection of 
TP products on LC-MS analysis. 
Possible causes for the issues with activity that were explored included 
presence of lysozyme, loss of activity with storage, the choice of substrates, 
and insufficient GT activity under the assay conditions. Omission of lysozyme 
from the purification of PBP1aD39 did not impact the rate of transpeptidation 
observed. In addition, assays conducted immediately upon purification of 
PBP1aD39 did not show greater activity of the enzyme than those conducted 
following storage of the enzyme at – 20 °C. Finally, despite the use of both 
Lipid II (iGln) and donor-only and acceptor-only substrates being used for 
transpeptidase assays, no appreciable increase in activity of PBP1aD39 could 
be achieved. Explorations of the contribution of GT activity to the detection of 
TP activity are discussed in Section 4.4.1.4. 
 
A recent publication has suggested that the role in peptidoglycan biosynthesis 
of Class A PBPs in the pneumococcus lies within remodelling of peptidoglycan 
(Straume et al., 2019), which would have implications for the substrate 
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preference of PBP1a. Further work could encompass the use of purified 
peptidoglycan as a substrate to further explore this possibility. Stimulation by 
protein-protein interactions could also be a key component of in vitro activity. 
This is further explored in Section 4.4.5. 
 
4.4.1.2 Detection of transpeptidation by LC-MSMS 
Analysis of transpeptidation by mass spectrometry did not detect TP products 
from reactions with S. pneumoniae PBP1aD39. TP products from reactions 
using Lipid II (iGln) as substrate have previously been detected under similar 
analysis conditions (Galley, 2015). The results are therefore likely to reflect 
lack of cross-linked product, rather than a failure of detection on LC-MS due 
to limited ionisation of the compound of interest.  
 
Reactions from an experiment testing the impact of detergent titration on TP 
activity did result in detection of a putative TP product (Section 4.3.2.2). The 
low abundance of the relevant ion precluded LCMSMS analysis to determine 
whether TP or CP product was observed. Up to 90 % signal loss can be 
expected when selecting ions for diversion into the second quadrupole of the 
mass spectrometer. In the case of the detergent titration experiment, the signal 
of the ion of interest was insufficient to allow fragmentation. 
 
In subsequent experiments, detection of TP products was attempted from 
samples that were in parallel analysed by Tris-tricine SDS-PAGE. Te 
experiment was designed to increase the amount of the putative TP product 
ion (and therefore hopefully the signal detected) by inclusion of longer 
incubation of the reactions, and concentration of the samples by lyophilization. 
These methods were unsuccessful in yielding detection of a TP product by 
mass spectrometry. 
 
The LC-MSMS detection method warrants revisiting in combination with the 




4.4.1.3 Variation in Lipid II (iGln) stocks 
Variation in the activity of some preparations of PBP1aD39 could be ascribed 
to differences between Lipid II (iGln) stocks. Mass spectrometry, and purity 
analysis by TLC, revealed that a polymeric contaminant in one stock of Lipid 
II (iGln); and that another was apparently less concentrated than was 
determined using a phosphate-release assay for Lipid II concentration. In 
future assays using Lipid II (iGln), a master stock that has been validated for 
use (i.e. with which D-Ala release activity has been detected with PBP1aD39) 
should be retained for testing of further stocks as they are made.  
 
4.4.1.4 Potential for rate-limiting GT activity of PBP1aD39 
It was considered that the apparent low rate of D-Ala release may be due to 
slow GT activity under the conditions of the TP assay, which would prove rate-
limiting to transpeptidation due to the need for supply of the TP donor from the 
GT site, as a polymeric species. Transpeptidase assays using Lipid II (iGln, 
Dans) in the presence of DMSO demonstrated similar rates of D-Ala release 
to those observed in assays using Lipid II (iGln). As significant and rapid GT 
activity could be detected using Lipid II (iGln, Dans), it was concluded that slow 
GT activity was unlikely to be the cause of limited D-Ala release activity. 
 
4.4.2 The impact of detergents on D-Ala release catalysed by PBP1aD39 
Analysis of D-Ala release in the transpeptidase assay revealed that the rate of 
D-Ala release was increased with decreasing concentrations of detergent. 
This effect could be related to the activity of the glycosyltransferase active site, 
as the substrates of the GT reaction are lipid-linked (Section 1.4.1), but in the 
TP reaction products are not lipid linked, so it seems less likely that 
transpeptidation would be affect by detergent so long as the enzyme is kept in 
solution adequately. This impact of lipid environment on PBP1a activity was 
further studied in Chapter 5. The inverse relation between detergent 
concentration and PBP1a activity was rationalised based on surface dilution 
kinetics, whereby decreasing concentrations of detergent would result in less 




4.4.3 Analysis of TP activity by SDS-PAGE 
Tris-tricine SDS-PAGE was an alternative technique that was explored to 
detect transpeptidase activity, as has been shown in the literature (Qiao et al., 
2017; Zapun et al., 2013). From the analysis of reaction products from 
PBP1aPn16 and PBP1a159, high molecular weight material was observed by 
Tris-tricine SDS-PAGE. However, there was no evidence of TP products by 
mass spectrometry. Two potential explanations for these results arise. It is 
possible that the high molecular weight material comprised large glycan 
polymers, though this would not reconcile with the loss of such material in the 
presence of ampicillin. Alternatively, the high molecular weight material could 
be cross linked peptidoglycan, but it could be that very few cross links are 
required to generate material that cannot enter the gel matrix. In this case, the 
detection of cross-linked material following mutanolysin digestion would prove 
difficult. There was therefore no evidence that the high molecular weight 
material was cross-linked product. 
 
The most convincing example of detection of transpeptidation by Tris-tricine 
SDS-PAGE in the literature was that of Qiao et al. (2017). Qiao et al. (2017) 
used treatment with lysostaphin to demonstrate that the high-molecular weight 
material was cross-linked, based on the loss of this band following cleavage 
of the cross-links with lysostaphin. Similar analysis could be pursued with 
PBP1aD39, in the absence of such a specific endopeptidase, by the use of Lipid 
II (iGln) where the materially was fluorescently labelled via the lipid chain or 
sugar moieties. In this case, an amidase could be used to cleave the high 
molecular weight material without loss of fluorescent labelling, thereby 
allowing a similar experiment to be conducted as that of Qiao et al. (2017).  
 
4.4.4 Further work to establish in vitro transpeptidase activity of 
PBP1aD39 
To begin to address the resistance mechanism of S. pneumoniae to b-lactam 
antibiotics, further work is needed to establish in vitro transpeptidase activity. 
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4.4.4.1 S2d substrate analogues  
One potential method for further characterising the conditions to establish 
PBP1a activity would be the use of S2d thioester analogues as a proxy for 
transpeptidase activity. These compounds could be used to establish optimum 
conditions for testing with Lipid II, thus decreasing the amount of this 
expensive reagent that need be used. In addition, previous uses of this assay 
have analysed the ratio of transpeptidase and D,D-carboxypeptidase activity 
(Adam et al., 1991). Such data would be of use to corroborate the findings 
described in this Chapter. 
 
4.4.4.2 Protein interactors with Class A PBPs 
Another key avenue for further exploration is the interactors of S. pneumoniae 
Class A PBPs. MacP, a protein interacting partner of PBP2a, was found to be 
essential for in vivo function of PBP2a (Fenton et al., 2018). By contrast, no 
activating partner protein of PBP1a has so far been established. A key next 
step would therefore be to clone and express MacP and test PG synthesis 
activity of PBP2a with that enzyme present. Additionally, Fenton et al. (2018) 
suggested that MacP interacted with the cytoplasmic tail or transmembrane 
anchor of PBP2a. It could therefore be of interest to express and analyse the 
activity of a PBP2a construct without the cytoplasmic domain. Studies of E. 
coli PBP1B isoforms with differing lengths of cytoplasmic tail have revealed an 
involvement of this region in association with PBP3 (Chalut et al., 2001). Loss 
of the transmembrane anchor has been shown to impair GT activity of PBP2a 
(Galley, 2015), so this would be unlikely to yield increased activity of the 
protein.  
 
4.4.5 BOCILLIN FL binding and interactions with substrates 
Under the conditions tested, no impact upon BOCILLIN FL binding was 
observed by the presence of Lipid II variants or MurNAc 5P (iGln) acceptor. 
Di Guilmi et al. (2003) used native PAGE to determine whether Lipid II binding 
to the TP domain of PBP2a could be observed on the basis of a gel-shift. 
Whilst binding of Lipid II to the GT domain was found to be associated with a 
gel-shift in the protein band, no such phenomenon was observed in the current 
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experiments. Native PAGE experiments could therefore be of utility in further 
characterisation of binding by substrates. However, this would render it difficult 
to distinguish between binding by the GT and TP active sites, whereas 
covalent interaction (as detected on SDS-PAGE) occurs only at the TP active 
site and not the GT active site. 
 
To follow up on this work, a technique such as fluorescent polarisation could 
be employed. By this technique, the impact of donor or acceptor-only 
substrates on BOCILLIN FL binding could be analysed, to provide insight into 
how linear and branched acceptors interact. However, a limitation of this 
technique is its amenability to detergent; large detergent micelles such as 
those formed by E6C12, the detergent of choice, could themselves contribute 
to the anisotropy signal, and thus limit the sensitivity of the assay.  
 
BOCILLIN FL gels revealed an experimental phenomenon of shift in migration 
of PBP1a upon binding of particular b-lactams. A similar shift in migration was 
not observed with PBP1aS370A, which illustrated that the phenomenon was 
associated with b-lactam binding. In addition, the shift in migration did not 
appear to be a general feature of b-lactam binding, as only a subset of b-
lactams caused the apparent shift, despite the use of concentrations sufficient 
to inhibit labelling by BOCILLIN FL. 
 
Gel shifting has previously been observed as a phenomenon associated with 
membrane proteins. Rath et al. (2009) showed that the shift in migration of a 
panel of hairpin sequences from TM 3 and 4 of the human cystic fibrosis 
transmembrane conductance regulator (CFTR) were associated with changes 
in the SDS-binding capacity and hairpin helicity of these constructs. Rath et 
al. (2009) thereby suggested that some gel shifts between the constructs may 
be explained by replacement of protein-protein contacts by protein-detergent 
contacts, which thereby altered the mass to charge ratio of the proteins.  
Other physical properties of proteins found associated with gel shifts included 
percentage of acidic amino acids, with difference between predicted and 
experimental molecular weight correlating with percentage of acidic amino 
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acids over a specific range (Guan et al., 2015); post-translational modifications 
such as phosphorylation (Hutchison et al., 1993; Lee et al., 2013); particular 
carboxyl-terminal amino acids (Wang et al., 2013); binding of Ni2+ ions by His-
rich protein (Shelake et al., 2017); and amino acid substitutions altering net 
charge, and therefore the number of SDS molecules bound (Shi et al., 2012). 
 
Ligand binding by proteins has been demonstrated to result in increased 
thermodynamic stability, and likely slower unfolding of protein (Chang et al., 
2012). This phenomenon was demonstrated with purified recombinant 
phosphoglyceromutase analysed under pulse proteolysis. Pulse proteolysis 
used selective digestion of unfolded proteins to provide a measure of the 
fraction of folded and unfolded protein in a mixture (Park & Marqusee, 2005). 
Chang et al. (2012) observed using pulse proteolysis that the transition 
midpoint of equilibrium unfolding (with urea as the chemical denaturant) was 
increased in the presence of ATP, thus indicating that binding of ATP 
increased the thermodynamic stability of phosphoglyceromutase. 
 
An interesting further experiment to the BOCILLIN FL and b-lactam panels 
presented in this Chapter would therefore be analysis of the impact of b-lactam 
binding on thermodynamic stability of PBP1a, with the hypothesis that 
stabilisation of PBP1a by b-lactam binding may result in the shift in apparent 
molecular weight of PBP1a on SDS-PAGE. 
 
4.4.6 Conclusions 
Summarily, conclusive in vitro transpeptidase activity of PBP1aD39 could not 
be established in the current work. Measurements of D-Ala release revealed 
optimum activity at E6C12 concentrations approaching CMC. In addition, 
factors relating to the substrates and protein preparation have been explored 
for their contribution to activity of PBP1aD39.  
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Chapter 5: Glycosyltransferase activity of pneumococcal 
PBP1a and PBP2a 
5.1 Introduction 
Mechanistic details of glycosyltransferase activity have been studied using 
techniques including thin-layer chromatography, high-pressure liquid 
chromatography (HPLC), continuous fluorescence-based assays and Förster 
resonance energy transfer (FRET)-based assays. Selected techniques are 
further discussed in Section 5.1.1.  
5.1.1 Techniques for study of glycosyltransferase activity 
The various available assays for glycosyltransferase activity are summarised in Table 
5.1. A review on these techniques was published by Galley et al. (2014).  
 
5.1.1.1 SDS-PAGE analysis of glycan polymers 
Electrophoresis of negatively charged glycan polymers by Tricine-SDS-PAGE 
(Schägger & Von Jagow, 1987) has been used extensively in the literature. 
Whilst high molecular weight material does not enter the gel matrix, good 
resolution of short and intermediate chains can be achieved depending upon 
the choice of gel system (Barrett et al., 2007). Lipid II starting material migrates 
just behind the dye front, and so reaction progress can be determined based 
on consumption of substrate.  
Applications of the technique have made use of both radiolabelled (Barrett et 
al., 2007) and fluorescently labelled (Helassa et al., 2012) Lipid II as substrate, 
to allow visualisation of glycan polymers. Barrett et al. (2007) used Lipid II or 
Lipid IV in reactions with high enzyme:substrate ratio to generate shorter 
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Although SDS-PAGE analysis is not quantitative, the technique offers the 
benefit of visualising the range of glycan polymers generated by a 
glycosyltransferase, thus allowing comparisons of enzyme processivity to be 
made. 
 
5.1.1.2 HPLC analysis of glycan polymer formation  
Schwartz et al. (2001) described a set of HPLC-based experiments to follow the GT 
and transpeptidase (TP) activity of E. coli PBP1b. Lipid II molecules in time-point 
samples were labelled, at the primary amine of meso-diaminopimelic acid in the 
peptide stem, using fluorescamine. The reaction mixture was then chromatographed 
by HPLC. Schwartz et al. (2001) were thus able to demonstrate moenomycin-
sensitive consumption of Lipid II by E. coli PBP1b. The inclusion of muramidase in 
the reaction mixture then allowed both consumption of the substrate and generation 
of the product (GlcNAc-MurNAc pentapeptide, as confirmed by mass spectrometry) 
to be followed from the same samples by fluorescamine labelling and HPLC as 
before.  
Fluorescamine-labelling and HPLC also proved amenable to follow D-alanine release 
by transpeptidase activity, by which Schwartz et al. (2001) demonstrated time-
dependent, penicillin G-sensitive release of D-alanine. The suitability of this HPLC 
technique for application to study of both GT and TP activities was beneficial as both 
activities could then be studied under the same reaction conditions. The detection by 
post-reaction labelling also allowed use of unmodified substrates for the assay, 
precluding the requirement for chemically labelling each substrate to be analysed 
prior to use in the reaction, and therefore eliminating concerns regarding the influence 
of chemical modification of glycosyltransferase substrates on glycosyltransferase 
activity. 
 
5.1.1.3 Fluorometric assay for glycosyltransferase activity 
The continuous fluorometric assay for glycosyltransferase activity measures 
the change in quantum yield of fluorescence of a dansyl fluorophore labelling 
the lipid substrate (Schwartz et al., 2002). Substrate labelled with a dansyl 
fluorophore at the third position side chain of the peptide stem (Lipid II (Dans)) 
was polymerised into glycan chains by E. coli PBP1b, while the resulting 
glycan chains were digested by an N-acetylmuramidase included in the 
reaction. The dansyl group was thus transferred from a hydrophobic micellar 
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environment (Lipid II and glycan polymers) to an aqueous environment 
(soluble monomer units), with an associated decrease in the quantum yield of 
fluorescence (Pompliano et al., 1992). The initial rate of change in 
fluorescence was then interpreted as the initial rate of glycosyltransfer.  
 
The continuous fluorometric assay has been scaled down to multi-well format 
(Offant et al., 2010), thus making it suitable for use in inhibitor screening 
(Derouaux et al., 2011). The continuous fluorescence-based assay format 
allows determination of kinetic parameters such as Km for 
glycosyltransferases, but limitations of this format included that the data could 
not be converted into units of molarity, thus allowing only relative estimates of 
kcat; and the potential impact of the modification of substrates on the activity 
under observation.  
Efforts towards quantitative assays of GT activity have used detection of 
undecaprenyl pyrophosphate release to generate the quantitative signal. 
Mesleh et al. (2016) developed a discontinuous GT assay using Rapid-Fire 
mass spectrometry to detect undecaprenyl pyrophosphate. Quantitative 
analysis was made by use of geranylgeranyl pyrophosphate (C20PP) as an 
internal standard for normalisation of the signal, and a standard curve of C55P 
against mass spectrometry signal. The continuous fluorescent assay for 
undecaprenyl pyrophosphate release of King et al. (2017) was based on a 
commercial fluorogenic anti-pyrophosphate antibody.  
 
5.1.1.4 FRET assay 
A FRET assay for glycosyltransferases was described by Huang et al. (2013). 
A FRET-based Lipid II Analogue (FBLA) formed the basis for the assay, 
whereby the loss of the dimethylaminoazobenzenesulfonyl quencher on the 
lipid moiety when FBLA was polymerised would allow detection of 
fluorescence, based on the Coumarin fluorophore at the third position of the 
peptide stem. The fluorescence signal was enhanced by inclusion of an N-
acetylmuramidase (as described for the continuous fluorometric assay, 
Section 5.1.1.3). This approach was suited to enzyme kinetic analysis as well 
as high-throughput screening. One limitation of this technique could be the 
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limit in application of the substrates required; by contrast, Lipid II (Dans) is 
suited for use in analysis by SDS-PAGE and the continuous fluorescence 
assay. Additionally, the impact of both fluorophores on the ability of the 
glycosyltransferase to recognise its substrate remains a question. 
 
The various assay technologies offer complimentary tools for the analysis of 
glycosyltransferase activities; continuous fluorescence assays have utility in 
the determination of kinetic parameters of glycosyltransferase activity, but did 
not shed light on the characteristics of the polymer made or allow application 
to TP analysis; HPLC assays allowed GT activity to be followed on the basis 
of substrate consumption or muramidase product accumulation; and SDS-
PAGE analysis has limited potential for quantitative analysis but can give 
extensive information on the characteristics of the polymers made and the 
distribution of different polymer lengths, in addition to the following of time 
courses of the accumulation of such polymers. The continuous assay 
technologies also offered the benefit that there was no requirement for 
separation of substrates and products, as with both the continuous 
fluorometric assay and the FRET assay, detection was based upon the 
polymerization. 
 
5.1.2 Important chemical features for glycosyltransferase activity 
The majority of techniques for analysis of GT activity involve use of fluorescently- or 
radio-labelled Lipid II as a substrate. Appendage of a dansyl fluorescent group to the 
third position e-amino moiety of the peptide stem of Lipid II prevents the substrate 
from acting as a transpeptidase donor (Figure 4.13). Assay techniques using Lipid II 
labelled in this way would therefore be specific for glycosyltransferase activity. 
Labelling at the side chain of position 3 of the peptide stem has been found not to 
greatly affect the kinetic parameters of glycosyltransferases; Schwartz et al. (2002) 
found corresponding kcat values for unlabelled and dansylated Lipid II. Zhang et al. 
(2007) found that acetylation of the L-Lysine R-group amines at the third position of 
the peptide stem in Lipid II did not affect the use of this substrate by E. coli PBP1A or 
PBP1B. 
Fraipont et al. (2006) used a paper chromatography assay with radiolabelled 
(meso-[14C]-diaminopimelic acid-labelled Lipid II) to dissect the important 
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chemical characteristics of the GT donor and acceptor for E. coli PBP1b 
activity, by analysis of the impact of Lipid II analogues on GT activity. 
Incorporation of these unlabelled analogues appeared as GT inhibition. 
Among the Lipid II analogues tested, UDP-MurNAc(pentapeptide)-GlcNAc 
inhibited GT activity by PBP1b, in a manner dependent on presence of the 
GlcNAc and MurNAc sugars, the reactive group at the C1 of MurNAc, and a 
full-length pentapeptide stem. These key features of the UDP compound in 
inhibiting the reaction were subsequently ascribed to donor recognition. The 
constituent amino acids of the peptide stem were determined, by these 
authors and others, to not be important for recognition, as dansyl-mDAP 
(Fraipont et al., 2006) and dansyl-Lysine (Chen et al., 2003) could be accepted 
for GT activity by E. coli PBPs in vitro, and Lysine could be accepted in vivo 
(Mengin-Lecreulx et al., 1999). 
The use of UDP-MurNAc(pentapeptide)-GlcNAc as a GT substrate was then 
assayed using radiolabelled UDP-MurNAc(pentapeptide)-GlcNAc and 
fluorescently (dansyl) labelled Lipid II, by which Fraipont et al. (2006) showed 
that the radio-labelled material was incorporated into the glycan polymer, and 
thus the UDP-compound was used as a substrate by E. coli PBP1b. No glycan 
chain formation was detected with supply of the UDP-compound as substrate 
alone, from which it was inferred that either donor or acceptor required a 
polyprenyl moiety.  
The use of UDP-MurNAc(pentapeptide)-GlcNAc as donor or acceptor was 
further analysed by use of muramidase, to digest the reaction products of GT 
activity when Lipid II (Dans) and [14C] UDP-MurNAc(pentapeptide)-GlcNAc 
were supplied as substrates. Digest products included radiolabelled 
MurNAc(pentapeptide)-GlcNAc, but not radiolabelled UDP-
MurNAc(pentapeptide)-GlcNAc, indicating that the UDP compound acted as a 
donor in the GT reaction (with resultant loss of the UDP moiety). This 
consequently suggested that Lipid II (Dans) participated in the reaction as an 
acceptor, and that the proposed requirement of a polyprenyl chain appended 
to one substrate was a necessary feature of the acceptor substrate. The data 
of Liu and Wong (2006) may also be in support of the importance of the 
polyprenyl chain for acceptor recognition. These authors found that when the 
substrate was a Lipid II analogue with the polyprenyl lipid moiety exchanged 
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for nitrophenol phosphate, no GT activity of enzymes including S. pneumoniae 
PBP1b was detected. This observation could be explained by the loss of an 
important feature (the polyprenyl moiety) of the GT acceptor, thus rendering 
the analogue inactive. 
Crystallographic evidence also supported the proposal of Lipid II as the GT 
acceptor. Lovering et al. (2007) modelled the position of the GT substrates into 
the active site of their crystal structure of a soluble, truncated construct of 
Staphylococcus aureus PBP2 (in complex with moenomycin). Their data 
suggested that Lipid II was likely to be the acceptor in glycosyltransferase 
activity, with the growing glycan chain as the donor. This was corroborated by 
modelling of substrate interactions in the structure of Staphylococcus aureus 
monofunctional glycosyltransferase (MGT) determined by Huang et al. (2012). 
5.1.2.1 Amidation at the second position of the peptide stem 
Amidation of the second position amino acid in the peptide stem (thus giving 
a glutamine at that position instead of glutamate) has been identified in the 
peptidoglycan of Gram positive organisms including S. pneumoniae, S. 
aureus, and Enterococcus faecalis. The MurT/GatD amidase complex 
responsible for this modification is further discussed in Section 1.6.2.1. 
The impact of amidation on pneumococcal PBP activity was analysed by 
Zapun et al. (2013), who used mixed reactions of unlabelled and dansylated 
Lipid II to observe PBP1a and PBP2a activity. Reactions were followed by the 
SDS-PAGE method previously described for analysis of GT activity (Section 
5.1.1.1). In the presence of such mixtures of substrates, a high molecular 
weight band remaining in the wells of the gel was observed, and formation of 
this band did not occur in the presence of penicillin. The use of this technique 
to assay transpeptidation is discussed in Section 4.1.1.3.  
A vast decrease in the amount of high molecular weight material was seen 
when the substrate was unamidated Lipid II (Lipid II (Glu)) compared to 
amidated Lipid II (Lipid II (Gln)), in addition to an apparent reduction in the 
glycan chain lengths formed. These data suggested that Lipid II (Glu) was a 
poorer substrate for pneumococcal PBPs than Lipid II (Gln). The activity of 
PBP2a appeared to be more sensitive to amidation of the substrate than that 
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of PBP1a, as residual formation of the high molecular mass material was 
observed with PBP1a, but to a lesser extent with PBP2a.  
Galley (2015) compared the usage of dansylated amidated (Gln, Dans) and 
dansylated unamidated (Glu, Dans) substrate by PBP1a and PBP2a by SDS-
PAGE and in the continuous fluorometric assay for glycosyltransferase 
activity. Time course experiments over 24 h, analysed by SDS-PAGE, 
demonstrated faster consumption of Lipid II (Gln, Dans) substrate by both 
PBP1a and PBP2a. Kinetic parameters derived from the continuous assay 
illustrated that the differential substrate usage was manifested in significantly 
tighter binding and catalytic efficiency with Lipid II (Gln, Dans) in comparison 
to Lipid II (Glu, Dans), and for both PBP1a and PBP2a.  
5.1.3 Lipid environment and PBP GT activity 
Both the bifunctional PBPs and their Lipid substrate are associated in vivo with 
the cell membrane, and so both require detergents for solubility under 
aqueous assay conditions. Assay systems have been described whereby 
soluble PBP constructs and alternative prenyl moieties on the lipid substrate 
facilitate the study of GT activity under aqueous conditions (Zhang et al., 
2007). However, previous study of pneumococcal PBPs has made use of full-
length enzymes and undecaprenyl-linked substrates (Galley, 2015; Helassa 
et al., 2012; Zapun et al., 2013). Consequently, it was of interest in the current 
work to further study how the components of the lipid environment of the 
glycosyltransferase reaction affected the activity of PBPs. 
 
5.1.3.1 Membrane anchors and PBP activity 
Helassa et al. (2012) characterised the reaction conditions required for 
observation of glycosyltransferase activity of PBP2a in the SDS-PAGE gel 
assay system. The authors found that no activity was observed using tagged 
variants of PBP2a. Helassa et al. (2012) determined that the specific activity 
of soluble and full-length PBP2a (i.e. without and with the membrane anchor 
respectively) constructs in the continuous fluorometric assay were similar, but 
demonstrated a decrease in processivity of the periplasmic construct, thus 
suggesting a role for the membrane anchor in this factor of enzyme activity. 
Galley (2015) also found that truncated, soluble constructs of PBP1a and 
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PBP2a demonstrated impaired processivity in comparison to full length 
constructs. Truncation of E. coli PBP1b to remove the transmembrane domain 
has also been found to impair both activity and inhibition by moenomycin 
(Sung et al., 2009). 
Berg et al. (2014) showed that exchange of the membrane anchor of PBP2x 
resulted in loss of in vivo function, and exchange of the PBP2b membrane 
anchor resulted in a phenotype resembling PBP2b depletion. 
5.1.3.2 Lipid moiety of substrates and PBP activity 
Chen et al. (2003), working with E. coli PBP1b, showed that kinetic parameters 
of GT activity (kcat and kcat/Km) were unaffected by the modification of the lipid 
substrate to include a betulaheptaprenyl (C35) lipid moiety in place of 
undecaprenyl. By contrast, Zhang et al. (2007) determined in their assay of E. 
coli PBP1b that betulaheptaprenyl Lipid II was a better substrate for 
glycosyltransferase activity as compared to undecaprenyl Lipid II. 
Liu et al. (2010) synthesized a Lipid substrate whereby the dansyl fluorophore was 
positioned on the lipid moiety, in comparison to other syntheses where the label was 
positioned on the peptide stem (Schwartz et al., 2002). Although the fluorophore 
remained attached to the glycan polymer at the reducing end of the glycan strand at 
each catalytic cycle, only one unit was retained per polymer strand (compared to one 
fluorophore per disaccharide when peptide-labelled substrate was used). This 
appears to have prevented detection of polymer upon subsequent HPLC analysis. 
Though Liu et al. (2010) suggested that positioning of the fluorophore at the lipid 
moeity may not have impacted upon substrate recognition by glycosyltransferases, 
there was no direct evidence in support of this. As discussed in Section 5.1.2, other 
studies have suggested the importance of the lipid moiety in recognition of acceptors.  
5.1.3.3 DMSO and lipid environment 
Glycosyltransferase assays using dansylated substrates have reported 
inclusion of 5 - 30 % (v/v) dimethylsulfoxide (DMSO) in the reaction mixture 
for optimal enzyme activity (Helassa et al., 2012; Offant et al., 2010; Schwartz 
et al., 2002). The contribution of DMSO may be explained by the impact of 
DMSO on micelle dynamics. Bruckdorfer and Sherry (1984) found that the 
impact of DMSO on micelle dynamics was an increase in the exchange of 
radiolabelled cholesterol from liposomes with unlabelled cholesterol from 
 
 197 
erythrocytes. In addition, 1.5 M DMSO was found to increase the CMC of 
cholesterol. 
Schwartz et al. (2002) analysed the impact of DMSO on glycosyltransferase 
activity using HPLC assays. The impact of DMSO on in vitro 
glycosyltransferase activity was to increase the steady-state rate, and further 
kinetic characterisation demonstrated that DMSO impacted catalysis, as kcat 
was increased in the presence of DMSO. The authors suggested that this 
effect was through enhanced solubility of Lipid II, in addition to the effect of 
DMSO on micelle dynamics. 
 
5.1.3.4 Phospholipids and enzyme activity 
The phospholipid components of the cytoplasmic membrane interact with 
transmembrane domains of proteins to anchor them and satisfy hydrophobic 
interactions. A growing body of evidence suggests that beyond serving as an 
attachment point for membrane proteins, the membrane itself influences, and 
is influenced by, the activity of the membrane proteins that coordinate cell 
division. Multiple such proteins have been found to interact with the membrane 
phospholipid, cardiolipin. Cardiolipin has been observed to accumulate at the 
poles of rod-shaped cells (Wood, 2018). The interaction of cardiolipin with one 
partner protein was shown to occur through ionic interactions with the lipid 
head groups, and van der Waals interactions between the lipid tails and 
intramembrane surface of the protein (McAuley et al., 1999). 
 
MurG overexpression was associated with increase of cellular cardiolipin, and 
cardiolipin was found to be enriched in the lipids copurified with the 
overexpressed protein (van den Brink-van der Laan et al., 2003). In addition, 
the activity of MurG on Lipid I was greater in vesicles containing cardiolipin 
than in those containing phosphatidylglycerol. 
Phospholipids had been suggested to be involved in the Lipid II flippase 
mechanism, as inhibition of phospholipid synthesis inhibited O-antigen 
synthesis, which shares in common the lipid carrier undecaprenyl phosphate 
(Ehlert & Höltje, 1996). This was supported by the study of the flippase enzyme 
MurJ by Bolla et al. (2018). Bolla et al. (2018) used native protein mass 
spectrometry to analyse the interactions of MurJ and FtsW with Lipid II. These 
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experiments revealed that cardiolipin decreased the binding of Lipid II by MurJ, 
such that the authors proposed that interaction with this phospholipid may play 
a role in the flippase mechanism. In addition, similarly to with MurG, the 
authors found that cardiolipin was enriched under overexpression of MurJ, and 
that a range of cardiolipins copurified with MurJ. 
 
Of particular importance is the established link between phospholipid 
synthesis and penicillin susceptibility in E. coli. Inhibition of phospholipid 
synthesis was associated with inhibition of PG synthesis, which the authors 
suggested was the result of involvement of phospholipids in the assembly of 
the PG synthesis machinery (Rodionov & Ishiguro, 1996). The impact of 
cardiolipin and phosphatidylglycerol on pneumococcal MurM activity has also 
been demonstrated. Cardiolipin was found to stimulate the in vitro activity of 
MurM, whilst strain-dependent impact of phosphatidylglycerol on MurM activity 




There remains to be explored the impact of membrane environment on PBP1a 
GT activity (and therefore indirectly TP activity), to rationalise the observed 
importance of the detergent choice and membrane anchor on glycosyltransfer. 
PBP1a variants may differ in their response to the micellar environment, as 
has been observed for MurM. Additionally, the characterisation of GT activity 
is a necessary first step to study of in vitro TP activity in relation to b-lactam 
resistance. GT activity of a bifunctional enzyme must be analysed to confirm 
whether any variation in activity is manifested in changes to transpeptidation. 
Finally, detailed analysis of glycan polymer assembly over early time points 
was of interest to further probe the impact of amidation on GT activity.  
 
Figure 5.1 Chapter 5 experimental questions summary A visual summary 
of the questions to be addressed in this thesis. GT, glycosyltransferase 
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5.2 Experimental Aims 
• To establish glycosyltransferase activity of PBP1a expressed from 
constructs using genes from pneumococcal D39, Pn16 and 159 strains 
• To find the optimum concentration of a detergent known to support TP 
activity (E6C12) for assay of glycosyltransferase activity of PBP1a 
• To test a range of ethylene glycol detergents for their ability to support 
PBP1a glycosyltransferase activity 
• To characterise the impact of pneumococcal phospholipids on 
formation of glycan polymers by PBP1a from D39, Pn16 and 159 
pneumococcal strains 
• To compare the formation of glycan polymers by PBP1a and PBP2a 
over 3 h with Lipid II (Gln, Dans) and Lipid II (Glu, Dans) substrates 
 
5.3 Results 
The activity of bifunctional penicillin-binding proteins has been considered to 
occur such that PBP1a GT activity supplies the donor substrate for 
transpeptidation. Reaction conditions that support GT activity can guide 
establishment of the conditions required for TP activity. Analysis of GT activity 
was therefore conducted with transfer to TP analysis in mind. For this reason, 
some conditions such as the starting detergent of E6C12 and the concentration 
used (12 x CMC) were informed by the conditions conducive to a previous 
observation of D-Ala release in the TP assay (Galley, 2015). Conditions of the 
GT assay were otherwise informed by optima determined by Galley (2015), 
including 25 % (v/v) DMSO and 150 mM NaCl. 
 
5.3.1 The effect of detergent on GT activity 
Rapid GT activity of S. pneumoniae D39 PBP1a was previously observed with 
Triton X-100 as the assay detergent (Galley, 2015). However, E6C12 assay 
detergent was demonstrated to support observation of transpeptidase activity, 
whilst the Triton X-100 assay detergent did not support transpeptidase activity 
(Galley, 2015). We therefore looked to further characterise the optimum 
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concentrations and detergent choice of PBP1a GT activity, to identify a 
detergent that may support in vitro TP activity. 
  
5.3.1.1 Detergent concentration and PBP1a activity  
The concentration of E6C12 in the GT assay mixture was contributed by the 
enzyme dilution buffer, the lipid resuspension buffer and the assay buffer. The 
optimum concentration of E6C12 detergent for GT activity in reactions 
containing 2 µM S. pneumoniae D39 PBP1a and 20 µM Lipid II (Gln, Dans) 
was determined by analysis of glycan polymer accumulation over 30 mins by 
SDS-PAGE (Figure 5.2). Concentrations from 12 x CMC to 1.7 x CMC were 
tested. The minimum concentration tested was based upon contribution of 
E6C12 from the Lipid resuspension buffer and enzyme dilution buffers only.  
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Concentrations of E6C12 approaching the CMC were associated with formation 
of longer glycan polymers over 30 mins, with higher concentrations associated 
with apparent inhibition of polymer accumulation. This result was in agreement 
with observations of the impact of detergent concentration on the rate of D-Ala 
release by PBP1a (Section 4.3.2.2). 
Figure 5.2 Effect of E6C12 detergent concentration on glycan polymer 
formation over 30 mins with 2 µM PBP1a and 20 µM Lipid II (Gln, Dans). 
Reactions comprised 50 mM HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 150 
mM NaCl, 2 µM PBP1a and 20 µM Lipid II (Gln, Dans). The E6C12 
concentration was varied by addition of assay buffer at the appropriate 
concentration, with the exception of the reaction with 1.7 x CMC, in which 
E6C12 was solely contributed by the enzyme dilution and Lipid resuspension 
buffers. Samples were taken at the stated timepoints and the reactions 
quenched with 0.3 mM moenomycin and 50 mM EDTA. A control was 
included (moe) in which moenomycin was added to the reaction prior to 
initiation, and the reaction incubated for 30 mins. Samples were analysed by 
electrophoresis on a 9 % Tris-Tricine gel, which was subsequently visualised 
using an ImageQuant LAS 4000 imager with transmitted light at 312 nm and 




To confirm the relation between E6C12 concentration and glycan polymer 
formation, the experiment was repeated using concentrations of 0.5 µM 
PBP1a and 5 µM Lipid II (Gln, Dans). As depicted in Figure 5.3, the equivalent 
relationship between concentration of E6C12 detergent and formation of glycan 
polymer was observed under these conditions.  
For subsequent optimisation experiments, a detergent concentration of 3 x 
CMC was chosen, as this would allow both an increase and a decrease in GT 
Figure 5.3 Effect of E6C12 detergent concentration on glycan polymer 
formation over 30 mins with 0.5 µM PBP1a and 5 µM Lipid II (Gln, Dans). 
Reactions comprised 50 mM HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 150 
mM NaCl, 0.5 µM PBP1a and 5 µM Lipid II (Gln, Dans). The E6C12 
concentration was varied by addition of assay buffer at the appropriate 
concentration, with the exception of the reaction with 1.7 x CMC, in which 
E6C12 was solely contributed by the enzyme dilution and lipid resuspension 
buffers. Samples were taken at the stated timepoints and the reactions 
quenched with 0.3 mM moenomycin and 50 mM EDTA. A control was included 
(moe) in which moenomycin was added to the reaction prior to initiation, and 
the reaction incubated for 30 mins. Samples were analysed by electrophoresis 
on a 9 % Tris-Tricine gel which was subsequently visualised using an 
ImageQuant LAS 4000 imager with transmitted light at 312 nm and a 605 nm 
filter.  CMC, critical micellar concentration; mins, minutes; moe, moenomycin 
 
 204 
activity to be detected. By comparison, the rapid activity in the presence of 1.7 
x CMC detergent may be expected to reduce the sensitivity towards detection 
of any increase in activity. 
 
5.3.1.2 The effect of assay detergent on GT activity 
A variety of ethylene glycol detergents was next investigated for their impact 
on GT activity on PBP1aD39. These covered a variety in both in the number of 
ethylene glycol moieties and the alkyl chain length. Lipid II (Gln, Dans) was 
delivered in CHAPS detergent for the initial screening. This allowed the Lipid 
to be delivered from the same master stock to all reactions. Consistency was 
also then achieved in that all reactions would occur within mixed micelles, as 
the use of E6C12 as the delivery detergent may otherwise have favoured 
activity in E6C12 assay buffer. GT activity in different detergents was analysed 
by SDS-PAGE as previously described. 
 
Some detergents, such as E5C8, did not support GT activity, as no glycan 
polymer formation was observed over 30 mins (Figure 5.4, lanes 7-8). 
Stimulation of PBP1a activity was observed in the presence of E8C10 (lanes 
13-14) and E4C12 (lanes 5-6) assay detergent, though the distribution of glycan 
chain length appeared shifted slightly towards longer polymers in the presence 
of E8C10. High concentration of CHAPS detergent was interpreted to be 
incompatible with the Tris-tricine gel system used for this experiment, as the 
Lipid II (Gln, Dans) substrate did not form a uniform band at the running front 
(lanes 1-2).  
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The apparent optimum detergent from these experiments, E8C10, was taken 
forward to an additional experiment in which either CHAPS or E6C12 was the 
lipid delivery detergent, to confirm the apparent faster activity of PBP1a in 
E8C10 as the assay detergent. Activity was monitored as before by SDS-PAGE 
gel (Figure 5.5). 
When Lipid was delivered in CHAPS detergent (Figure 5.5, lanes 2-5), PBP1a 
formed larger glycan polymers within 30 mins with E8C10 assay detergent 
compared to E6C12, in agreement with the observation from Figure 5.4. The 
same relationship was observed when E6C12 was used as the lipid delivery 
detergent (Fig. 5.5, lanes 6-9). This experiment further supported the 
observation of more rapid formation of large polymers in E8C10 assay 
detergent, independent of the choice of Lipid II delivery detergent. The impact 
Figure 5.4 Effect of assay detergent on glycan polymer formation over 
30 mins with 0.5 µM PBP1a and 5 µM Lipid II (Gln, Dans). Reactions 
comprised 50 mM HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 150 mM NaCl, 
0.5 µM PBP1a and 5 µM Lipid II (Gln, Dans), 3 x CMC of the stated detergent, 
and 0.33 x CMC CHAPS detergent (contributed by Lipid II (Gln, Dans) delivery 
buffer). Samples were taken at the stated timepoints and the reactions 
quenched with 0.3 mM moenomycin and 50 mM EDTA. Samples were 
analysed by electrophoresis on a precast 16.5 % Tris-Tricine gel which was 
subsequently visualised using an ImageQuant LAS 4000 imager with 
transmitted light at 312 nm and a 605 nm filter. CMC, critical micellar 
concentration; mins, minutes 
 
 206 
of the Lipid II delivery detergent itself on GT activity cannot be inferred from 
Figure 5.5, as there appears to be more Lipid II (Gln, Dans) present in those 
reactions to which Lipid II (Gln, Dans) was delivered in E6C12 detergent. 
 
Figure 5.5 Comparison of E6C12 and E8C10 as the assay detergent for 
analysis of glycan polymer assembly. Reactions comprised 50 mM 
HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 150 mM NaCl, 0.5 µM PBP1a and 
5 µM Lipid II (Gln, Dans) resuspended in CHAPS or E6C12, and either E6C12 
or E8C10 as the major assay detergent, at 3 x CMC. Samples were taken at 
the stated timepoints and the reactions were quenched with 0.3 mM 
moenomycin and 50 mM EDTA. A control was included (moe) in which 
moenomycin was added to the reaction prior to initiation, and the reaction 
incubated for 30 mins. Samples were analysed by electrophoresis on a 9 % 
Tris-Tricine gel, which was subsequently visualised using an ImageQuant 
LAS 4000 imager with transmitted light at 312 nm and a 605 nm filter. CMC, 
critical micellar concentration; mins, minutes; moe, moenomycin 
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5.3.2 GT activity of pneumococcal strain D39, Pn16 and 159 PBP1a 
variants 
A key aim of this thesis was to compare activity across PBP1a variants from 
different pneumococcal strains. The activity of different PBP1a constructs was 
therefore compared under the basic GT activity conditions, to establish 
whether similar activity was seen with each. There is 100% sequence identity 
in the GT domain between the PBP1a amino acid sequences of the enzymes 
of pneumococcal strains D39, Pn16 and 159 (Appendix 5.2) and so equivalent 
GT activity may be expected between different variants expressed and purified 
in the same way. We therefore sought to compare the GT activity of these 
proteins, to enable exclusion of variation in GT activity from subsequent 
comparison of TP activity. 
PBP1a variants were expressed and purified as described in Section 4.3.1. 
Formation of glycan polymers over 30 mins was followed by SDS-PAGE time 
course experiments (Figure 5.6). Similar activity was observed under these 
Figure 5.6 Comparison of glycan polymer assembly over 30 mins by 
PBP1a variants from S. pneumoniae strains D39, Pn16 and 159. Reactions 
comprised 50 mM HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 150 mM NaCl, 
0.0136 % (w/v) E8C10, 0.5 µM PBP1a and 5 µM Lipid II (Gln, Dans). Samples 
were taken at the stated timepoints and quenched with 0.3 mM moenomycin 
and 50 mM EDTA. Samples were analysed by electrophoresis on a 9 % Tris-
Tricine gel (D39) or precast 16.5 % Tris-Tricine gel, which was subsequently 
visualised using an ImageQuant LAS 4000 imager with transmitted light at 312 




conditions for the D39, Pn16 and 159 strain PBP1a variants. In all cases, 
polymer formation could be detected within 1.5 mins. High molecular weight 
material was observed at the top of each gel within 7.5 minutes, though the 
159 variant appears to have assembled such polymers slightly faster in this 
respect (by comparison of the 7.5 and 15 minute time points for the three 
variants). The resolution of low molecular weight polymers was comparably 
poorer on the gel depicting PBP1aD39 GT activity. This is due to the use of 
precast 16.5 % Tris-Tricine gels for analysis of PBP1aPn16 and PBP1a159 GT 
polymers. 
 
The rate of GT activity was then compared for each enzyme using the 
continuous fluorescence assay for GT activity, to more precisely quantitate the 
catalytic activity of D39, Pn16 and 159 PBP1a with respect to GT activity. Initial 
rates were measured under the same reaction conditions as were used for the 
Tris-tricine gels (50 mM HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 150 mM 
NaCl, 0.5 µM enzyme, and 5 µM Lipid II (Gln, Dans)). In place of E8C10 
Figure 5.7 Specific activity of PBP1a variants from S. pneumoniae  
strains D39, Pn16 and 159 in the continuous fluorometric assay. 
Reactions comprised 50 mM HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 150 
mM NaCl, 0.0116 % (w/v) E6C12, 0.5 µM PBP1a, 5 µM Lipid II (Gln, Dans), and 
0.1 mg.mL-1 lysozyme. Reactions were initiated with enzyme and monitored 
for 100 mins. Blank measurements were taken with reactions in which enzyme 
buffer was added in place of enzyme. Results were graphed in GraphPad 
Prism to determine the initial rate (a). The mean specific activity (n = 3) for 
each PBP1a variant was compared by one-way ANOVA, which indicated no 
significant difference (ns) between any of these mean values. RFU.sec-1.µg-





detergent, 3 x CMC E6C12 detergent was used, to facilitate subsequent testing 
of reaction conditions in the continuous fluorometric assay.  
The mean specific activities (Figure 5.7) of the three enzymes were 
determined by one-way ANOVA to not be significantly different. PBP1aD39, 
PBP1aPn16 and PBP1a159 were therefore concluded to exhibit comparable GT 
activity under the conditions tested. 
 
5.3.3 The effect of phospholipids on GT activity 
As previously discussed (Section 5.1.3.4), reconstitution of the in vivo lipid 
environment of cell wall synthesis enzymes has been demonstrated to 
influence their activity. In particular, cardiolipin has been observed to be 
involved in supporting the activity of enzymes including MurM, which is linked 
to PBP1a by supply of branched substrates and thus involved in the b-lactam 
resistance mechanism (Dr. A.J. Lloyd, University of Warwick, unpublished). 
Pneumococcal membranes contain two phospholipids; cardiolipin and 
phosphatidylglycerol (Brundish et al., 1967), in a ratio between 1:1 and 3:1 
(Trombe et al., 1979). We sought to test the effect upon PBP1a activity of 
adding pneumococcal membrane phospholipids to the GT assay system. We 
tested the effect of cardiolipin on the extent of Lipid II polymerisation over 30 
mins. Cardiolipin was dissolved in a solution of the assay buffer, E6C12, with 
the overall concentration of the detergent in the assay was fixed at 3 x CMC 
as previous.  
 
5.3.3.1 The effect of cardiolipin on GT activity 
The activity of PBP1a constructs from pneumococcal strains D39, Pn16 and 
159 was tested in the presence of 10, 1.0 and 0.1 µM cardiolipin, and these 
were compared to controls with E6C12 assay detergent only (Figure 5.8). We 
observed that there was a reproducible dose-dependent stimulation of GT 
activity by cardiolipin, as larger glycan polymers were assembled over 30 mins 
in the presence of higher concentrations of cardiolipin in the assay. The effect 




We surmised that mimicry of the in vivo lipid environment of PBP1a could 
underlie the detergent preference observed in Section 5.3.1.2. We thus titrated 
cardiolipin against PBP1aD39 activity in reactions where the assay detergent 
was either E8C10 or E5C8. We hypothesised that cardiolipin may offer no 
stimulatory effect in reactions where the beneficial physical properties of this 
phospholipid were provided by the assay detergent (e.g. with a detergent with 
which greater activity was observed - E8C10), whilst cardiolipin may be able to 
rescue PBP1a GT activity in reactions with a comparably ‘poor’ assay 
detergent (E5C8), as the detergent alone in this case was not able to 
Figure 5.8 Effect of cardiolipin on glycan polymer assembly over 30 
mins by PBP1a variants from S. pneumoniae strains D39, Pn16 and 
159. Reactions comprised 50 mM HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 
150 mM NaCl, 0.0116 % (w/v) E6C12, 0.5 µM PBP1a, 5 µM Lipid II (Gln, 
Dans), and varying concentrations of cardiolipin. Samples were taken at the 
stated timepoints and quenched with 0.3 mM moenomycin and 50 mM 
EDTA. A control was included (moe) in which moenomycin was added to 
the reaction prior to initiation, and the reaction incubated for 30 mins, in 
addition to a no enzyme control (-) to which the equivalent volume of enzyme 
dilution buffer was added. Samples were analysed by electrophoresis on a 
9 % Tris-Tricine gel, which was subsequently visualised using an 
ImageQuant LAS 4000 imager with transmitted light at 312 nm and a 605 




adequately recreate the important physical properties of the in vivo lipid 
environment. 
We observed (Figure 5.9) that there was no striking impact of cardiolipin on 
GT activity when the assay detergent was E8C10 (as determined by the similar 
extent of glycan polymer formation), and that the presence of cardiolipin did 
not rescue GT activity with E5C8 under the conditions tested (Figure 5.9).  
The effect of cardiolipin on the rate of GT activity was then compared for 
PBP1aPn16 using the continuous fluorescence assay for GT activity, to more 
precisely analyse the impact of the phospholipid on PBP1aD39, PBP1aPn16 and 
PBP1a159 GT activity. The dose-response experiment presented in Figure 5.8 
Figure 5.9 Effect of cardiolipin on glycan polymer assembly over 30 mins 
by S. pneumoniae PBP1aD39 in varying assay detergents. Reactions 
comprised 50 mM HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 150 mM NaCl, 
3 x CMC E8C10 or E5C8, 0.5 µM PBP1a, 5 µM Lipid II (Gln, Dans), and ± 10 
µM cardiolipin. Samples were taken at the stated timepoints and quenched 
with 0.3 mM moenomycin and 50 mM EDTA. Samples were analysed by 
electrophoresis on a 9 % Tris-Tricine gel, which was subsequently visualised 
using an ImageQuant LAS 4000 imager with transmitted light at 312 nm and 




was repeated in the continuous fluorometric assay to find the maximal 
response from cardiolipin on the initial rate of fluorescence change. 
Rate of GT activity appears to increase with cardiolipin concentration until 50 
µM, where there is a drop in the rate at 100 µM cardiolipin. This apparent ‘hook 
effect’ may result from a dilution of the hydrophobic environment of the assay, 
thus decreasing the likelihood of productive contact between enzyme and 
substrate. The 50 µM cardiolipin condition was taken forward for further 
studies of the impact on kinetics of GT activity. 
  
Figure 5.10 Dose-response analysis of the effect of cardiolipin on GT 
activity of PBP1aPn16 in the continuous fluorometric assay. Reactions 
comprised 50 mM HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 150 mM NaCl, 
3 X CMC E6C12 (0.0116 % (w/v)), 0.5 µM PBP1a, 0.1 mg.mL-1 lysozyme and 
a range of concentrations of Lipid II (iGln, Dans). Reactions were initiated 
with enzyme and monitored for 100 mins. Results were graphed in GraphPad 
Prism to determine the initial rate.  


















5.3.3.1.2 Kinetics of cardiolipin impact on GT activity 
The kinetics of cardiolipin usage were established by conducting GT assays 
where substrate concentration was titrated in the presence and absence of 50 
µM cardiolipin. The data were fit to a kinetic model (equation 1) incorporating 
cooperativity in activity (Copeland, 2004); 




Whilst insufficient Lipid II concentrations were reached to capture the full curve 
of the detergent-only condition, the profiles shown in Figure 5.11 for both 
PBP1aPn16 and PBP1a159 suggest that affinity of the enzymes for Lipid II (iGln, 
Dans) is enhanced in the presence of cardiolipin. The kinetic parameters 
extracted from these curve fits are presented in Table 5.2. 
  
detergent only 
50 µM cardiolipin 
Figure 5.11: Kinetics of Lipid II (iGln, Dans) usage in the presence and 
absence of 50 µM cardiolipin. The kinetics of Lipid II (iGln, Dans) usage in 
glycosyltransferase reactions by a) PBP1aPn16 and b) PBP1a159 were 
determined using the continuous fluorometric assay. Reactions comprised 50 
mM HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 150 mM NaCl, 0.0116 % (w/v) 
E6C12, 0.5 µM PBP1a, varied concentrations of Lipid II (Gln, Dans), and 0.1 
mg.mL-1 lysozyme. Reactions were initiated with enzyme and monitored for 
100 mins. Results were graphed in GraphPad Prism to determine the initial 
rate. Error bars: standard deviation. 
RFU.sec-1.µg-1, relative fluorescence units per second per µg PBP1a.  
 
detergent only 
50 µM cardiolipin 
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No kinetic parameters were determined for the detergent-only reactions due 
to the full curves not being captured. However, the curve profiles suggest an 
S0.5 value greater than those calculated for the cardiolipin reactions in each 
case. 
The estimates of S0.5 appear high in comparison to the profile of the curves. 
This may indicate poor fit to the proposed model, or be the consequence of 
few data points in the linear region of the curve. 
 
It was unclear from the data presented in Figure 5.8 whether the assembly of 
larger glycan polymers over 30 mins in the presence of cardiolipin could be 
entirely ascribed to the enhanced rate of GT activity (as illustrated in Figure 
5.10), or whether cardiolipin also altered the processivity of PBP1a to 
contribute to assembly of longer glycan polymers. Time course experiments 
were therefore conducted in the presence and absence of 50 µM cardiolipin, 
to allow comparison of the size of the glycan polymers assembled in each 
condition (Figure 5.12). This experiment illustrated that in the presence of 50 
µM cardiolipin, longer glycan polymers were assembled within 2 mins of 
initiating the reaction than the maximum polymer length synthesised in 30 
mins in the absence of cardiolipin. An apparent maximum polymer length was 
attained within 15 mins in the absence of cardiolipin. These data illustrate that 
 
Table 5.2: Kinetic parameters for PBP1aPn16 and PBP1a159 glycosyltransferase 
activity in the presence of 50 µM cardiolipin. Values for Vmax, S0.5 and the Hill 
coefficient for cooperativity (h) were extracted from the fits shown in Figure 5.11. 
 







detergent - - - - 0.98 




detergent - - - - 0.99 





cardiolipin increased the processivity of PBP1a, in addition to the 
enhancement of GT rate.  
Figure 5.12 Time course of glycan polymer assembly over 30 mins by 
S. pneumoniae PBP1aPn16 in the presence and absence of 50 µM 
cardiolipin. Reactions comprised 50 mM HEPES, 10 mM MgCl2, 25 % (v/v) 
DMSO, 150 mM NaCl, 3 x CMC E6C12, 0.25 µM PBP1a, and 5 µM Lipid II 
(Gln, Dans). Samples were taken at the stated timepoints and quenched with 
0.3 mM moenomycin and 50 mM EDTA. Samples were analysed by 
electrophoresis on a 9 % Tris-Tricine gel, which was subsequently visualised 
using an ImageQuant LAS 4000 imager with transmitted light at 312 nm and 
a 605 nm filter. CL, cardiolipin; mins, minutes 
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5.3.3.2 The effect of phosphatidylglycerol on GT activity 
The approach to testing of cardiolipin impact on PBP1a GT activity was 
similarly employed to analyse whether phosphatidylglycerol would affect GT 
activity of PBP1a from strains D39, Pn16 or 159. As before, 
phosphatidylglycerol was dissolved in a stock of E6C12 assay buffer and the 
effect on glycan polymer assembly was tested at concentrations of 10, 1.0 and 
0.1 µM phosphatidylglycerol (Figure 5.11). Under the conditions tested, no 
Figure 5.13 Effect of phosphatidylglycerol on glycan polymer assembly 
over 30 mins by PBP1a variants from S. pneumoniae strains D39, Pn16 
and 159. Reactions comprised 50 mM HEPES, 10 mM MgCl2, 25 % (v/v) 
DMSO, 150 mM NaCl, 3 x CMC E6C12, 0.5 µM PBP1a, 5 µM Lipid II (Gln, Dans), 
and varying concentrations of phosphatidylglycerol. Samples were taken at the 
stated timepoints and quenched with 0.3 mM moenomycin and 50 mM EDTA. 
Samples were analysed by electrophoresis on a 9 % Tris-Tricine gel, which was 
subsequently visualised using an ImageQuant LAS 4000 imager with 





impact was observed on GT activity over 30 mins, with any of the three PBP1a 
variants.  
The effect of phosphatidylglycerol on the rate of GT activity was then 
compared for each enzyme using the continuous fluorescence assay for GT 
activity. Whilst no effect of phosphatidylglycerol was observed in the gel-based 
assay, with 50 µM phosphatidylglycerol an increase in rate was observed. This 
indicates that the stimulation of GT activity by phosphatidylglycerol requires 
higher concentrations of the phospholipid. 
The mean specific activities (Figure 5.14) of the two enzymes in each of the 
three conditions were determined by one-way ANOVA to show a significant 
difference in the presence of phosphatidylglycerol or cardiolipin. These data 
indicate that both of these phospholipids stimulate activity of PBP1a.  
Figure 5.14 Comparison of the effect of 50 µM cardiolipin and 50 µM 
phosphatidylglycerol on the initial rate of glycosyltransferase activity 
of PBP1aPn16 and PBP1a159. Reactions comprised 50 mM HEPES, 10 mM 
MgCl2, 25 % (v/v) DMSO, 150 mM NaCl, 3 X CMC E6C12 (0.0116 % (w/v)), 
0.5 µM PBP1a, 0.1 mg.mL-1 lysozyme and 5 µM Lipid II (iGln, Dans), ± 50 
µM cardiolipin or 50 µM phosphatidylglycerol. Reactions were initiated with 
enzyme and monitored for 100 mins. Results were graphed in GraphPad 
Prism to determine the initial rate. The mean specific activity (n = 3) for each 
PBP1a variant in each condition was compared by one-way ANOVA, which 
indicated a significant difference between the mean values with 
phosphatidylglycerol and cardiolipin in each case. 








5.3.4 The effect of amidation on GT activity by PBP1aD39 and 
PBP2aD39 
We sought to extend the observations on the importance of amidation in GT 
activity by pneumococcal PBP1a and PBP2a, made by Galley (2015). The 
previous work demonstrated impact of amidation on the kinetic parameters of 
GT activity; this work aimed to demonstrate the difference in accumulation of 
glycan polymers over a similar time course to that in the continuous 
fluorometric assay.  
5.3.4.1 Expression of PBP2a 
Expression of untagged PBP2a from the construct pET30::pbp2a was 
attempted as described by Helassa et al. (2012). The expression under these 
conditions failed, and so different conditions were trialled to achieve sufficient 
expression for purification of PBP2a. The published method expressed PBP2a 
in BL21 (DE3) cells.  
Rare codon analysis of the D39 pbp2a gene sequence identified multiple rare 
codons (Table 5.3). Expression of PBP2a from pET30::pbp2a was therefore 
undertaken using BL21:: pRosetta cells, to supply tRNAs for a selection of 
those rare codons from the pRosetta plasmid. In this cell line, sufficient 
PBP2aD39 was expressed to allow purification of the enzyme. 
Purification was by cation and then anion exchange, made possible by the pI 
of certain defined areas of the PBP2a structure; and made necessary by lack 
of activity of tagged full-length PBP2a constructs (Helassa et al., 2012) .The 
purification protocol was altered such that the solubilisation step was earlier in 
the procedure, followed by pelleting of insoluble material by centrifugation at 
20 000 x g. This modification to the procedure shortened the overall process 
to allow more rapid storage of the final enzyme stock. The column steps were 
as described by Helassa et al. (2012) (Methods 2.4.5.2). Chromatograms from 
the two purification steps, along with a summary analysis of the purification by 
Table 5.3 Rare codon analysis of D39 pbp2a. Those codons for which tRNAs are 
provided by pRosetta (as found in BL21 (DE3) pRosetta cell line) are highlighted in 
bold. Analysis was completed using Rare Codon Caltor ( 
(http://people.mbi.ucla.edu/sumchan/caltor.html). 
 
Amino acid Arg Gly Ile Leu Pro Thr 
Rare codon CGA CGG AGG AGA GGA GGG AUA CUA CCC ACG 




SDS-PAGE, are presented in Figure 5.15. PBP2a was stored at a final 
concentration of 8 mg.mL-1.  
To demonstrate penicillin-binding activity of the purified PBP2a, BOCILLIN FL 
binding was analysed using the electrophoresis assay presented in Chapter 
5. The protein band was stained by BOCILLIN FL fluorescence in this 
experiment, and this staining was lost under preincubation with ampicillin 
(Figure 5.16). This demonstrated that the purified protein binds penicillin and 
therefore is likely PBP2a. 
 
Figure 5.15 Purification of S. pneumoniae PBP2aD39. Untagged PBP2aD39 
was purified by (a) cation exchange using a HiTrap SP HP column; and (b) 
anion exchange using a 6 mL RESOURCEÔ Q column. (i) indicates the peaks 
corresponding to PBP2aD39. (c) illustrates the purification as analysed by SDS-
PAGE using a 12 % acrylamide gel (with 5 µg protein loaded per sample). 1, 
cell suspension following lysis by cell disruption; 2, cell suspension following 
solubilisation of membrane proteins with 1 % (w/v) Triton X-100; 3, cell 
suspension following removal of insoluble material by centrifugation; 4, cation 
exchange peak; Final, the final protein stock following anion exchange. kDa, 
kilodaltons; mAU, milli-absorbance units. 
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5.3.4.2 Time course of GT activity with Lipid II (Gln, Dans) and Lipid II (Glu, 
Dans) 
The impact of amidation on the kinetics of GT activity was previously analysed 
by use of the continuous fluorometric assay (Galley, 2015), which 
demonstrated greater catalytic efficiency with and affinity for Lipid II (Gln, 
Dans), for both PBP1a and PBP2a.  
To complement the kinetic analysis of usage of Lipid II (Gln, Dans) and Lipid 
II (Glu, Dans), we sought to characterise how the formation of glycan polymers 
by PBP1a or PBP2a compared between these two substrates by SDS-PAGE 
analysis over a 3 h time course. The experiments presented in Figures 5.17 
and 5.18 were completed in collaboration with Dr. Ricky Cain, who quenched 
Figure 5.16 Analysis of BOCILLIN FL binding by PBP2aD39. Protein stocks 
were incubated with water or ampicillin for 30 mins at 25 °C, followed by 
incubation with BOCILLIN FL or DMSO for 1 h at 37 °C. Reactions were 
analysed by SDS-PAGE using 12 % acrylamide gels, and fluorescence was 
imaged (left-hand gel) using a Typhoon FLA 9500 laser scanner (GE 
Healthcare). Gels were then stained using InstantBlueÔ Protein Stain 
(Expedeon) and imaged for total protein (right-hand gel) using an ImageQuant 
LAS 4000 instrument (GE Healthcare).  
1, PBP2aD39 only; 2, PBP2aD39 and BOCILLIN FL; 3, PBP2aD39, ampicillin and 
BOCILLIN FL;  F.Mr, BenchMarkÔ Fluorescent Protein Standard 
(ThermoFisher Scientific); Mr, Color Prestained Protein Standard, Broad 




and loaded to gels the samples taken from the Lipid II (Glu, Dans) reactions 
in each Figure. 
Based upon the findings of (Galley, 2015), different time points were chosen 
to establish the polymerisation of Lipid II (Gln, Dans) and Lipid II (Glu, Dans) 
substrates. More frequent early time points were used for Lipid II (Gln, Dans), 
compared to the first time point at 15 minutes for Lipid II (Glu, Dans). This was 
informed by the slowed rate of GT activity by both PBP1a and PBP2a with the 
Lipid II (Glu, Dans) substrate previously observed by Galley (2015).  
With both PBP1a and PBP2a, high molecular weight polymers were formed 
more rapidly using Lipid II (Gln, Dans) than Lipid II (Glu, Dans), as expected 
from the fluorometric assay data. In PBP1a reactions, high molecular weight 
material was formed within 15 minutes with Lipid II (Gln, Dans) (Figure 5.17), 
whereas similarly sized material did not accumulate to the same extent in Lipid 
II (Glu, Dans) substrate reactions through the entire time course. A similar 
pattern was observed with PBP2a (Figure 5.18). The processivity of PBP2a 
appeared lower with Lipid II (Glu, Dans), as little increase in the polymer length 
synthesized was observed beyond 135 mins. These results corresponded well 
with previous observations on the effect of amidation on GT activity.  
Figure 5.17 Time course of assembly of glycan polymer by S. 
pneumoniae D39 PBP1a with Lipid II (Gln, Dans) or Lipid II (Glu, Dans). 
Reactions comprised 50 mM HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 150 
mM NaCl, 0.02 % (w/v) Triton X-100, 0.5 µM PBP1a, and 10 µM Lipid II (Gln, 
Dans) or Lipid II (Glu, Dans). Samples were taken at the stated timepoints 
and quenched with 0.3 mM moenomycin and 50 mM EDTA. Controls were 
included with (-) no enzyme, (-L) no lipid, and (+) both enzyme and lipid 
present, all of which were incubated for the full 180 mins. Samples were 
analysed by electrophoresis on a precast 16.5 % Tris-Tricine gel (Criterion), 
which was subsequently visualised using an ImageQuant LAS 4000 imager 




The positive control lanes of Figures 5.17 and 5.18 did not correspond with 
the 180 min reactions. This may have resulted from insufficient moenomycin 
added to these reactions. However, by comparison of each positive lane 
between usage of Lipid II (iGln, Dans) and Lipid II (Glu, Dans), the polymer 
length showed a clear shift to longer polymers under usage of Lipid II (iGln, 
Dans). 
5.4 Discussion 
5.4.1 Activity of PBP1a from different pneumococcal strains 
The aim of the investigation of pneumococcal PBP1a is to progress to 
comparison of TP activity between different constructs. As it has been 
observed that the GT activity of each protein was not significantly different, the 
GT specific activity of each construct could be a useful scaling factor for 
different PBP1a variants, and as a controlling factor for any batch-to-batch 
variation in activity. Zapun et al. (2013) used Bocillin-FL binding for this 
purpose. Bocillin FL binding as a scaling factor is limited as it only offers a 
measure of TP active site concentration, but does not necessarily prove that 
the TP active site is properly folded.  
 
Figure 5.18 Time course of assembly of glycan polymer by S. 
pneumoniae D39 PBP2a with Lipid II (Gln, Dans) or Lipid II (Glu, Dans). 
Reactions comprised 50 mM HEPES, 10 mM MgCl2, 25 % (v/v) DMSO, 150 
mM NaCl, 0.02 % (w/v) Triton X-100, 0.5 µM PBP1a, and 10 µM Lipid II (Gln, 
Dans) or Lipid II (Glu, Dans). Samples were taken at the stated timepoints 
and quenched with 0.3 mM moenomycin and 50 mM EDTA. Controls were 
included with (-) no enzyme, (-L) no lipid, and (+) both enzyme and lipid 
present, all of which were incubated for the full 180 mins. Samples were 
analysed by electrophoresis on a precast 16.5 % Tris-Tricine gel (Criterion), 
which was subsequently visualised using an ImageQuant LAS 4000 imager 
with transmitted light at 312 nm and a 605 nm filter. mins, minutes 
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5.4.2 Effect of detergent identity and concentration on PBP1a GT 
activity 
Detergent concentration can be considered to control the volume in which the 
GT reaction could occur, by virtue of the requirement of the enzyme and its 
substrate for a lipidic environment for solubilisation in aqueous solution.  
 
SDS-PAGE analyses demonstrated inhibition of PBP1a activity by detergent 
concentrations greater than 3 x CMC. These observations are in agreement 
with the data of Schwartz et al. (2002), who demonstrated that decyl-PEG 
detergent in concentrations above the CMC behaved as a reversible inhibitor 
of the activity of E. coli PBP1b. The effect of high concentrations of detergent 
compared to CMC is likely the result of decreasing probability of productive 
contact between micelles containing enzyme and those containing substrate 
(Schwartz et al., 2002), known as surface dilution kinetics (Carman et al., 
1995). In addition, Helassa et al. (2012) suggested that the high CMC typically 
associated with shorter detergents would decrease the likelihood of contact 
between enzyme and substrate-containing micelles. 
Full analysis of the relationship between detergent concentration and enzyme 
activity could involve a titration of enzyme concentration against detergent 
concentration, to analyse the impact on kinetics of glycosyltransfer. Such 
analysis was performed by Stein et al. (2000), who characterised the effect of 
Triton X-100 concentration on E. coli signal peptidase I (SPase I). Stein et al. 
(2000) found that the catalytic efficiency (kcat/Km) decreased with increasing 
concentration of Triton X-100 above the CMC. This effect was manifested in 
both increases in Km and decreases in kcat as the Triton X-100 concentration 
was increased. 
 
Rapid GT activity of S. pneumoniae PBP1a has previously been observed in 
Triton X-100 as the assay detergent (Galley, 2015). This detergent constitutes 
a mixture of ethylene glycol moieties, amongst which there may be species 
inhibitory to the activity of the enzyme. We therefore screened a set of defined 
ethylene glycol detergents to identify those offering the greatest activity of 
PBP1a. Such defined ethylene glycol detergents are also beneficial in 
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facilitating downstream analysis of PBP1a activity assays, for example by 
liquid chromatography-mass spectrometry (LC-MS). Triton X-100 is ill-suited 
to LC-MS analysis as it ionises in a polymeric series, thus obscuring any other 
ions of interest (Dr. A.J. Lloyd, University of Warwick, personal 
communication). 
Some studies have used liposomes to create the lipid environment necessary 
to maintain membrane proteins in a folded state and reconstitute the 
enzymatic activity (Hernández-Rocamora et al., 2018). The use of membrane 
lipid extracts from the originating bacterial species may be expected to best 
reconstitute the activity of a given enzyme. Use of liposomes instead of 
detergents to solubilise enzymes for assays would require prior identification 
of the preferred lipids of the enzyme in question, or use of an uncharacterised 
mixture. By contrast, detergents are beneficial in that their compatibility with 
various biochemical applications is known (Linke, 2009). 
 
5.4.3 Phospholipids and PBP1a 
Cardiolipin was found to stimulate GT activity, with a dose-dependent 
response, whilst no impact of phosphatidylglycerol on GT activity was 
observed under the conditions tested. 
The observation of stimulation of PBP1a activity by cardiolipin is in accordance 
with previous findings on the impact of cardiolipin on pneumococcal MurM (Dr. 
A.J. Lloyd, University of Warwick, unpublished). A growing body of evidence 
supports a role for cardiolipin in stimulation of enzymes of the cell wall 
biosynthetic pathway, with possible links to localisation of the cell wall 
synthesis machinery. 
A limitation of the current work is that cardiolipin was obtained from bovine 
heart preparations, and so differences in fatty acid moieties would be expected 
as compared to cardiolipin found in cell membrane of S. pneumoniae. In 
addition, phospholipid asymmetry is an important consideration for these 
results; it is difficult to determine the proportion of cardiolipin at the intracellular 
and extracellular faces of the cytoplasmic membrane. This factor is important 
to determine the relevance of inferred relationships between phospholipids 
and membrane proteins. Mukhopadhyay et al. (2007) used nonacrydyl-orange 
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(NAO) staining to analyse to phospholipid composition between the inner and 
outer leaflets of the S. aureus cytoplasmic membrane. The authors 
demonstrated that a large proportion of the total cardiolipin content of the 
membrane was found at the outer leaflet of the cytoplasmic membrane. 
A key further area of experimentation would therefore be the isolation of 
membrane lipids from relevant strains of S. pneumoniae, to allow comparison 
of the relative concentrations of particular phospholipids. Such extracts could 
also be used to create liposomes for reconstitution of PBP1a activity, and 
provide the source material from which those membrane components that did 
impact GT activity could be isolated. 
The mechanism of the stimulatory interaction between cardiolipin and PBP1a 
also remains to be determined. The interaction appears to be specific to 
cardiolipin, as the same stimulatory effect was not observed with 
phosphatidylglycerol at similar Lipid II concentrations.  
In light of the demonstrable importance of phospholipids in the activity of cell 
division proteins, a move away from the use of detergents for solubilisation 
would be a positive step in the ability to characterise the activities of cell 
division proteins. Alternative methods to detergents for solubilisation include 
nanodiscs, amphipols and reconstitution in liposomes.  
Among nanodisc technologies, styrene maleic acid (SMA) particles have been 
a successful technology for the reconstitution and study of membrane 
proteins. SMA lipid particles (SMALP). Mass spectrometry has been used to 
analyse the lipids co-extracted in SMALP, through which the lipid profiles 




5.4.4 Amidation and GT activity 
The results of our time course analysis are in agreement with previous data 
demonstrating an impact of amidation on the activity of bifunctional 
pneumococcal PBPs (Zapun et al., 2013). Both PBP1a and PBP2a 
demonstrated preference for amidation, with greater processivity confirmed in 
the current work. A remaining question surrounding the impact of amidation 
on PBP activity is whether amidation is also recognised by the TP active site. 
Zapun et al. (2013) demonstrated poorer accumulation of high-molecular 
weight material in the presence of Lipid II (Glu) on SDS-PAGE analysis, 
inferring slower transpeptidation. However, this observation could be the result 
of an indirect effect, in that activity of the GT site is boosted and thus provides 
donor substrate more efficiently; or could be a direct effect, with the 
transpeptidase active site recognising the second position amino acid, in the 
donor and/or acceptor substrate.  
In addition, the residues of the GT active site that are responsible for 
recognition of amidation remain to be determined. The data to date and some 
remaining experimental questions are summarised in Figure 5.19. 
5.4.5 Conclusions 
This work offers the first demonstration of the impact of phospholipids on PBP 
activity. Key areas for further characterisation include determination of the 
Figure 5.19 Summary of understanding to date on the impact of 
amidation on S. pneumoniae PBP1a and PBP2a function. 
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mechanism of the interaction between phospholipids and PBP1a, and 




Chapter 6: General Discussion and Conclusions 
Antibiotic resistance poses a major threat to healthcare and economies 
worldwide. To prevent the current projected death toll of 10 million per year 
worldwide by 2050 due to resistant infections, it is important that alongside 
education and sanitation initiatives, that we strengthen the antibiotic pipeline 
with promising new drug candidates. Better understanding and tools for study 
of key bacterial processes including cell wall biosynthesis can make a 
significant contribution to the delivery of new inhibitors. Cell wall biosynthesis 
is a crucial process for bacterial growth and a well-validated target for existing 
antimicrobials, and there remains much to be understood about cell wall 
biosynthesis, not least with regards to the PBPs themselves.  
This thesis aimed to contribute by deepening our knowledge of the penicillin-
binding proteins of Streptococcus pneumoniae, a key pathogen in terms of its 
healthcare burden and the prevalence of resistance to b-lactams. We aimed 
to develop methods in synthesis of pneumococcal peptidoglycan precursors, 
and assay of pneumococcal PBPs, in order to analyse the pneumococcal b-
lactam resistance mechanism. 
 
6.1 Synthesis of pneumococcal peptidoglycan precursors 
Methods for the synthesis of pneumococcal peptidoglycan intermediates have 
revolutionised our ability to assay peptidoglycan synthases, where progress 
was historically limited by availability of native substrate. We present the first 
synthesis of molecules that could in principle act as defined donor-only and 
acceptor-only substrates for transpeptidation by pneumococcal PBPs. These 
substrates will provide valuable tools for the understanding of these enzymes 
and how they function with natural substrates, which is key for addressing the 
biochemical details of pneumococcal b-lactam resistance.  
The methods for synthesis of these defined donor-only and acceptor-only 
pneumococcal peptidoglycan substrates can be extended to synthesis of the 
branched substrates key to the b-lactam resistance mechanism. Synthesis of 
acceptor-only branched substrates was attempted, but could not be confirmed 
by mass spectrometry due to the presence of a contaminating ion series, but 
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the origin of this contaminant is unconfirmed and may have been unrelated to 
the specific processes of the experiment. 
 
Synthesis of lipid linked, branched PG intermediates was demonstrated at 
analytical scale. These syntheses could now be scaled up to generate 
potential donor substrates for biochemical assays. It would also be of interest 
to exploit recently published methods for purification of lipid-linked, branched 
precursors from bacterial cultures (Qiao et al., 2017). Such purifications from 
pneumococcal cultures would be challenging due to the autolysis of 
pneumococcal cultures in stationary phase by the action of the autolysin LytA 
(Mellroth et al., 2012), necessitating careful monitoring of the cultures. Also, 
there is strain-by-strain variation in the extent and composition of indirect 
cross-links in peptidoglycan, likely reflecting variation in the peptidoglycan 
precursor pool (Filipe et al., 2000; Filipe et al., 2001). Purification of Lipid II 
directly from pneumococcal cultures would therefore be expected to generate 
a mixed product of linear and branched Lipid II. One could envision 
experiments whereby these mixed samples were incubated with PBP1a or 
PBP2a, and the products muramidase-digested analysed by LC-MS to 
determine whether transpeptidation had occurred, and the relative use of 
different substrates in this process. Such experiments would require internal 
standards for mass spectrometry to render them quantitative. This mass 
spectrometry approach could be an alternative for analysis of the results 
described here with use of linear Lipid II variants in the D-Ala release assay, 
where there was detection of D,D-carboxypeptidase activity only. HPLC 
analysis of the mixtures of substrates generated from cultures would also allow 
comparison of the substrate pools of the pneumococcal strains of interest in 
this work.  
 
In addition to use in assays of PBPs, pneumococcal peptidoglycan precursors 
are a useful research tool for applications such as study of immune responses 
to infection, as peptidoglycan fragments are bound by innate immune 
receptors (Koppe et al., 2011; Wolf & Underhill, 2018); and biophysical 
characterisations of proteins that bind peptidoglycan (Righino et al., 2018). 
The library of pneumococcal precursors could therefore be applied to answer 
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a variety of questions surrounding cell wall biosynthesis and the interaction of 
pneumococci with their environment. 
 
6.2 Development of Assay for Pneumococcal Transpeptidase Activity 
A variety of methods were explored to establish in vitro transpeptidase activity 
of pneumococcal PBP1a, but mass spectrometry detected only D,D-
carboxypeptidase activity. The results of SDS-PAGE-based analysis of PBP1a 
transpeptidase activity were similarly equivocal.  
 
Several key recent publications could inform further work to establish in vitro 
transpeptidase activity of pneumococcal PBPs. Class A PBPs have been 
suggested to remodel peptidoglycan synthesised by the FtsW/PBP2x 
peptidoglycan synthesis complex. This work was based on analysis of phases 
in resistance of pneumococcal cultures to the CbpD hydrolase under titration 
of oxacillin. Further work could focus on using purified PG from pneumococci 
as an acceptor or donor to reconstitute PG biosynthesis, or use of 
FtsW/PBP2x to generate polymeric substrate for PBP1a in vitro. 
Further work could also encompass the recently reported interactors with 
Class A pneumococcal PBPs (Fenton et al., 2018; Fenton et al., 2016), which 
may activate the activity of their partner proteins in vitro in a manner analogous 
to that described by lipoprotein activators of E. coli and P. aeruginosa Class A 
PBPs. Peptidoglycan synthesis by pneumococcal PBP2a has been 
demonstrated to be activated by MacP (Fenton et al., 2018), and so testing of 
the D-Ala release activity by this enzyme in the presence of the activating 
partner would be a key further experiment to the work presented in this thesis.  
 
Alternative techniques to analyse the usage by PBP1a of the substrate 
variants generated in this work could include assays with S2d thioester 
analogues as the transpeptidase donor, or techniques such as surface 





6.3 The Impact of Lipid Environment on Pneumococcal 
Glycosyltransferase Activity 
There is growing recognition of the importance of lipids in divisome activity. 
Interactions of cardiolipin with proteins at the lipid-linked stages of the 
peptidoglycan synthesis pathway have been described, with data indicating 
modulation of the Lipid II flippase MurJ by cardiolipin (Bolla et al., 2018) and 
stimulation of catalytic activity of MurG in the presence of cardiolipin (van den 
Brink-van der Laan et al., 2003). In this thesis, comparison of GT activity has 
identified a novel link between the phospholipids of the pneumococcal 
membrane, and the activity of the PBPs from both b-lactam sensitive and 
resistant strains. Cardiolipin was shown to accelerate GT activity in a dose-
dependent manner, via reduction of apparent Km for the Lipid II (iGln, Dans) 
substrate. This is the first observation of the impact of cardiolipin on the activity 
of a PBP, and corresponds with growing evidence in support of a role of 
cardiolipin in regulation of cell division proteins. These observations warrant 
extension of the studies to other pneumococcal peptidoglycan synthases, not 
least the SEDS glycosyltransferases which are integral membrane proteins. 
 
The observation of the impact of cardiolipin suggests some interesting further 
work to characterise the nature of the beneficial effect upon PBP1a activity. 
The transmembrane anchor of PBPs has been shown to be important for GT 
activity, with involvement in the formation of oligomeric states (Galley, 2015). 
This process, and the configuration of the substrate and enzyme, could be 
investigated using molecular dynamics simulation of the interaction of PBP1a 
and the lipid substrate in the presence of cardiolipin. Recent studies using 
molecular dynamics simulations have suggested a role for cardiolipin, in 
combination with AcrZ, in modulating the activity of the multidrug efflux pump 
AcrB (Du et al., 2019). Alternatively, interactions could be studied using ion 
mobility mass spectrometry, as applied to show modulation of E. coli 
aquaporin Z by cardiolipin (Laganowsky et al., 2014); or by non-denaturing 





This thesis describes progress towards the establishment of in vitro 
transpeptidase activity of pneumococcal PBPs, with the provision of a range 
of natural substrates; a study of the impact of lipid environment on PBP1a GT 
activity; and studies focussing on the use of a D-Ala release assay for 
transpeptidation by PBP1a. Further work is required to establish in vitro 
transpeptidase activity, but with recent advances in knowledge of the 
pneumococcal cell division machinery (Massidda et al., 2013; Vollmer et al., 
2019), several opportunities arise to test protein-protein interactions that may 
stimulate pneumococcal transpeptidase activity in vitro. 
Through deepening of our understanding of the mechanisms that underlie 
resistance to current antibiotics, we will build the knowledge base required for 
the design of new inhibitors that may bypass these mechanisms or restore 
activity.  
The importance of antibiotic resistance as a research and global healthcare 
challenge can be summed up by the words of Aminov (2010), who noted that 
“In fact, [antibiotic resistance] should be of everyone’s concern, because, in 
the end, there is always a probability for any of us at some stage to get infected 
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Appendices to Chapter 3 
Appendix 3.1: Ease of separation of UDP-MurNAc peptides with and 
without amidation 
Appendix 3.1 compares the elution profiles of amidated (UDP-MurNAc 5P 
(iGln)) and non-amidated (UDP-MurNAc 5P (Glu)). When purified by anion 
exchange on the same gradient of ammonium acetate, the peak elution of 
each substrate was separated by ~75 mL. This distinct elution would allow 
separation of un-amidated substrate arising from the UDP-MurNAc peptide 
synthesis. 
Appendices 3.2 and 3.3: Mass spectral analysis of UDP-MurNAc 5P 
(iGln) and Lipid II (iGln) 
Synthesis of UDP-MurNAc 5P (iGln) and Lipid II (iGln) was verified by 
nanospray TOF mass spectrometry. 
Appendix 3.1 Comparison of elution profiles UDP-MurNAc 5P (iGln) and 
UDP-MurNAc 5P (Glu). Synthesis reactions of UDP-MurNAc 5P were 
chromatographed by anion exchange. The position of the product peak is 
indicated for each reaction (as verified by nanospray TOF mass 





Appendix 3.2 Nanospray TOF mass spectrum of UDP-MurNAc 5P (iGln). Samples were analysed by negative ion nanospray 
TOF mass spectrometry. The full spectrum (a), along with focused views of the singly charged (b) and doubly charged (c) ions are 





Appendix 3.3 Nanospray TOF mass spectrum of Lipid II (iGln). Samples were analysed by negative ion nanospray TOF mass 
spectrometry. The full spectrum (a), along with focused views of the singly charged (b) and doubly charged (c) ions, are presented. 
Data collected and analysed by A.J. Lloyd, and mass spectra generated using MassLynx software (Waters). 








Expected (m-2)/2 936.030 
Expected (m + Na+ -1)/1 
1895.05 
Expected (m + 2Na+ -1)/1 1917.03 
Expected (m +Na+ -2)/2 
947.02 
a) Full spectrum 
b) Singly charged 




Appendices 3.4 – 3.11: Mass spectrometry analysis of carbodiimide 
coupling syntheses quenched with ethanolamine or hydroxylamine 
Carbodiimide coupling reactions were quenched with ethanolamine or 
hydroxylamine. The products were analysed by nanospray TOF mass 







Appendix 3.4 Nanospray TOF mass spectrometry analysis of carbodiimide coupling reactions quenched using ethanolamine. 
Samples were analysed by negative ion nanospray TOF mass spectrometry. These mass spectra were generated from a sample of the 
‘eth 18.7’ peak upon anion exchange chromatography of the reaction. The full mass spectrum (a) and spectra depicted singly (b), doubly 
(c) and triply (d) charged ions related to the desired product, UDP-MurNAc 6P (iGln, L-Ala) are given. See Appendix 3.6 for spectra 
depicting products of multiple alanylation. Data collected and analysed by A.J. Lloyd, and mass spectra generated using MassLynx 
software (Waters). 1a, UDP-MurNAc 6P (iGln, L-Ala); 4b, UDP-MurNAc 9P (iGln, (L-Ala)4; 5b, UDP-MurNAc 10P (iGln, (L-Ala)5; 6b, UDP-







Appendix 3.5 Nanospray TOF mass spectrometry analysis of 
carbodiimide coupling reactions quenched using ethanolamine – 
doubly and triply charged ions corresponding to products of multiple 
alanylation. Samples were analysed by negative ion nanospray TOF mass 
spectrometry. These mass spectra were generated from a sample of the ‘eth 
18.7’ peak upon anion exchange chromatography of the reaction. Data 
collected and analysed by A.J. Lloyd, and mass spectra generated using 
MassLynx software (Waters). 4b, UDP-MurNAc 9P (iGln, (L-Ala)4; 5b, UDP-
MurNAc 10P (iGln, (L-Ala)5; 6b, UDP-MurNAc 11P (iGln, (L-Ala)6; 7b, UDP-









Appendix 3.6 Nanospray TOF mass spectrometry analysis of 
carbodiimide coupling reactions quenched using ethanolamine. 
Samples were analysed by negative ion nanospray TOF mass 
spectrometry. These mass spectra were generated from a sample of the 
‘eth 20.4’ peak upon anion exchange chromatography of the reaction. The 
full mass spectrum (a), and the spectrum displaying the doubly charged 
series (b) corresponding to the ion of interest are displayed. Data collected 
and analysed by A.J. Lloyd, and mass spectra generated using MassLynx 
































Appendix 3.7 Nanospray TOF mass spectrometry analysis of carbodiimide coupling reactions quenched using 




(previous page) Appendix 3.7 Nanospray TOF mass spectrometry 
analysis of carbodiimide coupling reactions quenched using 
hydroxylamine – doubly and triply charged ions corresponding to 
products of multiple alanylation. Samples were analysed by negative ion 
nanospray TOF mass spectrometry. These mass spectra were generated from 
a sample of the ‘hyx 15.0’ peak upon anion exchange chromatography of the 
reaction. The full mass spectrum (a), and spectra corresponding to the singly 
charged (b), doubly charged (c) and triply charged (d) ions are displayed. Data 
collected and analysed by A.J. Lloyd, and mass spectra generated using 
MassLynx software (Waters).. 1a, UDP-MurNAc 6P (iGln, L-Ala); 2a, UDP-








































Appendix 3.8 Nanospray TOF mass spectrometry analysis of 
carbodiimide coupling reactions quenched using hydroxylamine – 
minor ions between doubly and singly charged ions. Samples were 
analysed by negative ion nanospray TOF mass spectrometry. These mass 
spectra were generated from a sample of the ‘hyx 15.0’ peak upon anion 
exchange chromatography of the reaction. Triply charged dimers, with and 
without sodiation, of ion 1c, were observed at (i), (ii), (iii) and (iv). Data 
collected and analysed by A.J. Lloyd, and mass spectra generated using 
MassLynx software (Waters). 1c, phospho-MurNAc 6P (iGln, L-Ala); 3a, 
UDP-MurNAc 8P (iGln, (L-Ala)3); 3c, phospho-MurNAc 8P (iGln, (L-Ala)3); 




Appendix 3.9 Nanospray TOF mass spectrometry analysis of carbodiimide coupling reactions quenched using 





(previous page) Appendix 3.9 Nanospray TOF mass spectrometry analysis of carbodiimide coupling reactions quenched 
using hydroxylamine – doubly and triply charged ions corresponding to products of multiple alanylation. Samples were 
analysed by negative ion nanospray TOF mass spectrometry. These mass spectra were generated from a sample of the ‘hyx 13.3’ peak upon 
anion exchange chromatography of the reaction. Data collected and analysed by A.J. Lloyd, and mass spectra generated using MassLynx 
software (Waters). 1a, UDP-MurNAc 6P (iGln, L-Ala); 1c, phospho-MurNAc 6P (iGln, L-Ala); 2c, phospho-MurNAc 7P (iGln, (L-Ala)2); 4a, UDP-
























Appendix 3.10 Nanospray TOF mass spectrometry analysis of carbodiimide coupling reactions quenched using 
hydroxylamine – products of multiple alanylation and cleavage. Samples were analysed by negative ion nanospray TOF 
mass spectrometry. These mass spectra were generated from a sample of the ‘hyx 13.3’ peak upon anion exchange 
chromatography of the reaction. Data collected and analysed by A.J. Lloyd, and mass spectra generated using MassLynx software 
(Waters). 1a, UDP-MurNAc 6P (iGln, L-Ala); 1c, phospho-MurNAc 6P (iGln, L-Ala); 2c, phospho-MurNAc 77P (iGln, (L-Ala)2); 4a, 
UDP-MurNAc 9P (iGln, (L-Ala)4); 5a, UDP-MurNAc 10P (iGln, (L-Ala)5); 6a, UDP-MurNAc 11P (iGln, (L-Ala)6); 7a, UDP-MurNAc 





Appendix 3.11 Nanospray TOF mass spectrometry analysis of 
carbodiimide coupling reactions quenched using 
hydroxylamine – doubly and triply charged ions corresponding 
to products of multiple alanylation. Samples were analysed by 
negative ion nanospray TOF mass spectrometry. These mass spectra 
were generated from a sample of the ‘hyx 13.3’ peak upon anion exchange 
chromatography of the reaction. The full mass spectrum (a), and spectra 
corresponding to the doubly charged (b) and triply charged (c) ions are 
displayed. Data collected and analysed by A.J. Lloyd, and mass spectra 
generated using MassLynx software (Waters). A, ions corresponding to 
unknown compound; B, ions corresponding to compound resulting from 
alanylation of A; C, ions corresponding to compound resulting from 
alanylation of B. 
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Appendix 3.12 – 3.19: Mass spectrometry analysis of carbodiimide 
coupling syntheses omitting quenching agent 
Carbodiimide coupling reactions omitting the quenching agent were analysed 
by nanospray TOF mass spectrometry, to determine the extent of multiple 
alanylation.  
Appendix 3.12 Nanospray TOF mass spectrometry analysis of 
carbodiimide coupling reactions for synthesis of UDP-MurNAc 6P (iGln, 
L-Ala), omitting the quenching agent – full spectrum and singly charged 
spectrum. Samples were analysed by negative ion nanospray TOF mass 
spectrometry. The full mass spectrum (a), and a spectrum corresponding to the 
singly charged (b) ions are displayed. Data collected and analysed by A.J. Lloyd, 
and mass spectra generated using MassLynx software (Waters). 1a, UDP-MurNAc 












Appendix 3.13 Nanospray TOF mass spectrometry analysis of 
carbodiimide coupling reactions for synthesis of UDP-MurNAc 6P 
(iGln, L-Ala), omitting the quenching agent – doubly and triply 
charged ions corresponding to products of multiple alanylation. 
Samples were analysed by negative ion nanospray TOF mass 
spectrometry. Spectra corresponding to the doubly charged (a) and triply 
charged (b) ions are displayed. Data collected and analysed by A.J. Lloyd, 
and mass spectra generated using MassLynx software (Waters). 1a, UDP-
MurNAc 6P (iGln, L-Ala); 2a, UDP-MurNAc 7P (iGln, (L-Ala)2); 3a, UDP-
















































Appendix 3.14 Nanospray TOF mass spectrometry analysis of 
carbodiimide coupling reactions for synthesis of UDP-MurNAc 7P 
(iGln, L-Ala-L-Ala), omitting the quenching agent – full spectrum and 
singly charged spectrum. Samples were analysed by negative ion 
nanospray TOF mass spectrometry. The full mass spectrum (a), and a 
spectrum corresponding to the singly charged (b) ions are displayed. Data 
collected and analysed by A.J. Lloyd, and mass spectra generated using 
MassLynx software (Waters). 2a, UDP-MurNAc 7P (iGln, (L-Ala)2); 3a, 
UDP-MurNAc 8P (iGln, (L-Ala)3); 4a, UDP-MurNAc 9P (iGln, L-Ala)4; 5a, 














Appendix 3.15 Nanospray TOF mass spectrometry analysis of 
carbodiimide coupling reactions for synthesis of UDP-MurNAc 7P (iGln, 
L-Ala-L-Ala), omitting the quenching agent – doubly and triply charged 
spectra. Samples were analysed by negative ion nanospray TOF mass 
spectrometry. Spectra corresponding to the doubly charged (a) and triply 
charged (b) ions are displayed. Data collected and analysed by A.J. Lloyd, and 
mass spectra generated using MassLynx software (Waters). 2a, UDP-MurNAc 
7P (iGln, (L-Ala)2); 3a, UDP-MurNAc 8P (iGln, (L-Ala)3); 4a, UDP-MurNAc 9P 






























Appendix 3.16 Nanospray TOF mass spectrometry analysis of 
carbodiimide coupling reactions for synthesis of UDP-MurNAc 6P 
(iGln, L-Ser) – full and singly charged spectra. Samples were analysed 
by negative ion nanospray TOF mass spectrometry. Spectra corresponding 
to the full spectrum (a) and singly charged (b) ions are displayed. Data 
collected and analysed by A.J. Lloyd, and mass spectra generated using 
MassLynx software (Waters). 
b) singly charged 
ions 
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b) triply charged ions 
a) doubly charged ions 
Appendix 3.17 Nanospray TOF mass spectrometry analysis of 
carbodiimide coupling reactions for synthesis of UDP-MurNAc 6P (iGln, 
L-Ser) – doubly and triply charged spectra. Samples were analysed by 
negative ion nanospray TOF mass spectrometry. Spectra corresponding to 
the doubly (a) and triply charged (b) ions are displayed. Data collected and 
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Appendix 3.18 Nanospray TOF mass spectrometry analysis of 
carbodiimide coupling reactions for synthesis of UDP-MurNAc 7P (iGln, 
L-Ser-L-Ala) – full and singly charged spectra. Samples were analysed by 
negative ion nanospray TOF mass spectrometry. Spectra corresponding to 
the full (a) and singly charged (b) ions are displayed. Data collected by A.J. 



























































Appendix 3.19 Nanospray TOF mass spectrometry analysis of 
carbodiimide coupling reactions for synthesis of UDP-MurNAc 7P (iGln, 
L-Ser-L-Ala) – doubly and triply charged spectra. Samples were analysed 
by negative ion nanospray TOF mass spectrometry Spectra corresponding to 
the doubly (a) and triply charged (b) ions are displayed. Data collected by A.J. 
Lloyd, and mass spectra generated using MassLynx software (Waters). 
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Appendix 3.20 - 3.23: Collision-induced fragmentation of UDP-MurNAc 
5P (iGln), UDP-MurNAc 6P (iGln, L-Ala) and UDP-MurNAc 7P (iGln, (L-
Ala)2) 
Mass spectrometry was used to confirm the correct positioning of the branch 
on UDP-MurNAc 6P (iGln, L-Ala) and UDP-MurNAc 7P (iGln, (L-Ala)2). 
Sample of the two substrates, and the starting material (UDP-MurNAc 5P 
(iGln)) were subjected to increasing collision energies until the parent ion was 
lost. The resultant ions were then assigned to fragmentation patterns of the 
parent ion to determine the positioning of the branch amino acids. 





Figure 3.20 Mass spectrometry analysis of UDP-MurNAc -5P (iGln), -6P (iGln, L-Ala), and -7P (iGln, L-Ala-L-Ala). Samples 
for analysis of fragmentation pattern were analysed by negative ion nanospray TOF mass spectrometry. Data collected by A.J. 




Appendix 3.21 Mass spectrometry experiment for collision-induced fragmentation of UDP-MurNAc 5P (iGln). Samples 
were analysed by positive ion nanospray TOF mass spectrometry. The parent ion was selected for fragmentation (blue panel), 
and then subjected to increasing collision energies, until loss of the parent ion to generate a fragmentation pattern. Data collected 




Appendix 3.22 Mass spectrometry experiment for collision-induced fragmentation of UDP-MurNAc 6P (iGln, L-Ala). 
Samples were analysed by positive ion nanospray TOF mass spectrometry. The parent ion was selected for fragmentation (blue 
panel), and then subjected to increasing collision energies, until loss of the parent ion to generate a fragmentation pattern. Data 




Appendix 3.23 Mass spectrometry experiment for collision-induced fragmentation of UDP-MurNAc 7P (iGln, L-Ala-L-Ala). 
Samples were analysed by positive ion nanospray TOF mass spectrometry. The parent ion was selected for fragmentation (blue 
panel), and then subjected to increasing collision energies, until loss of the parent ion to generate a fragmentation pattern. Data 
collected and analysed by A.J. Lloyd, and mass spectra generated using MassLynx software (Waters). 
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Appendix 3.24 - 3.27: Analysis of branched Lipid II (iGln) purifications 
Purifications of branched Lipid II (iGln) syntheses (Lipid II 6P (iGln, L-Ala) and 
Lipid II 7P (iGln, L-Ala-L-Ala)) showed two sets of spots on TLC analysis, 
eluting at different times. These are hereafter referred to as the ‘lower’ and 
‘higher’ spots. Samples were pooled and analysed by mass spectrometry to 




a) 6P lower spots full 
spectrum 
b) Doubly and triply charged 
spectrum 
c) Triply charged spectrum 
Appendix 3.24 Nanospray TOF mass spectrometry of Lipid II 6P (iGln, L-
Ala) ‘lower spot’ from purification. Samples were analysed by negative ion 
nanospray TOF mass spectrometry. The full spectrum (a), and double and triply (b 
and c) charged spectra are presented. Data collected by A.J. Lloyd, and mass spectra 




a) 6P higher spots full spectrum 
b) Doubly charged spectrum 
Expected (m-2)/2 
971.55 



















Appendix 3.25 Nanospray TOF mass spectrometry of Lipid II 6P (iGln, L-
Ala) ‘higher spot’ from purification. Samples were analysed by negative ion 
nanospray TOF mass spectrometry. The full spectrum (a), and doubly charged 
spectrum (b) are presented, alongside (c) a comparison to an isotope model for Lipid 
II 6P (iGln, L-Ala). Data collected by A.J. Lloyd, and mass spectra generated using 





































a) 7P lower spots full 
spectrum 
c) Comparison to isotope model of Lipid II 6P (iGln, L-Ala) 
b) Doubly charged spectrum 




















Appendix 3.26 Nanospray TOF mass spectrometry of Lipid II 7P (iGln, 
L-Ala-L-Ala) ‘lower spot’ from purification. Samples were analysed by 
negative ion nanospray TOF mass spectrometry. The full spectrum (a), and doubly 
charged spectrum (b) are presented, alongside (c) a comparison to an isotope 
model for Lipid II 6P (iGln, L-Ala). Data collected by A.J. Lloyd, and mass spectra 




















































a) 7P higher spots full spectrum 
Part of 7P lipid series, 
Expected (m-2)/2 
1007.569 
6P lipid Expected 
(m-2)/2 971.55 



















c) Comparison to isotope model of Lipid II 7P (iGln, L-Ala-L-Ala) 
Appendix 3.27 Nanospray TOF mass spectrometry of Lipid II 7P (iGln, 
L-Ala-L-Ala) ‘higher spot’ from purification. See legend following page. 
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(previous page) Appendix 3.27 Nanospray TOF mass spectrometry of 
Lipid II 7P (iGln, L-Ala-L-Ala) ‘higher spot’ from purification. Samples 
were analysed by negative ion nanospray TOF mass spectrometry. The full 
spectrum (a), and doubly charged spectrum (b) are presented, alongside a 
comparison to an isotope model for Lipid II 7P (iGln, L-Ala). Data collected by 
A.J. Lloyd, and mass spectra generated using MassLynx software (Waters). 
 
Appendix 3.28 – 3.30: Mass spectrometry analysis of putative donor-
only substrates 
To provide starting material for synthesis of donor-only Lipid II substrates, 
UDP-MurNAc pentapeptide variants were synthesised with altered groups at 
the side chain of the third position in the peptide stem. Negative ion nanospray 







 a) mass spectrum b) singly charged ions 
c) doubly charged ions d) triply charged ions 
Expected (m-2)/2 = 
594.181 
Expected (m-2)/2 = 
594.181 
Expected (m-1)/1 = 
1189.370 
Expected (m-1)/1 = 
1189.370 
Expected (m-3)/3 = 395.785 
594.200 1189.392 
594.200 395.796 
Appendix 3.28 Nanospray TOF mass spectrometry of UDP-MurNAc 5P (iGln, e-N-acetyl-L-Lys). Samples were analysed by 
negative ion nanospray TOF mass spectrometry. The full spectrum (a) along with singly (b), doubly charged (c) and triply (b) charged ions 





b) singly charged ions 
c) doubly charged ions d) triply charged ions 


























a) mass spectrum 
Appendix 3.29 Nanospray TOF mass spectrometry of Lipid II (iGln, e-N-acetyl-L-Lys). Samples were analysed by negative ion 
nanospray TOF mass spectrometry. The full spectrum (a) along with singly (b), doubly charged (c) and triply (b) charged ions are presented. 




  a) Full spectra 
i) MurNAc 2P (iGln) isotope model 
ii) UDP-MurNAc 5P (iGln, e-diMe-Lys) 
iii) UDP-MurNAc 5P (iGln, L-Arg) 
b) Doubly charged spectra 
i) MurNAc 2P (iGln) isotope model 
ii) UDP-MurNAc 5P (iGln, e-diMe-Lys) 
iii) UDP-MurNAc 5P (iGln, L-Arg) 
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(previous page) Appendix 3.30 Nanospray TOF mass spectrometry of 
putative donor-only peptides. Samples were analysed by negative ion 
nanospray TOF mass spectrometry. a) Full spectra for (i) isotope model of UDP-
MurNAc dipeptide (iGln); (ii) UDP-MurNAc 5P (iGln, e-diMe-Lys) synthesis; (iii) UDP-
MurNAc 5P (iGln, L-Arg) synthesis. b) Doubly charged spectra for (i) isotope model 
of UDP-MurNAc dipeptide (iGln); (ii) UDP-MurNAc 5P (iGln, e-diMe-Lys) synthesis; 
(iii) UDP-MurNAc 5P (iGln, L-Arg) synthesis. Data collected by A.J. Lloyd, and mass 














Appendix 3.31 - 3.36: Mass spectrometry of acceptor-only substrate 
syntheses 
The substrates and starting material for acceptor-only substrates were 


































Expected (m-1)/1 761.37 
Appendix 3.31 Nanospray TOF mass spectrometry of MurNAc 5P(iGln). The sample was analysed by negative ion nanospray 




Expected (m-2)/2 537.66 




Expected (m-2)/2 537.66 



















Expected (m-2)/2 + 
2Na
+




Appendix 3.32 Nanospray TOF mass spectrometry of UDP-MurNAc 4P 
(iGln) Samples were analysed by negative ion nanospray TOF mass spectrometry 
a) Full spectrum b) Singly charged spectrum and c) doubly charged spectrum. Data 
collected by A.J. Lloyd, and mass spectra generated using MassLynx software 
(Waters). 
a) Full spectrum 
b) Singly charged spectrum 



























Expected (m-1)/1 690.33 




Appendix 3.33 Nanospray TOF mass spectrometry of MurNAc 4P (iGln) 
Samples were analysed by negative ion nanospray TOF mass spectrometry. a) Full 
spectrum and b) Singly charged spectrum. Data collected by A.J. Lloyd, and mass 
















Expected (m-2)/2 502.14 




Appendix 3.34 Nanospray TOF mass spectrometry of UDP-MurNAc 3P 
(iGln) Samples were analysed by negative ion nanospray TOF mass 
spectrometry. a) Full spectrum b) Singly charged spectrum and c) Doubly charged 
spectrum. Data collected by A.J. Lloyd, and mass spectra generated using 
MassLynx software (Waters). 
a) Full spectrum 
b) Singly charged spectrum 














Expected (m-1)/1 619.29 
Expected (m-1)/1 619.29 
Appendix 3.35 Nanospray TOF mass spectrometry of MurNAc 3P (iGln) 
Samples were analysed by negative ion nanospray TOF mass spectrometry. a) Full 
spectrum and b) Singly charged spectrum. Data collected by A.J. Lloyd, and mass 
spectra generated using MassLynx software (Waters). 
a) Full spectrum 






Appendix 3.36 Nanospray TOF mass spectrometry of Lipid II 3P (iGln) Samples were analysed by negative ion nanospray TOF 





Expected (m-1)/1 1730.99 
Expected 
(m-2)/2  




Appendices to Chapter 4 
Appendix 4.1 – 4.3: Mass spectrometry analysis of mutanolysin-
digested TP products 
Mass spectrometry was used to detect transpeptidation products formed by 
PBP1aD39. Transpeptidase reactions of PBP1aD39 using Lipid II (iGln) as a 
substrate were digested using mutanolysin and analysed by liquid 
chromatography-mass spectrometry (LC-MS). Two independent samples 




























(next page) Appendix 4.1 LC-MS analysis of TP reactions with PBP1aD39 
and Lipid II (iGln) (C) or Lipid II (iGln) only. The total ion chromatograms (Ai 
and Bi) were queried for mass to charge ratios corresponding to the triply (iv), 
doubly (ii) and singly (i) charged ions that would correspond to the putative TP 
product. The blue box highlights the peak of interest in sample A, and the 
corresponding timepoint in sample B. Data collected by A.J. Lloyd, and mass 
































A: PBP1aD39 and Lipid II (iGln) 






















b) Doubly charged series 
c) Theoretical mass spectrum of TP product from Lipid II 
(iGln) 
d) Observed doubly charged series 
a) Full mass spectrum 
Appendix 4.2: Mass spectra generated from LC-MS analysis of TP reactions 
with PBP1aD39 and Lipid II (iGln). See legend following page. 
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(previous page) Appendix 4.2: Mass spectra generated from LC-MS 
analysis of TP reactions with PBP1aD39 and Lipid II (iGln). From a peak in 
the total ion chromatogram containing an ion of interest, a full mass spectrum 
(a) was generated. The doubly charged series (b) identified in the LC-MSMS 
analysis was compared (d) to the theoretical mass spectrum (c) of the putative 
TP product. Data collected by A.J. Lloyd, and mass spectra generated using 








Appendix 4.4 – 4.5: Mass spectrometry analysis of mutanolysin-
digested TP products from detergent titration experiments 
 
Mass spectrometry was used to detect transpeptidation products formed by 
PBP1aD39 in reactions containing varied concentrations of E6C12 detergent. 
Transpeptidase reactions of PBP1aD39 using Lipid II (iGln) as a substrate were 
digested using mutanolysin and analysed by liquid chromatography-mass 
spectrometry (LC-MS). Two independent samples were analysed in this way 
(spectra illustrated for one sample).
Appendix 4.3 LC-MS analysis of TP reactions with Lipid II (iGln) 
Reactions were digested using mutanolysin and analysed by liquid 
chromatography-mass spectrometry (LC-MS) by positive ion electrospray 
time of flight mass spectrometry, to detect ions corresponding to putative 
TP product. m/z, mass to charge ratio.  Data collected by A.J. Lloyd, and 























TP or CP 
product 
(m + 1)/1 1842.87 - - - - 













a) 1.7 x CMC, peak 7.71 b) 3 x CMC, peak 7.70 









1842.87 Expected (m+1)/1 1842.87 
Appendix 4.4 LC-MS analysis of TP reactions with varied concentrations of E6C12 detergent – singly charged spectra. 
Samples were analysed by positive ion nanospray TOF mass spectrometry. The total ion chromatogram for each reaction was queried for mass 
to charge ratios corresponding to the singly charged ions of putative transpeptidase or carboxypeptidase products, generating mass spectra 
for peaks containing those ions (a-d). Mass spectra are labelled according to the reaction of origin (multiple of CMC), and the peak in the total 









a) 1.7 x CMC, peak 7.71 b) 3 x CMC, peak 7.70 










Appendix 4.5 LC-MS analysis of TP reactions with varied concentrations of E6C12 detergent – doubly charged spectra. 
Samples were analysed by positive ion nanospray TOF mass spectrometry. The total ion chromatogram for each reaction was queried for mass 
to charge ratios corresponding to the doubly charged ions of putative transpeptidase or carboxypeptidase products, generating mass spectra 
for peaks containing those ions (a-d). Mass spectra are labelled according to the reaction of origin (multiple of CMC), and the peak in the total 







Appendix 4.5 – 4.8: Mass spectrometry of Lipid II (iGln) stocks 
Transpeptidase assays identified variation between stocks of Lipid II (iGln), 
where one stock supported activity (stock 2), another did not (1), and another 
(3) appeared to have a contaminant that was reactive with the coupling 
system. These three stocks of Lipid II (iGln) were analysed by negative ion 

































Appendix 4.6 Nanospray TOF mass spectra of Lipid II (iGln) stocks – singly charged spectra. Samples were analysed by 
negative ion nanospray TOF mass spectrometry. Singly charged spectra for each stock are shown. Data collected and analysed 





Appendix 4.7 Nanospray TOF mass spectra of Lipid II (iGln) stocks – doubly charged spectra. Samples were analysed by 
negative ion nanospray TOF mass spectrometry. Doubly charged spectra for each stock are shown. Data collected and analysed 




















Appendix 4.8 Nanospray TOF mass spectrum of Lipid II (iGln) stock 3, 
illustrating polymeric contaminant. Sample was analysed by negative 
ion nanospray TOF mass spectrometry. Data collected and analysed by A. 





Appendix 4.9: Mass spectrometry analysis of mutanolysin-digested TP 
products from donor-only and acceptor-only substrates 
 
Mass spectrometry was used to detect transpeptidation products formed by 
PBP1aD39 in reactions using donor-only and acceptor-only substrates. 
Transpeptidase reactions were digested using mutanolysin and analysed by 
liquid chromatography-mass spectrometry (LC-MS).  
Appendix 4.9 LC-MS analysis of TP reactions with PBP1aD39 and donor-
only and acceptor-only substrates. The total ion chromatogram for a 
reaction containing acceptor-only (MurNAc 5P (iGln)) and donor-only (Lipid II 
(iGln, e-N-acetyl-Lys)) substrates was queried for mass to charge ratios 
corresponding to the doubly charged ions of putative transpeptidase and 
carboxypeptidase (CP) products, generating mass spectra for peaks 
containing those ions (a). Only ions corresponding to the CP product of Lipid 
II (iGln, acLys) were identified (b). Data collected by A.J. Lloyd and mass 
spectra generated using MassLynx software (Waters). 
 
  
a) Full mass spectrum from chromatogram peak of interest 







Appendix 4.10 – 4.11: Glycan polymer assembly under the conditions of 
the TP assay plus DMSO 
Whilst GT activity of PBP1aD39 had been demonstrated in vitro using both 
continuous fluorescence and SDS-PAGE assays, no TP activity by this 
enzyme was observed using the D-Ala release assay. We questioned whether 
this was the consequence of lack of GT activity under the conditions of the D-
Ala release assay. Glycan polymer assembly under the conditions of the D-
Ala release assay (50 mM HEPES, 10 mM MgCl2, 0.0116 % (w/v) E6C12; 
PBP1aD39 and Lipid II substrate as required) plus 25 % (v/v) DMSO was 
therefore analysed by Tris-Tricine SDS-PAGE. DMSO appeared to be 
required for glycan chain assembly using Lipid II (iGln, Dans). Transpeptidase 
assays were then conducted with donor substrate consisting of either Lipid II 
(iGln, Dans) or Lipid II (iGln, e-N-acetyl-L-Lys), in the presence and absence 
Appendix 4.10 Glycan polymer assembly under conditions for the TP 
assay, with and without DMSO. Reactions comprised 50 mM HEPES, 10 mM 
MgCl2, ± 25 % (v/v) DMSO, 0.0116 % (w/v) E6C12, 2 µM PBP1aD39 and 20 µM Lipid 
II (Gln, Dans). Samples were taken at the stated timepoints and the reactions 
quenched with 0.3 mM moenomycin and 50 mM EDTA. Samples were analysed by 
electrophoresis on a 9 % Tris-Tricine gel, which was subsequently visualised using 
an ImageQuant LAS 4000 imager with transmitted light at 312 nm and a 605 nm 
filter. mins, minutes; -DMSO control, reaction without DMSO, incubated for 120 




of DMSO. This allowed analysis of the need for DMSO for transpeptidation; 
and also for transpeptidase activity to be analysed under conditions known to 
support glycan chain formation. 
  
Appendix 4.11 Transpeptidase activity of PBP1aD39 ± DMSO. D-Ala 
release catalyzed by PBP1aD39 was followed in the presence and absence of 
25 % (v/v) DMSO, and using either Lipid II (iGln, Dans) or Lipid II (iGln, e-N-
acetyl-L-Lys) as a donor substrate. Reaction mixes comprised 50 mM HEPES 
pH 7.6, 10 mM MgCl2, 2 µM PBP1aD39, 20 µM Lipid II (iGln, acetyl-Lys or 
Dans), 20 µM MurNAc 5P (iGln), 33.51 mM.min-1 R. gracalis D-amino acid 
oxidase, 14.82 mM.min-1 horseradish peroxidase, 50 µM Amplex Red and 3 
X CMC (0.0116 % (w/v)) of E6C12. Reactions are labelled in the order of 
addition of the substrates (or buffer). mins, minutes; LII, Lipid II; M5P, 





Appendix 4.12: Mass spectrometry analysis of mutanolysin-digested TP 
products from reactions followed by SDS-PAGE 
Mass spectrometry was used to detect transpeptidation products formed by 
PBP1aD39 in reactions using Lipid II (iGln, Dans) and Lipid II (iGln, tripeptide). 
Transpeptidase reactions were digested using mutanolysin and analysed by 



















(next page) Appendix 4.12 LC-MS analysis of TP reactions with Lipid II 
(iGln, Dans) and Lipid II (iGln, 3P) Reactions were digested using 
mutanolysin and analysed by liquid chromatography-mass spectrometry (LC-
MS) by positive ion electrospray time of flight mass spectrometry, to detect 
ions corresponding to putative TP product. Data are representative of two 
samples.. m/z, mass to charge ratio; amp, reaction performed in the presence 
of 2 uM ampicillin. Data collected by A.J. Lloyd and mass spectra generated 





c) PBP1a159 amp b) PBP1a159 only 
b) PBP1aPn16 only 
CP product  
Expected (m+1)/1 1248.48 CP product  Expected (m+1)/1 1248.48 
CP product  






Appendices to Chapter 5 
Appendix 5.1: CMC of detergents used in biochemical assays 
In development of the GT assay for PBP1aD39, a variety of detergents were 
tested for optimum activity, at a defined multiple of their critical micellar 
concentration (CMC). The values used for these experiments are given in 
Appendix 5.1. 
 
Appendix 5.1: CMC of detergents used in biochemical assays. 
 
Detergent  (CMC) % (w/v) Source 




0.49 Hjelmeland et al. 
(1983) 
DDM (n-dodecyl-b-D-maltoside) 0.0087 VanAken et al. (1986) 
E4C12 (Tetraethylene glycol 
monododecyl ether) 
0.0026 Pons et al. (2010) 
E5C8 (Pentaethylene glycol 
monooctylether) 
0.25 Anatrace catalogue 
no. P350 
E5C10 (Pentaethylene glycol 
monodecylether) 
0.031 Anatrace catalogue 
no. P340 
E6C12 (Hexaethylene glycol 
monododecylether) 
0.0044 Carroll et al. (1982) 
E8C10 (Octaethylene glycol 
monodecylether) 
0.0048* Approximate based 
on CMC of E8C12 
E8C12 (Octaethylene glycol 
monododecylether) 
0.0048 le Maire et al. (1983); 




Appendix 5.2: Amino acid sequence alignment over GT domain of 
PBP1aD39, PBP1aPn16 and PBP1a159. 
To support comparison of the activity of PBP1a variants from different 
pneumococcal strains, the amino acid sequence over the N terminal protein of 
the proteins of interest was aligned to analyse the sequence identity. This 
analysis revealed 100 % sequence identity over the GT domains of PBP1aD39, 
PBP1aPn16 and PBP1a159.  
Appendix 5.2 Amino acid sequence comparison of the glycosyltransferase domains of 
the PBP1a variants used in this project. The three proteins show 100 % sequence identity 
over the glycosyltransferase (GT) domain. Sequences were aligned using Clustal Omega. 
The GT domain is highlighted in blue, and the N-terminal portion of the transpeptidase (TP) 
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